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Background: Dissolution testing has been proposed as a sensitive and discriminatory in vitro 
test for evaluating the quality or similarity of inhaled pharmaceuticals.  This has led to a number 
of bespoke respirable particle collection and dissolution techniques being developed by academic 
and industrial pharmaceutical scientists.  However, each comes with limitations and there is no 
standard or universal dissolution system for orally inhaled products.  A dissolution test system 
would ideally reproduce conditions that represent the in vivo lung environment and would have 
the potential to be used for both quality control purposes and as a predictive in vitro-in vivo 
correlation tool. However, test systems proposed to date do not meet these criteria fully, for 
example many have not utilised media designed to simulate respiratory tract lung fluid (RTLF). 
Dissolution methodology should fulfil requirements such as simplicity, reproducibility, ease of 
handling, robustness and be able to discriminate differences between inhaler batch, product and 
formulation types.   
 
Aim: The aim of this thesis was to develop dissolution methods for OIPs by identifying the critical 
attributes and shortcomings of current systems and designing and evaluating improved systems 
using fluticasone propionate (FP) as the model drug. 
 
Methods:  Two dissolution systems were evaluated: a Next Generation Impactor/Rotating paddle 
system and a Twin stage Impinger/Transwell® system.  A novel simulated lung fluid (SLF) based 
on the major components of human RTLF was manufactured and characterised in terms of its 
physicochemical properties and stability in solution and after freeze-drying.  The solubility and 
dissolution of inhaled drugs, including FP, were evaluated in the SLF and compared to other 
media.  The impact of using SLF as a dissolution media was evaluated in a biorelevant dissolution 
system, the novel DissolvIt® system, and an in-silico PBPK model was developed and applied to 
evaluate the impact of in vitro data on drug pharmacokinetics and enable comparison with in vivo 
data.  To develop the TSI/Transwell system as a biorelevant system, a Design of Experiments 
(DOE) approach was used to identify the influence of temperature, stirring and the solubilising 
capacity of dissolution media on dissolution profiles of FP.  Finally, a biorelevant methodology 
was used to compare the dissolution of nebulised suspension and microemulsion formulations to 
other inhaled formulations. 
 
Results: Both dissolution systems were simple and easy to handle, producing reproducible data.  
Although the novel NGI/rotating paddle system was a convenient starting point for quality control 
purposes, the TSI/Transwell system was more amenable to development as a biorelevant 
technique as it was able to mimic the low fluid volume of RTLF and could be used with lung fluid 
simulants that are expensive and only available in limited volume.  A SLF of biorelevant 
composition, consisting of proteins (albumin, transferrin and IgG), lipids (DPPC, DPPG and 
cholesterol) and antioxidants, was characterised.  It was shown to possess physiochemical 
properties comparable to those of RTLF, such as being an isotonic solution with a physiological 
pH of 7.2, viscosity of 1.138 x 10-3 Pa s, conductivity of 14.5 mS/m, surface tension of 54.9 mN/m 
and density of 0.999 g/cm3.The simulant was stable for 24 and 48 h at 37 and 20°C and for 14 
days at 4°C and when freeze-dried.  A novel and sensitive solid phase extraction and LC-MS/MS 
technique for the assay of FP was established and validated successfully to quantify the drug in 
low concentrations in biological matrices, in picogram concentrations.  In the DissolvIt system the 
use of SLF as a dissolution medium did not impact on dissolution profiles compared to the 
standard polymer solution (P>0.05), but DOE using the TSI/Transwell system found solubilising 
capacity of the medium to be a major factor.  Biorelevant conditions assigned as a dissolution 
medium of 0.1% w/v SDS in PBS (providing the same solubilising capacity as SLF), temperature 
37°C and stirring rate 15 rpm.  These biorelevant dissolution test conditions indicated that the 
dissolution of FP from a novel microemulsion formulation reached approximately 70% (almost 
double) over the 8 h experiment, compared to the dissolution of FP from the Flixotide suspension 
formulation (P< 0.05). 
 
Conclusion: A simulated lung fluid has been developed for use in a dissolution system tailored 
to orally inhaled products.  The dissolution technique is sensitive to temperature, stirring and the 
solubilising capacity of the dissolution medium and in preliminary tests has shown promise in 
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Unlike most solid or semi-solid pharmaceutical dosage forms, the particles that 
form the drug delivery units of inhaled aerosol medicines have not historically been 
investigated for drug release, i.e. dissolution.  However, evidence is emerging that 
dissolution may be a determining factor in the pharmacokinetics of some inhaled drugs 
and should be considered as a critical product attribute of inhaled medicines (Hastedt et 
al., 2016).  An impediment to determining how and to what extent dissolution influences 
pulmonary and systemic exposure to inhaled drugs is a lack of validated, robust 
dissolution methods for quantitative investigation.  This shortcoming raises the research 
questions that provide the basis for the research describer in this thesis: 
• how do different dissolution methods compare? 
• what factors influence in vitro dissolution data and do these interact? 
• are in vitro methods fit for purpose or can they be improved? 
• how can dissolution data be interpreted in terms of in vivo 
pharmacokinetics? 
• is dissolution indicative of inhaled product quality or equivalence? 
For a dissolution test for an inhaled product, it is important to consider both dose 
collection and dissolution techniques currently available when evaluating the challenges 
associated with developing such a test or system.  An understanding on how to interpret 
the results obtained in vitro, and their implications is also very important which can be 
informed by the modelling approaches undertaken to estimate impacts on 
pharmacokinetics.  To provide essential context to the topic and challenges described 
above, this introductory chapter discusses the anatomy of the lungs, dissolution 
mechanisms, considerations associated with developing a dissolution test for orally 
inhaled products, the techniques currently available and the methodologies and 




1.1 Anatomy of the lung and deposition of particles 
1.1.1 Anatomy of the lung 
The respiratory tract is a huge complex network of branches, predominantly 
divided into two main regions, the upper airway and the lower airway (Petersson and 
Glenny, 2014).  The upper airway consists of the nose, mouth, pharynx and larynx and 
acts as an air transport system and the lower airway consists of the tracheobronchial, 
the gas-conducting airways and the gas exchanging acini.  The lower airway is further 
subdivided into three zones: the respiratory, conducting and transitional zones.  The 
respiratory zone mainly comprises of respiratory bronchioles and alveoli (Yu and Chien, 
1997; Petersson and Glenny, 2014).  The bronchial tree trunk that constitutes the lower 
airways, begins with the trachea that divides into the left and right primary bronchi then 
each bronchus divides into further smaller secondary bronchi.  The secondary bronchi 
continue to branch into many tertiary bronchi that then continue to multiply divide, giving 
rise to many tiny bronchioles.  It finally forms terminal bronchioles and respiratory 
bronchioles.  The respiratory bronchioles sub-divides into alveolar ducts that end in 
clusters of small thin-walled air sacs known as alveoli (Thompson, 2004).  A schematic 




Figure 1. 1. A schematic diagram of the anatomy of the lung and the processes that 
occur to a drug particle once it lands in the lungs. Adapted from Hastedt et al (Hastedt 




The alveolus provides the huge surface area exhibited by the lungs, giving a total 
human lung area of approximately 140 m2.  This causes it to become the principal site of 
gas exchange between the air and the blood, in the airways (Thompson, 2004).  There 
are about 100 million alveoli found in each lung (Thompson, 2004) and the gases taken 
up by inhalation need to cross the alveolar epithelium, the capillary endothelium as well 
as their basement membranes to reach the blood, making the distance the air needs to 
travel up to around 500 nm in length (Thompson, 2004).  As the air travels from the 
trachea to the alveolar sacs, two physical changes occur in the lungs, to allow for 
adequate penetration of air to the lower airways.  These are, the airway diameter such 
as the tracheal diameter decreases with the respiratory branches and the high surface 
area of the airways increases. 
The human lung also consists of five lobules and ten broncho-pulmonary segment 
(Crapo et al., 1982).  The luminal face of the airways in lined with ciliated cells, which are 
the most common cell types and these cells have mucus cells intermingles among them.  
The mucus cells secrete a layer of mucus, coating the walls of the conducting airways 
with an adhesive, viscoelastic layer with a thickness of 5-55 µm (Lai et al., 2009).  The 
mucus contains antibacterial proteins, peptides and lysozymes that inhibit microbial 
colonization of the airways and has several roles such as promoting the saturation of 
inhaled air and protecting the lungs from inhaled chemicals.  The clearance of mucus 
from the lungs is driven by the motion of the ciliated cells, termed the ‘mucociliary 
escalator’, which generates a mucus flow rate of approximately 5 mm/min (Lai et al., 
2009).  The main role of the mucociliary escalator is to serve as an important protective 
mechanism for removing small inhaled particles from the lungs.   
The alveolar epithelium is predominantly composed of Type I and Type II alveolar 
cells.  The Type I cells are thin pneumocyte cells that cover most of the surface of the 
alveoli, approximately 95% of the surface area.  The Type II cells are cuboidal secretory 
pneumocyte cells, which are interspersed amount the Type I cells (Thompson, 1996).  
The alveolar space is coated with a complex surfactant lining that reduces the surface 
tension to minimise the work of breathing and to prevent the collapse of the alveoli during 
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expiration (D’Angelis, 2011).  The surface activity of the surfactant is mainly provided by 
the phospholipids and surfactant proteins B and C.  
 
1.1.2 Deposition and fate of an inhaled particle 
Particles deposit in the respiratory tract via five mechanisms: impaction, 
sedimentation, Brownian motion, interception and electrostatic precipitation.  The most 
crucial variable that dictates where the particles deposit, is the mass median 
aerodynamic diameter (MMAD) of the particle.  It is important to note that the lung has a 
relative humidity of approximately 99.5% RH and the addition and removal of water can 
significantly affect the particle size of a hygroscopic aerosol and thus its deposition 
(Labiris and Dolovich, 2003).  Small drug particles are known to be hygroscopic and a 
hygroscopic aerosol that is delivered at relatively low temperature and humidity into the 
high humidity exhibited by the lungs, would be expected to increase in size when inhaled 
into the lungs.  This increase in size above its initial size further affects the deposition 
and distribution of particles within the lungs (Labiris and Dolovich, 2003). 
Impaction is the inertial deposition of a particle onto an airway surface and the 
progressive branching and narrowing of the airways encourage impaction of the 
particles.  It occurs at bifurcation of airway where flow velocities are at their highest and 
sudden change in direction of flow takes place, generating considerable inertial forces.  
The large particles with a MMAD of more than 5 µm experience the impaction forces in 
the oropharynx and the large conducting airways, due to their high momentum.  The 
particle’s momentum is also influenced by the speed and mass of the particle and hence, 
this impaction-based deposition is increased by higher velocity, high rate of breathing, 
and particle > 5 µm size and high density (Vaughan and Vaughan, 1969).  The inspiratory 
and expiratory air flow rate in normal healthy lung range from 4.3 to 32.7 mL/s, depending 
on the pressure and region of the lung (Sul et al., 2014).  Sedimentation or gravitational 
sedimentation is an important mechanism for deposition of particles over 0.5 µm and 
below 5 µm in size in the small conducting airways, where the air velocity is low i.e. in 
the deeper airways and bronchioles.  Deposition due to gravity is increased by large 
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particle size and by longer residence times and decreases with increasing breathing rate 
(Vaughan and Vaughan, 1969). 
For particles with MMAD < 0.5 µm, the impact of the surrounding air causes a 
random motion in them, termed the ‘Brownian motion’.  This causes particles to deposit 
by diffusion in the small airways and alveoli, where air flow is low in contrast to the upper 
respiratory airways.  However, most of these small particles remain suspended in air and 
are exhaled during normal breathing.  The interception mechanism of deposition is 
usually significant for fibres and aggregates.  In terms of electrostatic precipitation, some 
freshly generated particles can be electrically charged during the mechanical generation 
of aerosols and hence may exhibit enhanced deposition due to charge-induced 
deposition, though this is a low contribution in comparison to other mechanisms 
(Martonen and Katz, 1993).   
The deposition of aerosol particles in the respiratory tract also depends on density, 
hygroscopicity, and the shape of the aerosolised particle.  Deposition can also be 
affected by the patient’s inhalation parameters such as flow rate, ventilation volume, end-
inspiratory breath holding, and the aerosol delivery system.  Therefore, the deposition 
pattern can be expressed as a function of these three key classes of variables: the 
respiratory tract morphologies, the aerosol characteristics such as particle size, shape 
and density as well as the ventilatory parameters.  Hence, the efficiencies of the different 
deposition mechanisms of inertial impaction, sedimentation and diffusion can, in turn, be 
formulated in terms of these variables.  Table 1.1 summarises the deposition of the 
inhaled particles in the lungs. 
 





1.1.3 Clearance mechanisms of the lungs  
Several mechanisms are involved in the removal of particles from the respiratory 
tract, depending on where the particles have deposited in the airways.  The most 
prominent defence mechanism of the respiratory region is the macrophage clearance.  
This occurs to the slow dissolving drug particles that have deposited deeper into the 
airways, in the alveolar region.  A thin layer of alveolar fluid is secreted on the surface of 
the alveoli epithelium, composed of phospholipids and lung surfactants excreted by the 
Type II pneumocytes, as described in section 1.1.1.  The phospholipid surfactant proteins 
B and C are responsible for lowering the surface tension of the lungs whereas the 
surfactant proteins A and D are responsible for opsonising foreign matter in the lungs 
(Goerke, 1998).  The alveolar macrophages located in the alveoli rapidly engulf these 
foreign particles by phagocytosis.  They then slowly migrate out of the lung and either 
follow the broncho-tracheal escalator or the lymphatic system (Geiser and Kreyling, 
2010).  The blood supply to the lung is provided by a pulmonary circulation and a 
systemic circulation, and the drug delivered in the lower airways can enter the systemic 
circulation by absorption into the alveolar capillaries.   
Most of the insoluble particles that have deposited in the upper airways, 
approximately > 5 µm in size, are eliminated by mucociliary clearance (Geiser and 
Kreyling, 2010).  The mucus cells intermingled amongst the ciliated cells at the luminal 
surface of the airways, secrete a layer of mucus.  In the lungs of a healthy individual, the 
production of mucus reaches about 10-20 mL/day (West, 2013).  It coats the walls of the 
conducting airways and the ciliated cells in the epithelium transport this mucus, together 
with any deposited particles in a proximal direction where eventually, the mucus is 
expectorated or swallowed (West, 2013).  The smaller particles can penetrate the mucus 
and enter the bronchial epithelium.  The smaller the particles, the faster they reach the 
epithelium and thus escape mucociliary clearance (West, 2013).   
In healthy individuals, the mucus moves upwards at a rate of about 1 mm/min in 
the small peripheral airways but can be as quick as 20 mm/min in the trachea (West, 
2013).  The rate of mucociliary clearance decreases with age in healthy individuals but 
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can also be affected by airway diseases (Messina et al., 1991; Munkholm and 
Mortensen, 2014).  When mucociliary clearance is decreased, cough becomes an 
increasingly important mechanism for the removal of secretions from the airways 
(Puchelle et al., 1980).  It has been shown for example, a considerable large proportion 
of centrally deposited particles were eliminated by coughing, in patients with chronic 
obstructive pulmonary disease (COPD) compared with healthy individuals, 60% versus 
8% of the particles (Puchelle et al., 1980). 
 
1.2 The dissolution process 
1.2.1 Definition and theories of dissolution 
Dissolution is a stepwise process, defined as the mass transfer of particles from a 
solid surface into the dissolution medium or surrounding solvent.  It entails the separation 
of a solute molecule from adjacent solute molecules, followed by their transfer from the 
solid phase into a solution.  The individual molecules insert into a vacancy in the solvent 
phase, large enough to accommodate for them, forming a homogenous mixture (Amiji 
and Sandmann, 2003). 
Mathematically, dissolution is described in accordance to the Nernst-Brunner 
stagnant film theory, also termed the ‘Diffusion Layer Model’ (Larsson, 2009; Ashok, 
2014). According to the theory the solute is initially transferred into a stagnant layer of 
solvent in direct contact with the solid surface, before being solvated by the solvent.  The 
solvated molecule species subsequently diffuse through this stagnant diffusion layer to 
the interface of the bulk solvent region via convection.  Therefore, the dissolution process 
is thought to be influenced by the effective diffusion boundary layer thickness, ∂, as 
approximated by Brunner and by the velocity of the stagnant layer in the immediate 
vicinity of the solid surface; where most efficient dissolution occurs with maximum 
contact between the dissolving solute and the dissolution medium i.e. maximum 
interfacial area.  Since the dissolution operation predominantly involves mass transfer of 
solute particles, dissolution is also characterised by the mass transfer coefficient, k, 
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which accounts for the concentration difference between the interface and the bulk 
solution and is in turn determined by the degree of turbulence in the vicinity of the solid 
particles.  Initially, Noyes and Whitey described the rate of dissolution in accordance to 
Fick’s second law of diffusion (Ashok, 2014), as stated in equation (1): 
dC/dt = k (Cs-Cb)                                                                                                (1) 
where dC/dt is the dissolution rate of the drug, k is the dissolution rate constant, Cs is 
the concentration of the drug in the stagnant layer and Cb is the concentration of the 
drug in the bulk of the solution at time t.  
However, Nernst and Brunner used their theory to develop the equation further and 
incorporated Fick’s first law of diffusion, modifying the Noyes-Whitney equation to 
equation (2): 
dC/dt = [DAKw/o (Cs–Cb)] / Vh                                                                               (2) 
where D is the diffusion coefficient of the drug. A is the surface area of the dissolving 
solid, Kw/o is the water/oil partition coefficient of the drug, V is the volume of dissolution 
medium, h is the thickness of stagnant layer and (Cs-Cb) is the concentration gradient 
for the diffusion of drug. 
Taking these dissolution model parameters into consideration, the rate of 
dissolution can be further summarised into a simpler Noyes-Whitney equation (3): 
dm/dt = DACs/h                                                                                                    (3) 
Where m is the mass of the solute dissolved at time t, dm/dt is the mass rate of 
dissolution, Cs is the difference between equilibrium solubility of the drug and its solubility 
in the solvent and h is the thickness of the solvent diffusion boundary layer, which is 
influenced by the rate of stirring and temperature.  The Noyes-Whitney equation 
assumed that the surface area of the dissolving solid remains constant during 
dissolution. 
Since diffusion is often rate limiting, it is of special significance within the Noyes-
Whitney equation.  The D parameter in the equation is dependent on the Boltzmann 
constant, the absolute temperature, viscosity of the medium and the radius of the solute 
molecule and this is described by the Stokes-Einstein equation (4): 
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D = kT/6πηr                                                                                                            (4) 
Where D is the diffusion coefficient of the drug in solution, k is the Boltzmann constant 
of 1.381 x 10-23 J/°K, T is the absolute temperature, η is the viscosity of the solvent and 
r is the radius of the drug molecule.  The equation assumes a spherical particle, that is 
often influenced by Brownian motion, diffusing through a fluid of dynamic viscosity, with 
a low Reynolds number and at an absolute temperature (Kholodenko and Douglas, 
1995).  The Noyes-Whitney equation provides practical information relevant to the 
dissolution process and both the Noyes-Whitney and Stokes-Einstein equations reveal 
the parameters or factors that can affect the dissolution of a solute in a solvent. 
Consequently, dissolution may also be described as diffusion-controlled 
dissolution, according to the particle dissolution model derived from Wang and Flanagen.  
The model suggests that under sink conditions, the smaller the ratio of particle size to 
diffusion layer thickness, the greater the nonlinearity of the concentration-time profile 
(Wang and Flanagan, 1999).  It was found during the generation of the model, that the 
dissolution rate is dependent on the radius of curvature of the particle surface (Wang 
and Flanagan, 1999).  Another study emphasised the influence of particle shape on 
dissolution and found that the effect of particle shape on dissolution is particularly 
significant for particles that deviate from sphericity (Mosharraf and Nyström, 1995) 
Furthermore, dissolution may be described as a mixed-kinetic-controlled 
dissolution, in that the dissolution process is controlled by both the interfacial step and 
transport, according to Berthoud (Berthoud, 1912).  Berthoud viewed the interfacial step 
as an equivalent permeation process through an interfacial barrier.  However, it was 
realised that since all surface processes are lumped together into a single effective 
permeability coefficient, p, it does not provide a clear physical picture of the events 
occurring at the solid surface.  This led to the development of another mixed-kinetic-
controlled dissolution model, proposed by Rickard et al., who assumed that the interfacial 
reaction rate could be normalised with respect to the dissolving surface area (Rickard 
and Sjoberg, 1983).  Dissolution could also be described as an interface-controlled 
process.  This type of dissolution has little or no dependence on agitation type or 
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intensity, since fluid flow has no apparent effect on the interfacial step (Dokoumetzidis et 
al., 2008).  Dokoumetzedis et al. developed an interface-controlled dissolution model, in 
which the interfacial step was regarded as a reversible reaction.   
 
1.2.2 Factors that affect dissolution 
The therapeutic effect of an inhaled drug, following its deposition, is realised after 
its dissolution in the respiratory tract lining fluid and subsequent absorption into the blood 
circulation.  As explained in section 1.2.1, consideration of the Noyes-Whitney dissolution 
model and the Stokes-Einstein equation, and assuming diffusion-controlled dissolution, 
dissolution is driven by drug solubility (Cs), the surface area of the solid wetted by the 
dissolution fluids and the concentration of the drug in the surrounding liquid film, which 
in turn are governed by both the physical state of the inhaled compound and the 
thickness, composition, temperature and hydrodynamics of the lung dissolving media.  
Hence, dissolution is predominantly affected by interactions of all these variables. 
In terms of the physicochemical properties of the drug, solubility of the drug in the 
respiratory lining fluid is determined by its physical form, size, lipophilicity and 
solubilisation by present surfactants and its pKa, in relation to the lung lining pH profile 
(Mangal et al., 2018).  With respect to the physical form for example, the solubility of a 
crystalline polymorph or an amorphous compound is greater than the solubility of a 
molecular high-order crystalline state.  Different crystalline polymorphs tend to exhibit 
different solubilities to each other whereas, amorphous compounds generally have 
greater apparent solubility than the crystalline form.  This is due to the amorphous state 
being less thermodynamically stable (Freiwald et al., 2005).  Hence, formulating poorly 
aqueous soluble drugs into the amorphous forms has become a well-recognised 
approach to improving solubility, dissolution and the overall efficacy (Khadka et al., 
2014).   
In terms of particle size, it is well known that the smaller the size of the particles, 
the better the solubility and dissolution into fluids, since solubility is intrinsically related 
the particle size.  A small sized particle corresponds to an increase in surface area and 
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hence an increase in the dissolution rate, dm/dt, when referring to the Noyes-Whitney 
equation.  Based on this principle, particle size reduction has been one the oldest 
strategies to improving solubility of drugs, as it relies on safe methods and increases 
solubility without altering the chemical nature of the drug (Khadka et al., 2014).  However, 
for particles that exhibit large aerodynamic sizes, there have been attempts to reduce 
their mass density by making them porous, which can improve the deposition of the 
particles deeper within the lungs as well as its dissolution.  For example, in a study 
conducted by Edwards et al, it was found that particles with mean diameters exceeding 
5 µm and a mass density of less than 0.4 g/cm3, were inspired deep into the lungs 
(Edwards et al., 1997), and in a study by Khadka et al, the technique of producing porous 
particles, that exhibit low densities, has shown to improve the solubility of an inhaled 
solid and subsequently improve its dissolution, by means of providing large exposed 
surface area (Khadka et al., 2014; Zhou et al., 2017).  
The lipophilicity of a drug particle also affects its solubility and determines the 
extent of tissue affinity and whether an inhaled drug will have a more localised effect in 
the lungs or not (Tolman and Williams, 2010).  For example, formoterol, which has an 
intermediary lipophilicity is likely to be retained in the membrane and interact with the 
lung receptors in a rapid and prolonged manner (Anderson, 1993; Lötvall and Ankerst, 
2008).  Consequently, a more lipophilic salmeterol molecule is likely to be retained in the 
tissue for long periods, meaning it becomes less available for a rapid onset of action  
(Anderson, 1993).  This is because its lipophilicity results in very high partitioning of 
salmeterol in plasma membranes, very slow release from the membrane and very slow 
diffusion to the β2-receptors (Lötvall, 2001; Szczuka et al., 2009).  Although this present 
some advantages in terms of achieving a prolonged effect in the lungs, since the 
composition of the epithelial lung lining fluid is known to be mainly water, contributing 
96% to the fluid composition, it is important the inhaled drug exhibits relatively good 
aqueous solubility.  A highly lipophilic drug would inevitably present poor solubility in the 
lining fluid.  However, the lung lining fluid also consists of lipids and proteins which can 
increase the wetting, solubility and hence the dissolution of poorly soluble inhaled drugs 
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(Wiedmann et al., 2000).  The lung surfactants present can effectively enhance the 
solubility of small lipophilic drug molecules, and this has been demonstrated with a 
number of glucocorticoids and cationic compounds (Wiedmann et al., 2000; Liao and 
Wiedmann, 2003).   
With respect to pKa, it is defined as the pH at which the ionised and unionised form 
of a drug exists in equal concentrations (Peck et al, 2008).  If a solute is ionizable and/or 
a weak electrolyte, altering the solvent pH can affect the surface or saturation 
concentration, Cs.  Depending on the characteristics of the solute and solvent, this 
change can either increase or decrease Cs, causing either a decrease or increase in the 
concentration gradient and hence an increase or decrease in the dissolution rate, 
respectively.  For the ionizable solute, the pKa will determine its degree of ionisation 
which then influences the solubility of the drug in a fluid.  For a weak base for example, 
that exhibits a pKa value close to the physiological pH of the lung, it will have more 
molecules in the unionised lipid-soluble form, and hence have poor solubility in the lung 
lining fluid.  The more the drug is in its ionised form, it will have an improved solubility 
and hence improved dissolution in the lung media. 
In terms of the composition and hydrodynamics of the lung lining fluid, the 
dissolving media, its viscosity, temperature and movement speed properties very likely 
influence both solubility and dissolution of drug particles. Apart from the proteins and 
lipids present in the lung lining fluid that affect dissolution as mentioned previously, with 
regards to the dissolution media viscosity in general, it is well known that solutes will tend 
to dissolve more slowly in more viscous solvents.  According to equation (4), the diffusion 
coefficient, D, is in part related to the solvent viscosity.  The relationship is inversely 
proportional and hence, the diffusion coefficient decreases with increasing solvent 
viscosity with then decreases the dissolution rate as a result, considering equation (3).   
With regards to temperature and in relation to equations (3) and (4), as the solution 
temperature increases, the diffusion coefficient increases and hence so does the 
dissolution rate.  Practically, for many solids dissolved in media, the solubility increases 
because the increase in kinetic energy that comes with higher temperatures allows the 
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solvent molecules to break apart the solute molecules, that are held together by 
intermolecular forces, more effectively.  This exposes more solute molecules to the 
solvent, increasing the rate at which the solute dissolves.  Any added agitation and speed 
to the fluid would further introduce disturbances to the solute-solvent system.  Stirring 
distributes the solvent molecules around the solute more quickly and increases the 
chances of the solute encountering the solvent, influencing the dissolution.  The stirring 
rate has shown to affect the dissolution rate by virtue of the thickness of the diffusion 
layer of the particle (Ahuja and Scypinski, 2001); it decreases the thickness of the 
unstirred/stagnant layer, decreases the diffusion gradient, d, and hence increases the 
dissolution rate, dm/dt, inevitably. 
 
1.3 The need for a dissolution test for OIPs 
1.3.1 Current regulatory requirement for OIPs 
The European Medicines Agency (EMA) issued guidelines describing the steps 
that need to be taken to approve a generic inhalation drug product and demonstrate 
therapeutic equivalence between two inhaled products (EMA, 2006).  With regards to 
the formulation, the test and reference product must have the same active substance 
and identical dosage form.  The pharmaceutical performance and safety profile of the 
inhaled product should be maintained and not influenced by differences in crystalline 
structure and/or qualitative differences in excipients.  With regards to the device, the 
handling and resistance to airflow of the test and reference product should be identical.  
To assess the in vitro equivalence between the test and reference product, the key 
quality attributes are the dose delivery uniformity and particle size distribution profile, 
with a similar delivered dose.  If the test product or generic product satisfies the 
pharmaceutical criteria enlisted, the use of only in vitro data may be considered 
acceptable for product approval.  
In vitro dissolution testing is well established for solid oral dosage forms, as both a 
quality control test model and a predictive model to establish in vitro-in vivo correlation 
34 
 
(IVIVC) between in vitro dissolution data and pharmacokinetic data (Fotaki et al., 2009; 
Fotaki and Vertzoni, 2010).  Evidently, in the case of orally inhaled products (OIPs), the 
only requirements by the regulatory guidance are to assess the dose content uniformity 
and the aerodynamic particle size distribution (APSD) (US FDA CDER, 1998; EMA, 
2006).  Otherwise, in vivo studies would need to be carried out to understand the 
pharmacokinetics or pharmacodynamics of the product and substantiate equivalence.  
However, these approaches come with their limitations.  These in vitro tests have shown 
to not fully predict the in vivo performance of the product, and the methods available to 
evaluate APSD does not have a direct relationship to pulmonary deposition profile 
(Newman and Chan, 2008).  This is because in vitro methods do not reflect the realistic 
oropharyngeal geometry or inhalation manoeuvres but assumes the in vitro data can 
predict in vivo performance.  The currently recommended tests do not account for the 
potential impact of dissolution rate on the clinical performance of an inhaled drug (Forbes 
et al., 2015). 
Since the dose of OIPs delivered to the patients is variable and dependent on the 
patient’s inhalation techniques, disease state as well as the characteristics of the device 
itself, it makes it difficult to develop a suite of tests to demonstrate the effectiveness of 
OIPs in vitro.  Hence, requirements for demonstrating the quality or equivalence of these 
products is still an evolving area of research. OIPs present unique challenges for in vitro 
testing and characterisation of the aerosol cloud generated and delivered by these 
devices.  The advisory panel of USP has concluded in the past that dissolution is not 
necessarily ‘kinetically and/or clinically crucial’ for the approval of OIPs (Gray et al., 
2008).  However, data has emerged to question whether dissolution should be used as 
a key quality attribute for current inhaled products (Davies and Feddah, 2003; Son and 
McConville, 2009; Arora et al., 2010; May et al., 2012; Rohrschneider et al., 2015).  
Dissolution has proven to be useful and is already used widely in the pharmaceutical 
industry, for the optimisation of formulations, and for the development of quality control 




1.3.2 Applications and principles of a dissolution test 
An in vitro dissolution test may provide a means for establishing quality criteria and 
inform the development and regulation of both generic and innovator products.  As a QC 
tool, dissolution has the potential to provide inhaled pharmaceutical product quality 
information, helping identify formulation factors that influence the bioavailability of an 
active pharmaceutical ingredient (API) from the inhaler.  It could also be used to follow 
up any post-approval changes to products such as changes in manufacturing site or 
process, allowing for the identification of critical manufacturing variables.  Dissolution 
testing as a QC tool could assess quality during scale-up and production of batches, 
demonstrating any consistency or inconsistency in product manufacturing (Anand et al., 
2011).  It could be used to support bioequivalence of an equal inhaled product for 
example, by demonstrating similarity between different product formulations of an active 
substance or a new or essentially similar product, and the reference medicinal product 
(Anand et al., 2011). 
Examples where the QC dissolution test would be useful, is for the comparison of 
formulation types, e.g. aerOsols delivered via dry powder inhalers (DPIs) with those 
delivered via the pressurised metered dose inhalers (pMDIs).  This would provide an 
indication on whether the inhaled drug is delivered in the same physical form or not and 
hence, whether manufacturing an inhaled product in the form of a DPI or a suspension 
pMDI or solution pMDI has any influence on dissolution performance in vivo (Forbes et 
al., 2015).  This is because unlike for the DPI, where the actual solid particle structures 
within the inhaler deposit on the lung mucosal surface, the drug particles dissolved in the 
propellant in a solution pMDI, generate a new solid phase due to the precipitation of the 
non-volatile solvent upon activation of the device.  A study has previously demonstrated 
a difference and found that presence of glycerol as a non-volatile solvent significantly 
decreases the dissolution rate of beclomethasone dipropionate in vitro (Grainger et al., 
2012).  Dissolution testing can also potentially help determine whether presence of a 
second drug in a combination inhaler influences the dissolution of the first API (Buttini et 
al., 2014).  For example, new formulations are being developed for triple therapy for 
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inflammatory lung disease or for the administration of antibiotic combinations for 
synergistic antimicrobial effects and dissolution testing can potentially address issues 
such as whether interaction between individual particles of two or more drugs occurs 
during product storage (Buttini et al., 2014). 
With regards to clinical tests, both pharmacokinetic and pharmacodynamic studies 
are often components of OIPs bioequivalence studies, to help ensure equivalence in the 
safety and efficacy between a test and the reference inhalation product.  Such studies 
would ensure that the pulmonary and systemic exposure i.e. the rate and extent of drug 
availability at the site of action and in the systemic circulation, are confirmed in an in vivo 
situation.  It seems many regulatory agencies have currently put strong emphasis on PK 
and PD data because IVIVC correlations are not yet fully developed for OIPs.  Hence, 
developing a dissolution tool to help establish IVIVC becomes necessary, since it allows 
the use of in vitro assessments as substitutes for such expensive time-consuming in vivo 
studies.  Although it may seem ambitious to attempt to reproduce the lung environment 
faithfully, the need for a physiological representative in vitro method to evaluate the 
bioavailability of inhaled drugs has become apparent (Forbes and Ehrhardt, 2005).  In a 
study conducted on solid oral dosage forms, dissolution testing using the biorelevant 
media, Fasted- and Fed – state simulated intestinal fluid (FaSSIF and FeSSIF), 
demonstrated clear improvements in establishing the IVIVC versus the compendial 
media (Sunesen et al., 2005; Okumu et al., 2008).  Consequently, in studies conducted 
by Vertzoni and Fotaki et al, where they tested various aspects of dissolution media 
simulating the intralumenal composition of the small intestine, although it was found that 
using non-physiologically relevant buffers may be inevitable in some cases, there were 
certain components that must be necessary in the media for biorelevant purposes and 
to reflect the physiology as well as to predict the in vivo performance successfully 
(Vertzoni et al., 2004; Fotaki and Vertzoni, 2010).  This emphasised that development of 
an IVIVC tool for OIPs would require the design and application of a more biorelevant 




Dissolution testing would also help in developing a Biopharmaceutics Classification 
System (BCS) for OIPs.  There is currently one in place for oral immediate release drugs, 
utilised by Research and Development (R&D) scientists and regulators to streamline 
product development (Hastedt et al., 2016).  This approach considers a combination of 
drug physicochemical properties and physiological properties with respect to their oral 
administration, and is based on three in vitro parameters: dose, dissolution and 
absorption (Hastedt et al., 2016).  A classification system, if fully developed, would 
certainly be useful for formulators and discovery scientists.  Hence, there is huge interest 
in applying a similar principle or system to OIPs, with the current focus being on the 
dissolution of drugs in the lung.  The dissolution of inhaled powders is a very crucial 
component of the BCS system, and so a standardised test methodology should be 
carefully considered.  
According to the pharmacopeia and US FDA CDER (US FDA CDER, 1997), which 
defines the standards in which dissolution testing must be assessed, to conduct a reliable 
test, the dissolution apparatus reproduces the key in vivo environmental features.  Since 
the aim is to evaluate how a product will dissolve in a physiological setting, the test should 
ideally be carried out at body temperature (37°C) and the aqueous based medium should 
exhibit a pH of 5 to 7.  For a poorly soluble drug, it is a requirement to modify the medium 
in such a manner that it solubilises the drug but remains physiologically relevant.  A fixed 
practical volume of medium is important, sufficient to dissolve the amount of drug 
released from the product and hence maintain ‘sink conditions’ for the quantitation of the 
drug.  Another principle method development consideration is how to reproducibly 
present the particles to the dissolution test apparatus.  This is because inhalation 
powders may deposit aggregated clumps of particles due to the electrostatic interactions 
in one instance, and free separate particles in another (Finlay, 2001).  Consequently, the 
test should overall be robust, simple and easy to conduct as well as capable of 
discriminating between different drugs and inhaled formulations.  A summary of the 








1.4 Challenges with developing a dissolution test for OIPs 
1.4.1 Challenges associated with the geometry of the human respiratory tract 
The challenge with assessing dissolution in the lungs stems predominantly from 
the complexity of the human respiratory tract geometry, making it difficult to replicate 
such an environment on an in vitro system.  It has been recognised that the very small 
lung fluid (VLF) available for particle dissolution, 10-30 mL, is a significant limitation since 
it is likely to be stagnant, and this can inhibit dissolution (Patton et al., 2010).  Considering 
that a clinically relevant dose of an inhaled drug, such as poorly soluble fluticasone 
propionate, would require excessive volumes for a complete dissolution in stationary 
liquid, assessment of its dissolution in vitro would not be accurately represented. 
The surface-lining layer in the alveoli consists of numerous endogenous 
surfactants such as phosphatidylcholine (DPPC).  Surfactants influence dissolution by 
increasing the wetting of poorly soluble drugs and as a result, increasing their dissolution 
rate.  However, it has been recognised that the exact composition of the lung aqueous 
fluids and surfactants is not accurately established (Marques et al., 2011) and the 
preparation of DPPC solutions is perceived to be difficult, since it may be lengthy and 
variable.  Furthermore, the clearance mechanisms in the upper and lower lung, as 
discussed in section 1.1.3, provide physical and chemical barriers to particle diffusion 
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and dissolution, making it difficult to reliably reflect their dissolution in vitro.  In addition 
to this, unlike the gastrointestinal tract in which dissolution is described as a ‘continuous 
process’ over a sequence of tanks (Yu et al., 1996), the lung constitutes several different 
dissolution processes occurring in parallel, which is very difficult to consider when 
developing an in vitro dissolution test. 
 
1.4.2 Challenges associated with the patient 
In addition to the challenges listed in section 1.4.1, the specific relationship 
between dissolution and pharmacokinetic or pharmacodynamic data for OIPs is difficult 
to evaluate due to these being product or patient-specific.  It is dependent on factors like 
the inhalation manoeuvre, inspiratory flow profile and the physiology and anatomy of the 
lung.  The lung physiology tends to vary amongst a target population for example, their 
pulmonary disease state, whether severe or moderate, or treated condition, whether it is 
asthma or COPD.  A study indicated clear lung physiological changes occur with aging; 
the alveoli dilate, the airspaces in the lungs enlarges and there is a general decrease in 
the exchange surface area and loss of supporting tissue for peripheral airways, which 
results in a decreased static elastic recoil of the lung and increased residual volume and 
functional residual capacity (Janssens et al., 1999).  With regards to disease state, an 
asthmatic lung tends to have an increased amount of mucus, because as the airways 
become irritated and inflamed, the cells produce more mucus.  The principle defect in 
asthma is the occlusion of the airway lumen by liquid, fibrin and the built-up mucus.  The 
airways also become smaller as there is a general loss of lung volume, as a direct 
response to muscle tightening (Irvin and Bates, 2009).  With regards to COPD, chronic 
expiratory flow limitation, hyperinflation and inspiratory muscle weakness are its 
mechanical hallmarks, with hyperinflation varying between chronic and acute airway 
obstruction (Scano et al., 1999).  Inspiratory muscle weakness leads to significantly lower 
aerosol penetration into the lungs, in comparison to a healthy lung, decreasing the depth 
of inhaled particle deposition and hence influencing the rate of dissolution of the inhaled 
drug; drugs deposited in the central airways dissolve in the fluid at a much slower rate 
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due to the presence of mucins and the increase in lung fluid viscosity in comparison to 
the peripheral airways (Labiris and Dolovich, 2003).  Bronchial obstruction further 
modifies the deposition and distribution patterns of aerosols, affecting the rate and extent 
of dissolution of the inhaled drug.  Again, the aerosolized drug becomes deposited more 
centrally in the lungs by inertial impaction compared with the uniform distribution 
achieved in the normal lung, influencing the therapeutic effectiveness of an inhaled drug 
(Labiris and Dolovich, 2003).  Attempting to develop a standardised dissolution test to 
account for all these factors would be particularly challenging. 
 
1.4.3 Challenges associated with experimentation 
An important aspect to consider when developing a standardised method 
applicable to the lungs, is the challenges involved with sample preparation.  To maximise 
the probability of generating data reflective of in vivo pulmonary dissolution, the test 
method requires the collection of the relevant respirable fraction of the aerosol dose 
emitted from the inhaler device i.e. collection of the particles with an aerodynamic size 
of 1-5 µm.  The use of aerosol fractionation to prepare samples for dissolution testing 
compared to sampling the entire respirable fraction, may affect outcomes and influence 
the discriminatory power of the dissolution method (Forbes et al., 2015).  Consequently, 
for DPIs for example, the micronized API is blended with larger carrier lactose particles 
which requires detachment before conducting the dissolution test. The presence of very 
fine particles and the characteristics of the electrostatic powder within the inhaler may 
cause experimental difficulties (Telko and Hickey, 2005).  For pMDIs, the drug is often 
suspended within propellant and therefore to collect the desired particles, the product 
would need to be fired into an apparatus where the particles can dry prior to their 
deposition on the collecting system (Labiris and Dolovich, 2003). 
Consequently, the apparatus used to develop the dissolution test can present 
challenges since they do not entirely mimic the in vivo lung environment.  For example, 
the Transwell® dissolution technique relies on a polyester, or other semi-permeable 
membranes attached to the transwell insert, to collect the respirable fraction of the 
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aerosol and provide a diffusion restriction (Arora et al., 2010).  This will be described in 
more detail in section 1.6.  Another example, is the Rotating Paddle methodology which 
relies on the Next Generation Impactor (NGI) to collect the respirable fraction.  Using this 
technique, the dissolution rate has shown dependence on drug loading, since the 
particles tend to accumulate under the air jets, and this causes poorly reproducible 
results (Son and McConville, 2009; Son et al., 2010).  Consequently, although the 
rotating paddle method uses substantial amount of media, ensuring sink conditions could 
be maintained, it does not reflect the limited amount of volume provided by the lungs, to 
allow for particle dissolution.  This will also be discussed in more detail in section 1.6. 
Furthermore, there is no standard dissolution medium that can be applied to the 
proposed dissolution methods for OIPs, presenting a further challenge.  There are a huge 
variety of fluids that have been utilised to mimic or simulate the lung lining fluid, causing 
a general confusion as to what medium should be used.  This will be discussed in section 
1.7. 
   
1.5 Dose collection methods available for OIPs 
Despite the challenges and obstacles described above, several in vitro approaches 
of aerosolisation and inhaled dose collection have been proposed and evaluated for use 
in dissolution testing of OIPs. 
 
1.5.1 NGI and ACI 
Approaches used to collect the aerosolised particle fractions include using 
multistage impactors such as the Next Generator Impactor (NGI) and the Anderson 
Cascade Impactor (ACI).  Both apparatus are incorporated into the US and European 
Pharmacopoeia for measurement of the aerodynamic size of pharmaceutical inhalation 
aerosols (Mitchell and Roberts, 2012).  Generally, the particles impact on a dry surface 
and by modifying the geometry of the nozzle, they divide the emitted dose from the 
inhaler product into several fractions according to the particle aerodynamic size.  The 
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primary advantage offered by these techniques is that they allow determination of an 
assay for the fine particle fraction and other size fractions and provide differentiation 
between the API and any other components in the formulation (Mitchell and Roberts, 
2012).  Hence, such techniques would ensure that the FPF is targeted for dissolution. 
However, there are several limitations associated with these methods as dose 
collection methods for dissolution, which includes the difficulty in attempting to insert a 
collecting membrane into an impactor without affecting the air flow condition inside the 
instrument.  Also, repeated actuations of the inhaler device are necessary to ensure the 
same amount of drug is captured from the different formulations.  This is widely 
recommended, especially when the purpose of the study is to compare the kinetics of 
release from the different formulation types, since the amount of drug loading on the 
collecting surface may significantly influence the drug release and dissolution rate, 
especially for hydrophobic APIs (Forbes et al., 2015).  However, when repeated doses 
are actuated, a powder bed is formed, and the thickness of the bed can influence the 
release rate of the molecules.  In the case of impactors, rather than particles depositing 
evenly over the collection surface, powders may collect in clusters below the nozzle.  To 
correct this, some modifications to the system have been attempted such as designing 
a membrane holder to be incorporated into the NGI for the collection of the API dose, 
positioning particulate filters in certain stages of the NGI to avoid capturing the coarse 
carrier particles when analysing DPIs (Mees et al., 2011) or mounting a glass microfiber 
filter on the end of the induction port of an ACI to form a greater surface area for the 
collection of the aerosolised particles (Davies and Feddah, 2003).  When such 
modifications have been applied improvements in dissolution profiles were evident (Son 
and McConville, 2009; Son et al., 2010). 
 
1.5.2 TSI and FSI 
Another approach is collecting particles deposited onto a liquid surface via a 
Fasted Screening Impactor (FSI) or Twin Stage Impinger (TSI), where they separate 
aerosols into two fractions according to the aerodynamic size.  Essentially for both 
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methods, the collection stages are kept moist with a solvent to prevent impacted particles 
from re-entraining in airstream.  Based on proven NGI preseparator technology, the FSI 
represents a purpose-made approach that segregates the dose into coarse particle mass 
(CPM) and fine particle mass (FPM) and uses the same induction port as the NGI.  The 
TSI however,  operates on the principle of liquid impingement to divide the dose emitted 
from the inhaler into respirable and non-respirable fractions, where the non-respirable 
dose that impacts on the oropharynx and is subsequently swallowed, is reflected by the 
back of the glass throat and the upper impingement chamber, and the respirable dose 
that penetrates the lungs, is collected in the lower glass impingement chamber.  These 
techniques are considered relatively easy to use and assemble. 
A limitation to these methods however relative to dissolution of OIPs, is that since 
they do not collect dry particles for introduction into the dissolution experiment, they are 
not useful for collecting aerosol particles for this purpose without modifications to the 
collection modality (Buttini et al., 2013).  Nevertheless, the advantages of the impinger 
system include its usefulness in capturing aerosol particle sizes reflective of the entire 
respirable dose and if the collection stages are moist, they simulate realistic impaction 
processes of particles on the liquid lining of the lungs.  The TSI for example, has been 
adapted for the collection of drug particles from solution metered dose inhalers in a 
number of studies, and its performance in particle collection has been well documented 
(Grainger et al., 2012). 
 
1.5.3 PreciseInhale® 
The PreciseInhale is a bespoke aerosol generator and particle collection method, 
developed by Inhalation Sciences in Sweden (Gerde et al., 2017).  It provides an 
exposure platform to collect the aerosolised powder on glass coverslips and has the 
advantage of simulating human breath using an automated system.  A jet of high 
pressure air is shot through the powder chamber, aerosolising the powder upwards into 
the holding chamber, in a plume, then settles downwards in the holding chamber where 
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a controlled air flow ‘pulls’ the API past a real-time aerosol monitor.  The real-time aerosol 
concentration and dose is logged, and the exposure is automatically calculated.   
Despite the advantages of the PreciseInhale system, it does not separate the non-
respirable fraction from the respirable fraction i.e. it does not entirely ensure that only 1-
5 µm sized particles are collected on the platform.  This often leads to collection of the 
coarse particles which are then taken further into the dissolution experiments, using the 
complimentary DissolvIt® system.  This has led to modifications by the team at Hovione, 
where they studied the influence of a newly designed pre-separator on the particle 
collection (Noriega et al., 2017).  A schematic diagram of this system is shown in chapter 
4, figure 4.1. 
 
1.6 Dissolution techniques available for OIPs 
Using convenient dose collection techniques as a starting point, multiple 
dissolution techniques have been used in an attempt to create a suitable dissolution 
testing system for OIPs.  For example, a study by McConville et al., (McConville et al., 
2000), was one of the first to employ a modified twin stage liquid impinger to disperse 
the inhaled powder onto an air-liquid interface and evaluate the dissolution of the inhaled 
drug in a specially designed dissolution reservoir.  The dissolution system was not 
configured to specifically mimic the environment of the lungs.  The powder particles that 
were <4.7 µm impinged on an air-water interface, presenting the fine particle mass for 
dissolution.  In another study by Salama et al., a modified Franz diffusion apparatus was 
used that incorporated a heated membrane holder at its surface and a heated dissolution 
reservoir containing phosphate buffered saline (Salama et al., 2009).  Prior to this, 
Davies and Feddah reported using an NGI apparatus with a filter positioned to collect 
the aerosol powder at the base of the USP throat (Davies and Feddah, 2003), which was 
then sealed into a flow-through holder and a HPLC pump was used to pump the 
dissolution media through the filter.  The technique used the oversized powder fraction, 
dispersed with the fine powder fraction.  In a study by Jaspart et al., the aerosol powder 
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was sealed within a filter membrane and immersed within the basket of a USP type 1 
dissolution method (Jaspart et al., 2007), which demonstrated limitations in contact area 
between the particles and the media. 
Predominately, the dissolution apparatuses that have been reported to date are 
the compendial (USP 2) paddle apparatus, the flow-through apparatus, diffusion-
controlled cell systems, namely the Franz cell or Transwell® system, and the DissolvIt® 
system which is a module designed to interface with the PreciseInhale® aerosol delivery 
system.  These techniques are discussed below. 
 
1.6.1 USP 2 paddle apparatus 
The paddle apparatus involves a cylindrical glass vessel with a paddle rotating at 
a speed of typically 50 or 75 rpm.  The dosage form should remain at the bottom of the 
vessel and therefore, a ‘sinker’ such as a membrane cassette containing the membrane 
in which the inhaled dose is collected via an impactor, is used.  In the case of paddle 
over disk, a stainless support disk is placed under the paddle and the membrane filter 
used to collect the respirable fraction can be directly positioned on top of the support 
(Son et al., 2010). 
The main advantage of this technique is that it is a standard USP 2 apparatus, 
which can be used in conjunction with different types of aerosol particle collection filters 
in different filter holders placed into the vessel (May et al., 2012).  However, the main 
limitation is the large volume of dissolution medium required, at least 300 mL, making it 
difficult to develop such a method if more complex dissolution media are used that are 
not available in such quantities.  For reproducibility, unless the particle collector can be 
orientated consistently in the bath, its orientation could influence the contact area of the 





1.6.2 Flow-through cell apparatus 
The flow-through cell systems used for OIPs are referred to as a modified USP 4 
apparatus (European Pharmacopoeia, 2012).  The system consists of a cylindrical cell 
with a filter placed at the top, to prevent the escape of any undissolved products, as the 
dissolution medium is pumped through the cell from a reservoir.  The bottom of the cell 
is filled with small glass beads in which the membrane used to collect the particles form 
the inhaler, is placed on or within the beads.  The drug concentration is measured either 
directly in the flowing system or via the collection of samples from the cell exit.  A 
schematic diagram of the modified flow through cell is shown in Figure 1.2. 
Advantages of this method include the reduced influence of diffusion during 
dissolution testing and its suitability for poorly-soluble drugs since ‘sink’ conditions can 
be maintained due to the high volume of dissolution media pumped through.  However, 
due to the geometry of the system, any air entrapment can potentially interfere with 
wetting and dissolution (Colombani-Dauvergne et al., 2006). 
 
Figure 1. 2. A schematic diagram of the Flow Through Cell dissolution system.  
Adapted from May et al., (May et al., 2012)  
 
1.6.3 Diffusion-controlled systems 
In the diffusion-controlled systems, the drug transfers between two compartments 
separated by a semi-permeable barrier.  For dissolution of inhaled products using the 
Franz cell, a semi-permeable membrane with the test formulation has been added to the 
donor chamber and the receptor medium is stirred and heated to 37°C with samples 
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collected through a sampling arm in the receptor side of the cell.  In the Transwell® 
apparatus, a membrane filter with the deposited drug collected from the NGI for example, 
can be placed on top of the insert membrane or alternatively the respirable fraction can 
be directly deposited onto the insert membrane, using the TSI for example. 
A limitation to these methods is the inability to distinguish between the diffusion 
effects through the membrane and the dissolution rate (Arora et al., 2010).  However, a 
principle advantage of such systems is the very low volume of dissolution medium on 
the donor chamber in comparison to the receptor chamber, which offers the opportunity 
to mimic the limited lung lining fluid volume, providing an environment more reflective of 
the lung lumen.  Some investigators have developed this system further to use the 
Transwell membrane to support culture respiratory cell monolayers, providing more 
mucosal-like conditions for the deposited particles to dissolve in, thus mimicking the lung 
permeability barrier that drugs must permeate, prior to their dissolution (Fiegel et al., 
2003; Forbes et al., 2003; Grainger et al., 2009).  These advantages open a greater 
opportunity to develop a biorelevant methods for IVIVC purposes. 
 
1.6.4 Dissolvit® 
The DissolvIt system is an in vitro model designed to incorporate features reflective 
of the absorption and dissolution processes of respirable particles in the lungs.  Aerosol 
particles are deposited on a glass surface via the PreciseInhale, then brought into 
contact with a simulated lung/airway mucus, represented by a polyethylene oxide gel. 
Dissolution (solid particle disappearance) is studied from the ‘lumenal’ side by optical 
microscopy and ‘permeated drug’ is quantified from the ‘vascular’ side by chemical 
analysis of the flow-past perfusion medium.  The system is thermostatted at 37°C.  It 
consists of a dissolution chamber, a precision-controlled peristaltic pump and an inverted 
microscope with a camera.  The dissolution chamber is perfused in single-pass mode, 
after which the perfusate is collected in an automated fraction collector into a deep-well 
plate for analysis. 
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A key advantage of the system is that it simulates the physiological conditions in 
the lung more closely in comparison to the other methods and allows for monitoring of 
both permeation and dissolution processes.  The optical microscopy shows real-time 
dissolution of particles and the programmable Fraction Collector allows for flexible 
sampling.  The system provides in vitro-predictive PK data for the inhaled drug analysed, 
providing parameters such as the Cmax and Tmax, giving a greater insight into the 
critical coupling between dissolution and absorption for sparingly soluble drugs in the 
lungs for example (Gerde et al., 2017).  However, a limitation to the system is the 
DissolvIt represents a 60 µm air-blood barrier, simulating the absorption kinetics in the 
trachea and larger bronchi rather than the thinner barriers in the rest of the bronchi and 
alveoli.  Therefore, when used as a general tool for lung dissolution, the DissolvIt likely 
overestimates the half-life of retention for the test formulations (Gerde et al., 2017).  A 
schematic diagram of the system is shown in chapter 4, figure 4.1. 
 
1.7 Dissolution media 
A critical factor in dissolution testing, is the dissolution medium, the selection of 
which strongly depends on the purpose of the study and the compound investigated.  For 
routine QC purposes, using simple dissolution media such as methanol and water, are 
preferred over complex media due to their higher reproducibility, lower costs and ease 
of preparation (Marques et al., 2011).  However, for prediction and modelling purposes 
using medium as close to the biological fluid is preferred. 
The epithelial lining fluid is the first physical interface with which aerosolised drugs 
come into contact in the airways.  It is the biological fluid in which the aerosolised drug 
dissolves, before absorption into the lung tissue.  The composition and properties 
attributed to the lining fluid vary greatly along the respiratory tract and can also vary 
markedly in different airway pathologies (Bicer et al., 2012).  For example, the large 
airways possess periciliary layer and gel mucus layer, consisting of water with 
antibacterial factors, ions, mucins and heparin sulphate (Rubin, 2014).  The lung lining 
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fluid of the alveolar region however, is composed of a watery layer, known as the 
hypophase, and surfactants (Fehrenbach, 2001).  The hypophase contains a range of 
surfactant proteins, complement proteins and antioxidants (Kobzik, 2007).   
Although the composition of the lining fluid has been documented, the exact 
concentrations are generally subject to speculation (Cheng et al., 1997; Son and 
McConville, 2009; Marques et al., 2011).  A wide range of dissolution media have been 
proposed for use for the dissolution testing of OIPs.  They have ranged from simple 
aqueous fluids, buffered in the pH range of 6.8-7.4, such as water or phosphate buffered 
saline (PBS), representative of physiological electrolyte levels, through to fluids 
consisting of certain proteins or lipids.  The medium used is also often supplemented 
with surfactants such as DPPC or co-solvents, particularly when analysing poorly soluble 
API, since they tend to significantly influence the dissolution rate (Davies and Feddah, 
2003; Son et al., 2010).  It was hypothesised that data obtained from using such 
surfactant-containing media most likely replicate the effect lung surfactants would have 
on inhaled particle in vivo.  However, with regards to biorelevance, the highly abundant 
proteins, composing the aqueous component of the fluid are often not included.  Other 
media that have been tested include the commercially available surfactant preparations 
or diluted surfactant replacement products, used for the treatment of respiratory distress 
syndrome in neonates, such as Alveofact®, Exosurf®, Curosurf® and Survanta®.  These 
are used clinically as well as applied for in vitro investigations (Pham and Wiedmann, 
2001; El-Gendy et al., 2013).  The main limitations of these fluids is that they are 
expensive, and hence are often used in their diluted forms, and they only represent the 
surfactant component of distal respiratory tract lung lining fluids. 
Another medium used to represent lung fluids in dissolution tests is Gamble’s 
solution.  This solution has been designed to model interactions of the particles with 
interstitial lung fluids and evaluate the bio-accessibility of aerosol inhaler products 
(Davies and Feddah, 2003).  However, limitations to the preparation of such solution 
include the likelihood of salt precipitation if components were not added in the correct 
manner, and the solution often uses citrate instead of proteins to avoid foaming and use 
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acetate instead of organic acids, deviating from the original components of the lung lining 
fluid.  Some researchers have attempted to modify Gamble’s solution by including 
proteins and other organic components.  However, it was found that addition of proteins 
can affect reproducibility of results due to putrefaction in the lab (Takaya et al., 2006). 
Although some of the media currently available and being used in dissolution 
testing have some physiological relevance, they do not fully simulate the epithelial lung 
fluid.  In some cases, the fluid presents a low buffering effect, making them unsuitable 
for formulations that show pH dependency or sustained release dissolution profiles.  For 
example, it was observed for one of the proposed DPPC-containing fluid, that the pH 
increased in 24 h from 7.4 to 8.8 (Son et al., 2010).  Consequently, in the study by Son 
et al., (Son et al., 2010), the dissolution profiles of budesonide in phosphate buffer pH 
7.4 were similar to the ones obtained in their version of simulated lung fluid, indicating 
that the version of simulated lung fluid used in the study much closely resembles a simple 
PBS solution rather than truly simulating the RTLF.  Furthermore, for fluticasone 
propionate and beclomethasone dipropionate, the solubility values in water were 
unaltered from those in PBS (Arora et al., 2010). 
These limitations suggest there may be a need to develop a ‘fit for purpose’ 
simulant that possesses physiological relevance to simulate the in vivo epithelial lung 
fluid.  For such a fluid to find sufficient application to evaluate its advantages and 
usefulness it would have to fulfil criteria of being able to be manufactured in a simple, 
standardised and cost-effective manner. 
 
1.8 Comparison of dissolution profiles 
The comparison of dissolution profiles is a critical test for assessing the 
performance of many drug products (Solid and Dosage, 1997).  It can help establish the 
similarity of the pharmaceutical dosage forms, for which composition, manufacture site, 
scale of manufacture and the manufacture process or equipment may have changed 
within defined limits. 
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Graphical method is the first step in comparing dissolution profiles and is easy to 
implement (Leblond et al., 2016).  It is the method of plotting a graph of time versus 
concentration of drug in the dissolution medium and comparing the dissolution pattern 
and concentration of drug at each point.  If two or more curves are overlapping then the 
dissolution profile is comparable however, if the difference is small, then it is acceptable 
but higher differences indicate that the dissolution profile is not comparable. It is very 
difficult to make definitive conclusions from the graphical method.  Therefore, dissolution 
profiles of two pharmaceutical products can be compared by other methods such as 
statistical t-Test or ANOVA-based methods, via multivariate ANOVA, multiple univariate 
ANOVA and the level and shape approach or by various model independent methods 
such as comparing the mean dissolution time, the similarity and difference factor and 
sampling time or by model-dependent approaches.  Table 1.3 lists the methods that can 
be applied to compare dissolution profiles. 
 





1.8.1 Statistical approaches 
One of the statistical approaches that can be applied is the student’s t-test (Leblond 
et al., 2016).  The two tests commonly used are the paired t-test and unpaired t-test.  It 
is calculated using equation 5: 
t = D/SE                                                                                                                   (5) 
where D is the mean difference and SE is standard error.  The calculated t value is 
compared with tabulated value of t and if the magnitude of difference between the two 
gives a p<0.05, then the null hypothesis should be rejected and vice versa. 
In terms of the ANOVA method, the test is generally applied to different groups of 
data where the variance of different groups of data is compared and a prediction is made 
on whether the data is comparable or not.  A minimum of three sets of data are required 
and first the variance within each individual group is found then compared with each 
other. These approaches are relatively easy to apply and provide detailed, discriminative 
information between dissolution profiles and data. 
 
1.8.2 Model-independent approaches  
Flanner and Moore proposed the model-independent mathematical approach to 
compare dissolution profiles (Flanner and Moore, 1996).  The model-independent 
approaches can be classified into two groups: Ratio test procedures and Pairwise 
procedures (Costa and Sousa Lobo, 2001).  Example of ratio test procedures are ratio 
of percent dissolved, ratio of area under the dissolution curves and ratio of mean 
dissolution time.  Pairwise procedures include the Difference factor (f1) or the Similarity 
factor (f2).  Both procedures compare the dissolution profiles of a pair of products and 
employ a 90% confidence interval approach.  The difference factor calculates the percent 
difference between the two dissolution curves at each time point and is a measurement 
of the relative error between the two curves.  It is determined using equation 6: 
f1 = (∑ |𝑹𝒕 − 𝑻𝒕|𝒏𝒕=𝟏  / ∑ 𝑹𝒕
𝒏
𝒕=𝟏 ) x 100                                                                          (6) 
Where n is the number of dissolution sample time points, t is the time sample index, and 
Rt and Tt are the individual or mean percent dissolved at each time point for the reference 
53 
 
and test dissolution profiles respectively.  A calculated value of zero for f1 indicates that 
the profiles of the test and reference are identical.  As the value increases from zero, 
dissimilarity between the two profiles increases, and usually a value of 15 or below 
suggests similarity (Costa and Sousa Lobo, 2001). 
The similarity factor is a measurement of the similarity in the percent dissolution 
between the two dissolution curves and is determined using equation 7: 
f2 = 50 x log {[1 + (1/n)∑ 𝑹𝒕𝒏𝒕=𝟏 − 𝑇𝑡)
2]-0.5 x 100}                                                   (7) 
The f2 values are between 0 and 100, and if the calculated value is greater than 50, the 
test and reference profiles are considered similar.   
The similarity factor is gaining popularity due to its recommendation by a number 
of regulatory authorities, such as the FDA, as a criterion for the assessment of similarity 
between dissolution profiles (Costa and Sousa Lobo, 2001).  Advantages of this method 
is that they are easy to compute and interpret, it is the most widely used method to 
compare dissolution profiles and they provide a single number to describe the 
comparison of dissolution profile data.  Consequently, they directly compare the 
dissolution data without having to rely on model functions that may prove to be artificial.  
However, the values of f1 and f2 are sensitive to the number of dissolution time points 
used i.e. it is a more appropriate method when more than three or four dissolution time 
points are available.   
 
1.8.3 Model-dependent approaches 
There are many different types of model-dependent approaches that can be 
applied to compare dissolution profiles.  Examples of these models are Zero-order, First-
order, Hixson-Crowell, Higuchi, Korsmeyer-Poppas, Weibull, Gompertz, Baker-Lonsdale 
and Hopfenberg model. 
For the zero-order kinetics, a plot of cumulative amount of drug dissolved versus 
time is made.  The model can be expressed by equation 8: 
Qt = Q0 + K0t                                                                                                          (8) 
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Where Qt is the amount of drug dissolved in time t, Q0 is the initial amount of drug in the 
solution and K0 is the zero-order release constant expressed in units of 
concentration/time.  The release mechanism associated here is a constant release rate.  
The model often represents drug dissolution from pharmaceutical dosage forms that do 
not disaggregate and releases the drug slowly and is often applied to transdermal 
systems and modified release dosage forms such as matrix tablets with low solubility 
drugs.   
For the first-order kinetics, a plot of log concentration of drug remaining versus time 
is made, yielding a straight line with a slope of -K/2.303.  It follows equation 9: 
Log C = Log C0 – Kt / 2.303                                                                                    (9) 
Where C0 is the initial concentration of drug, K is the first order rate constant, and t is the 
time.  This relationship originated by the Noyes-Whitney equation as stated in equation 
1 and follows Fick’s first law of diffusion mechanism.  It can be used to describe the drug 
dissolution in pharmaceutical dosage forms such as those containing water soluble drugs 
in porous matrices (Costa and Sousa Lobo, 2001). 
For the Hixson-Crowell model, Hixson and Crowell recognised that the particle 
regular area is proportional to the cubic root of its volume and described dissolution via 
equation 10: 
W01/3- Wt1/3 = Kt                                                                                                      (10) 
Where W0 is the initial amount of drug, Wt is the remaining amount of drug at time t and 
K is a constant incorporating surface-volume relation.  The data is plotted as cube root 
of drug percentage remaining in matrix versus time and gives a linear relationship.  It 
presumes an erosion release mechanism and the expression can be applied to 
pharmaceutical dosage forms such as tablets, where dissolution occurs in planes that 
are parallel to the drug surface if the tablet dimensions diminish proportionally in such a 
manner that the initial geometrical form keeps constant all the time (Costa and Sousa 
Lobo, 2001). 
For the Higuchi model, a plot of cumulative percentage drug release versus square 
root of time is made and follows a simple expression, equation 11: 
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Q = K √T                                                                                                                (11) 
Where Q is the amount of drug released in time t per unit area, K is the Higuchi constant 
and T is time in hours.  Higuchi describes drug dissolution as a diffusion process based 
in the Fick’s law, square root time dependent.  It is often applied to modified release 
pharmaceutical dosage forms, transdermal systems and matrix tablets with water soluble 
drugs (Costa and Sousa Lobo, 2001).   
For the Korsemeyer Peppas kinetics, a plot of percent drug dissolved versus 
square root time is made which gives rise to a linear graph.  The model assumes 
dissolution is diffusion-controlled and describes dissolution via equation 12: 
Mt/M∞ = Ktn                                                                                                              (12) 
Where Mt/M∞ is fraction of the drug dissolved, t is time, K is a constant which includes 
structural and geometrical characteristics of the dosage form and n is the release 
component which is indicative of drug dissolution mechanism.  If n=1, the dissolution is 
zero order, n=0.5, the dissolution is best described by the Fickian diffusion and if n is 
between 0.5 and 1, then dissolution is through anomalous diffusion or case two diffusion 
(Ramteke et al., 2014).  To use this equation, it is necessary that release occurs in a 
one-dimensional way and that the system width thickness or length thickness relation is 
at least 10 (Ramteke et al., 2014).  It is therefore a semi-empirical model and is generally 
applied to pharmaceutical polymeric dosage forms, when the dissolution mechanism is 
not well known or when it is likely that there is more than one type of dissolution 
phenomena involved. 
The Weibull model is a general empirical equation that is adapted to dissolution, 
giving a linear relationship when a plot of log amount of drug dissolved versus log time 
is made (Langenbucher, 1972).  The equation described by Weibull can be applied to 
almost all kinds of dissolution curves. The Weibull equation is expressed as equation 13: 
Log [-ln(1-m)] = b log (t-Ti) – log a                                                                        (13)     
Where m is the accumulated fraction of the drug dissolved and b is a shape parameter 
that characterises the curve as either exponential if b=1, sigmoidal S-shape with an 
upward curvature followed by a turning point if b>1 or parabolic, with a higher initial slope 
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followed by consistency with the exponential if b<1.  The parameter, t, is time, Ti is the 
location parameter, which represents the lag time before the onset of the dissolution and 
in most cases, Ti is equal to zero, and a is the scale parameter.  The parameter, a, can 
be replaced by a more informative dissolution time parameter, Td, which represents the 
time taken to dissolve 63.2% of the drug present in the pharmaceutical dosage form 
(Langenbucher, 1972).  This is because a=(Td)b and is read from the graph at the time 
value corresponding to the ordinate -ln(1-m)=1 which is equivalent to m=0.632.  It is 
considered to have a lifetime distribution function.  Since Weibull is an empirical model 
and has no kinetic fundament, it comes with some limitations.  For example, it can only 
describe dissolution and does not adequately characterise the dissolution kinetic 
properties of the drug, there is not any single parameter related to the intrinsic dissolution 
rate of the drug and it is of limited use for establishing IVIVCs.   
The Gompertz model describes dissolution profiles of pharmaceutical dosage 
forms via equation 14: 
X(t) = Xmax exp[-a eβ log t]                                                                                       (14)   
Where X(t) is the amount dissolved at time t divided by 100, Xmax is the maximum 
dissolution, α describes the location or scale parameter and determines the undissolved 
proportion at time t=1 and β corresponds to the dissolution rate per unit of time and 
describes the shape parameter.  This model tends to have a steep increase in the 
beginning and converges slowly to the asymptotic maximal dissolution (Maharjan, 2014) 
and is more useful for comparing the dissolution of drugs that have good solubility and 
intermediate release rate (Dash et al., 2010).                        
The Baker-Lonsdale model was developed from the Higuchi model and is 
expressed via equation 15: 
3/2 [1-(1-Mt/M∞)2/3] – Mt/M∞ = kt                                                                             (15) 
Where Mt is the amount of drug dissolved at time t and M∞ is the amount of drug dissolved 
at an infinite time.  The parameter k corresponds to the slope of a linear graphical 
presentation relating the left side of the equation and the time.  This model can be applied 
to microcapsule formulations or microspheres (Dash et al., 2010). 
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In terms of the Hopfenberg model, Hopfenberg developed a general mathematical 
equation, equation 16, that correlates the drug dissolution from surface-eroding polymers 
so long as the surface area remains constant during the degradation process: 
Mt/M∞ = 1-[1-K1t(t-l)]n                                                                                                                                                (16) 
Where Mt is the amount of drug dissolved at time t, M∞ is the amount of drug dissolved 
at an infinite time and K1 is equal to K0/C0a0 (k0 is the erosion rate constant, C0 is the 
initial concentration of drug in the matrix and a0 is the initial radius for a sphere or 
cylinder).  The model comes with the assumption that the rate-limiting step of drug 
dissolution is the erosion of the matrix itself and that the time-dependent diffusional 
resistance internal or external to the eroding matrix, does not influence it.  It was 
developed to describe dissolution from surface-eroding devices such as slabs, spheres 
and infinite cylinders displaying heterogenous erosion (Ramteke et al., 2014). 
 
1.8.4 Application and selection of models 
The models can be applied to the dissolution data manually by plotting the graphs 
associated with each model, as described in section 1.8.3.  Linearity is used to identify 
the model that is most appropriate for the data set.  Otherwise, a newly developed 
program by Zhang et al., (Zhang et al., 2010) can be used.  The DDSolver program was 
developed to facilitate the modelling and comparison of drug dissolution data, where it 
fits the data with non-linear optimization techniques using Excel spreadsheet.  The 
program automatically calculates all the parameters associated with each model, 
especially the R2, and facilitates the complicated calculations associated with dissolution 
data analysis.  This provides the advantage of minimising calculation errors and time and 
hence provides a quicker method to screen for the most appropriate model to apply. 
There are various criteria for the selection of the mathematical model to be applied 
to dissolution or release profiles.  The selected model should be able to predict future 
data, without being too highly sensitive to small changes in data.  The most widely used 
method employs the coefficient of determination, R2, to assess the fit of the model 
equation.  This method is often used when the parameters of the model equations are 
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similar.  However, since this value inevitably increases with more model parameters, 
when the number parameters of the comparing equations are different, a modification is 
incorporated in this technique.  Instead, an adjusted coefficient of determination is used 
to assess the fit of the model and this is given by equation 17: 
R2 adjusted =1 – {[(n-1)/(n-p)][1-R2]}                                                                       (17) 
Where n is the number of dissolution data points and p is the number of parameters in 
the model.  The best model is the one with the highest R2 or adjusted R2 value. 
Other criteria used include the correlation coefficient (R), the sum of squares od 
residues (SSR), the mean square error (MSE), the Akaike Information Criterion (AIC) 
and the F-ratio.  The AIC is a measure of goodness of fit based on maximum likelihood 
and the model that provides the lowest AIC value is regarded as the best fit model 
(Bozdogan, 1987).  This method is only appropriate when comparing models using the 
same weighting scheme and requires calculation of the weighed sum of the SSR. 
 
1.9 Models for characterising the pharmacokinetics of OIPs 
Following aerosol drug deposition and dissolution in the lung, the particles are 
absorbed through the pulmonary membrane barriers primarily via diffusion (Hastedt et 
al., 2016).  It has been reported that for low molecular weight drugs, the intrinsic lung 
absorption rates are generally fast with absorption half-lives ≤ 1 h, irrespective of 
lipophilicity (Hastedt et al., 2016).  The permeability of a compound across the epithelial 
membrane is dependent on a combination of its lipophilicity, molecular size and charge 
(Fan and de Lannoy, 2014).  Small molecules that are highly water-soluble permeate 
readily via paracellular transport through tight junctions between epithelial cells, whereas 
small lipophilic compounds cross the cell membrane via passive diffusion down a 
concentration gradient.  Exceptions may occur if small compounds are also substrates 
for efflux transporters that can limit their net permeation across the membrane and there 
may be exceptions to the above general rule, if there is sustained binding or slow 
dissociation from the lung membrane components such as the target proteins or if there 
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are any intracellular trapping (Patton et al., 2010).  These intrinsic properties of lung 
absorption or permeability can be studied via in vitro lung epithelial cell monolayer 
systems, such as using Calu-3 cells (Forbes and Ehrhardt, 2005).  Since permeability 
values are well-correlated with the in vivo rate constants (Ka) for lung absorption in 
animals, this makes them useful in rank ordering and screening drugs with respect to 
their intrinsic lung absorption rates.  However, in the lung, the absorptive elimination is 
in kinetic competition with non-absorptive elimination such as mucociliary clearance from 
the upper regions of the lungs, making it more complicated to predict inhaled drug 
absorption.  Consequently, the overall performance of an inhaled drug i.e. its local 
therapeutic lung effect and systemic adverse effects not only depends on its intrinsic 
absorption and permeability properties, but also on the aerosol formulation, device, 
delivery and drug dissolution properties which contribute to determination of their PK/PD 
profiles.  For example, it has been reported that a poorly soluble and highly permeable 
selective glucocorticoid receptor modulator caused a 2-fold change in PK profiles, the 
Cmax and AUC, in humans following inhaled delivery from different dry powder inhalers 
and nebulizers, and this was attributed to the differences in dissolution rate (Leach, 
Davidson and Boudreau, 1998).  Hence, dissolution data has a potential to provide 
relevant PK/PD outcomes or predictions for aerosol drugs, via application of 
compartmental modelling or computational simulations. Generally, modelling dissolution 
profiles in this manner is a useful technique to help develop IVIVC, which can ultimately 
help reduce costs, speed up product development and reduce the need to perform costly 
bioavailability human volunteer studies. 
 
1.9.1 Compartmental PBPK modelling 
To predict the pharmacokinetic behaviour of OIPs in humans using preclinical data, 
physiologically-based pharmacokinetic (PBPK) modelling and computer simulations can 
be carried out.  PBPK modelling is gaining popularity in drug discovery and development 
and is utilised to have a better understanding on the absorption, distribution, metabolism 
and excretion (ADME) of a drug candidate as well as explore the effects of age, ethnicity 
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or disease state on human pharmacokinetic and hence help guide dose and dose 
regiments (Zhuang and Lu, 2016). 
PBPK models are made of compartments corresponding to the different 
physiological organs of the body of the species of interest, linked by the circulating blood 
system.  Each compartment is described by a tissue volume and each tissue is defined 
as either perfusion-rate limited or permeability-rate limited.  Perfusion-rate limited 
kinetics often applied to small lipophilic molecules when the blood flow to the tissue is 
the limiting process of absorption (Jones et al., 2015).  Permeability-rate limited kinetics 
occurs for larger hydrophilic drugs where the permeability across the cell membrane is 
the limiting process of absorption (Jones et al., 2015). 
It has been suggested through previous studies, that factors that increase the lung 
residence time such as slow dissolution, low permeability and hence slow absorption 
and intracellular trapping, tend to increase pulmonary targeting of drugs following 
inhalation (Tayab and Hochhaus, 2005; Olsson et al., 2011; Weber and Hochhaus, 
2013).  Consequently, since mucociliary clearance only occurs in the upper regions of 
the lungs, an optimal dissolution rate would further maximise pulmonary targeting.  
Based on these theories, many realistic compartmental lung deposition kinetic models 
have been developed for poorly soluble corticosteroids, incorporating regional lung i.e. 
central and peripheral deposition, dissolution rate-controlled absorption and mucociliary 
clearance (Tayab and Hochhaus, 2005; Gray et al., 2008; Weber and Hochhaus, 2013; 
Sakagami, 2014; Fröhlich et al., 2016; Salar-Behzadi et al., 2017).  There has been 
reported success in these models simulating and describing the different PK profiles of 
poorly soluble fluticasone propionate (FP) formulated in various inhaler products, while 
yielding its lung region-independent, dissolution-controlled slow absorption rate with a 
half-life of approximately 3.5 h (Tayab and Hochhaus, 2005; Weber and Hochhaus, 
2013).  Another study implied that in vitro-based mean dissolution times may be an 
indicator for the in vivo lung absorption rates of slowly-dissolving, lipophilic 




1.9.2 In-Silico (computational) PBPK modelling 
More current studies tend to utilise mechanistic computer-based modelling to 
provide a better understanding on how deposition, dissolution, clearance and absorption 
influence the clinical performance of an inhaled product.  An example of a computational 
model is the GastroPlusTM (Simulations Pluc Inc).  The concept behind these models 
includes the use of computational fluid dynamics (CFD) simulations that can capture 
aerosol formation, inhaler-patient interface, airway deposition and PK.  Generally, the 
CFD process subdivides the geometry into small discrete volumes which then make up 
the grid or mesh. 
One-dimensional (1D) algebraic approaches, such as ICRP-96, treat the airways 
as a series of filters in which gravitational settling, diffusion and impaction are competing 
deposition processes and this helps with the interpretation of drug exposure data (Forbes 
et al., 2015).  However, more recently with CFD modelling, transport equations are 
solved in realistic 3D geometries, which are constructed from medical scans and 
literature data, providing improved predictions of aerosol deposition on airway surfaces 
(Forbes et al., 2015). 
Benefits of in silico modelling have been demonstrated extensively.  In a study 
conducted by Olsson and Backman in 2014 for example, where they developed a mouth-
throat model to mimic the in vivo situation and predict initial total lung deposition, 
evaluation of the results demonstrated that the shape of the plasma PK profile was well 
predicted by the mechanistic model (Olsson and Bäckman, 2014).  It was demonstrated 
in the study that computational methods based on the ex-throat particle size distribution 
and knowledge of the biopharmaceutical properties may allow modelling regional 
distribution, dissolution, clearance and absorption and therefore help predict the 
pulmonary bioavailability of drugs.  Consequently, in a study conducted by Wu et al, it 
was found that the data such as lung bioavailability and drug plasma levels were 
simulated well by the GastroPlusTM, since they corresponded to the in vivo data in healthy 
individuals (Wu et al., 2014).  The findings suggested that since the GastroPlusTM in silico 
modelling software correctly identified changes in lung deposition upon changes in the 
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tidal volume and airflow, it could be suitable for identification of most promising candidate 
formulations in the context of development of inhaled compounds at reduced costs. 
 
1.10 Fluticasone Propionate as the model drug 
Dissolution is likely to be a key rate-limiting step for the systemic absorption of 
OIPs containing drugs or formulations with low aqueous solubility (Forbes et al., 2015; 
Hastedt et al., 2016).  Poor solubility has shown to be a major problem encountered with 
formulation development of new chemical entities and for generic drug/formulation 
development (Gowthamarajan and Singh, 2010).  Hence, meaningful dissolution tests 
for such products are particularly useful to both the pharmaceutical industry and the 
agencies that regulate them.   
The challenges associated with this include developing and validating the 
dissolution test method, ensuring the method is appropriately discriminatory and 
addressing the potential for IVIVC (Rohrs, 2001).  Satisfying these challenges have 
proven to be a large task, because the extent of release is too low i.e. it is difficult to get 
100% of the dosage form to dissolve and the rate of release is too slow i.e. it is difficult 
to get dissolution fast enough for a convenient test.  Thus, drugs with limited water 
solubility provide an excellent starting point to developing dissolution tests for OIPs since 
tests that provide discriminatory outcomes using these drugs, have the potential to be 
developed as appropriate and universal dissolution system for all types and classes of 
inhaled drugs.  
Examples of inhaled drugs that possess the property of poor aqueous solubility 
include fluticasone propionate (FP), beclomethasone dipropionate, budesonide and 
ciclesonide.  FP, in particular, has been subject of many dissolution studies, used as a 
comparator for the remainder of inhaled compounds (Davies and Feddah, 2003; Arora 
et al., 2010; May et al., 2014).  FP is a neutral glucocorticoid administered by inhalation, 
either as a DPI, pMDI or nebulisation formulation, as a first line treatment of chronic 
obstructive pulmonary disease (COPD) and asthma allergic rhinitis.  It is often delivered 
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alone under the brand names Flovent® or Flixotide®, and available in varied strengths 
such as an Accuhaler of 50, 100 and 250 µg strengths or Evohaler of 50, 125 and 250 
µg strengths.  However, FP is also available in combination with other drugs such as 
salmeterol, a long-acting β2-andrenergic agonist, under the brand names of Advair® or 
Seretide®.  FP predominantly works on the air passages in the lungs to help inhibit the 
inflammatory processes responsible for causing airway obstruction associated with both 
diseases.  It is often required as a long-term preventer inhaler, not to help control asthma 
immediately. 
With regards to its physicochemical properties, it is highly hydrophobic with a low 
aqueous solubility of approximately 0.1 µg/mL (Hastedt et al., 2016).  It exhibits a log P 
value of 4.5 and a high molecular weight of 500.6 g/mol.  Due to its properties, FP exhibits 
slow dissolution rates and since both DPI and pMDI formulations deliver solid FP 
particles to the lung, these formulations often tend to rely on API particle size reduction 
techniques in order to modify dissolution rates (Patel et al., 2008).  Consequently, FP 
has been shown to present a challenge in attempting to maintain sink conditions or 
ensure reproducible data are obtained when developing dissolution systems for OIPs 
(Rohrschneider, 2012; May, 2013).  For these reasons, FP was selected as the model 














Aim & Objectives 
Despite increasing interest in dissolution as a critical product attribute determining 
the performance of inhaled pharmaceuticals, there is yet no standard dissolution 
technique for OIPs.  To date, ad hoc comparisons have been made to dose collection 
and dissolution methods to discern the most promising dissolution techniques for 
development; however, there is still a need to understand and evidence the factors that 
make a dissolution system reliable, representative of the lung environment and suitable 
for QC purposes or for the establishment of IVIVC.  Using FP as a model drug, the major 
aim of this thesis was to develop dissolution methods for OIPs and determine their 
advantages and limitations. 
 
To address this aim, the specific objectives were: 
(1) To explore the critical parameters of dissolution tests and identify where 
improvements are required. 
(2) To design a biologically-based simulated lung fluid (SLF) that can be applied to 
dissolution systems for OIPs, based on the recognition on the lack of biorelevant 
medium currently available 
(3) To assess the impact of using SLF in dissolution testing 
(4) To discern the interaction and impact of variables relevant to a biorelevant 
dissolution system for OIPs 
(5) To measure the dissolution of different inhaled formulations, using dissolution 









Development and evaluation of the dissolution methods 
 
2.1 Introduction  
It has been established that dissolution testing is widely and routinely employed 
within the pharmaceutical sector, for various pharmaceutical formulation types, 
underpinning both their development and quality control.  Characterising and controlling 
the dissolution rate of inhaled active ingredients, particularly those designed for systemic 
therapy, would enable tailoring of formulation properties, dosing levels and dosing 
frequencies.  It would allow the study of drug-release mechanisms, enable batch-to-
batch consistency, monitoring of formulation stability and demonstration of 
bioequivalence between formulations (Burmeister Getz et al., 2016).  Consequently, for 
the assessment and implementation of a Quality by Design of any pharmaceutical 
product, the dissolution rate of the product is typically a Critical Quality Attribute.  This is 
because the PK of a drug is very sensitive to differences in dissolution and its regional 
deposition, which affects the absorption and permeation rates of the drug (Hochhaus et 
al., 2015).  Hence, a clear understanding of dissolution is important to obtaining an IVIVC 
insight (Cardot et al., 2007) and an important requirement for the proposed development 
of a BCS for inhaled medicines. The IPAC-RS Dissolution Working Group concluded that 
dissolution testing would certainly be a valuable technique in the development of inhaled 
dosage forms; it can be used as a selection tool for drug substances and formulations 
and as a quality test.  Yet, as mentioned in Chapter 1, it is not currently recognised as a 
key in vitro investigation, during drug R&D processes for OIPs.   
However, over the years there have been several reports assessing the 
implications of dissolution testing for inhaled products or proposing different 
methodologies for assessing the dissolution behaviour of OIPs (Davies and Feddah, 
2003; Son and McConville, 2009; Arora et al., 2010; Son et al., 2010; Riley et al., 2012; 
Rohrschneider et al., 2015).  Of these methods, two are emerging as the predominant 
choices for measuring dissolution, (i) the Rotating Paddle dissolution apparatus and (ii) 
66 
 
the Transwell® system.  It was identified and concluded by the research conducted by 
Sabine May, where comparisons were made between various proposed dissolution 
methods, that these two techniques are the most suitable for inhaled formulations, 
capturing a suitably representative sample for OIP dissolution testing (May et al., 2012, 
2014).  The Transwell system provides a platform that can represent the lung 
environment because it allows drug particles to dissolve in a limited volume of medium 
and can be configured to provide sink conditions for the dissolution of drugs. It has been 
adapted to allow the application of aerosols to cell layers, for transport and permeability 
studies or for the investigation of the effects of biorelevant medium or physiological 
surfactants on the dissolution of OIPs, moving towards potentially establishing IVIVC 
(Davies and Feddah, 2003; Meindl et al., 2015). However, a theoretical limitation to the 
system is the presence of the membrane which creates a diffusion barrier and limits the 
rate of drug transfer to the receptor compartment. This has led to modification of the 
system and assessment of alternative membranes on the dissolution of drug particles 
(May et al., 2014; Rohrschneider et al., 2015). In terms of the rotating paddle method, 
the principle advantage is the use of USP 2 standard apparatus, which can be used in 
conjunction with different types of aerosol particle collection methods (Riley et al., 2012). 
It uses a large volume of dissolution medium which readily provides sink conditions. This 
system has also been under development, to optimise its ability to evaluate the 
dissolution of inhaled formulations.  In a study by Son et al, particles were collected on 
a filter paper placed on a cup in the NGI then transferred this to the dissolution vessel 
(Son et al., 2010).   An alternative method has been proposed, where the aerosol 
particles are collected directly onto a stainless-steel filter and placed directly into the 
dissolution bath (Mees et al., 2011). However, a limitation to these methods is the inability 
to collect evenly-distributed drug particles on the surface of the filter, since the particles 
tend to clump on the central region (Price, 2015).   
These limitations suggest that the current in vitro aerosol collection and dissolution 
testing methods are not as reliable and predictable of the in vivo performance of the drug 
as anticipated.  Hence, it provides motive to further develop and evaluate these systems 
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to overcome the pitfalls associated with them.  During the development of a dissolution 
system, before any type of IVIVC can be considered, it must be realised that the 
dissolution test can be used to make a comparison between formulations under 
standardised conditions.  Consequently, the test, just like any other in vitro test, must be 
sufficiently reproducible so as to provide confident results and also be very easy to set 
up and easy to use. 
 
Aim: 
In this chapter, using FP as the model drug, the aim was to develop and compare 
the dissolution methods based on a pharmacopoeial standard dissolution apparatus 
(rotating paddle) and a diffusion labware apparatus (Transwell system) as suitable 
dissolution systems for the evaluation of OIPs.  The comparisons would allow the 
exploration of the critical parameters required for a dissolution test and would help 
identify the most robust, simple, easy to conduct, repeatable and reliable methodology, 




To reach the aim, the objectives were to, (i) validate a RP-HPLC-UV for analysis 
and quantification of FP in the dissolution media, (ii) develop the TSI/Transwell® system 
and the NGI/Rotating Paddle system (iii) compare and evaluate the performance of both 







2.2 Materials  
For FP assay validation, micronized FP (USP grade, purity 98%) was supplied by 
LGM pharma Inc (Boca Raton, USA).  Flixotide® 50 µg Evohalers were provided by GSK. 
For mobile phase preparation, HPLC-grade methanol (MeOH) and HPLC-grade water 
were supplied by Fischer Chemicals (Loughborough, UK). Ammonium acetate was 
supplied by VWR International Ltd (Lutterworth, UK).  Sodium Dodecyl Sulphate Lauryl 
(SDS) was obtained from Thermo Fisher Scientific (Paisley, UK) and Phosphate Buffer 
Saline tablets (PBS) were purchased from Sigma-Aldrich Ltd (Dorset, UK). Whatman 
Grade GF/A glass microfiber filter sheets were purchased from Scientific Laboratory 
Supplies Ltd (Nottingham, UK). The equipment/glassware necessary for the setup of the 
Twin Stage Impinger (TSI) were purchased from Copley Scientific Limited (Nottingham, 
UK).  The equipment necessary for the setup of the rotating paddle dissolution system 
were provided by Copley Scientific Limited (Nottingham, UK). 
 
2.3 Methods 
2.3.1 Validation of RP-HPLC-UV for assay of FP 
Validation was carried out using a calibration series prepared over a concentration 
range of 0.05-10 µg mL-1.  A 100 µg mL-1 FP standard solution was prepared in 50% v/v 
MeOH in water, by accurately weighing out 10 mg of FP powder and making it up to 100 
mL; dissolving by sonication, before being made up to final volume.  The calibration 
series was prepared by serial dilution of the standard solution to achieve the desired 
concentration range. 
 Linearity of peak area response was determined by replicate injections (n=6) of 
each of the eight concentration standards.  The relative standard deviation (%CV) of the 
peak area of the six injections was used to estimate instrument precision.  For intra-day 
variability, the calibration standard series prepared on day 1 were re-analysed three 
times and the %CV at each of the concentration levels was calculated.  For inter-day 
variability, two further calibration curves were analysed by the preparation of a fresh 
69 
 
series of calibration standards on days 2 and 3.  The concentration was the same from 
day-to-day since same weight of FP was ensured during the preparation of the standard 
solution.  The %CV at each of the concentration levels was calculated. Additionally, 
linearity of the combined data from the three calibration curves was determined.  The 
limits of detection (LOD) and limits of quantification (LOQ) were calculated based on 
equations (18) and (19) respectively (ICH, 1996): 
 
LOD = 3.3 x [SD/slope]                                                                                               (18)    
                                                                                                
LOQ = 10 x [SD/slope]                                                                                                (19)    
 
Where SD is the standard deviation of the y estimate and slope is the gradient of the 
line, obtained from linear regression analysis, using Microsoft Excel.  
 
2.3.2 Quantification of FP by RP-HPLC-UV 
Quantification of FP in the samples was achieved using a novel, specially 
developed and validated RP-HPLC-UV method (Waters 2795 Separations Module).  
Integration was carried out using an Empower Pro data analysis software.  Separation 
was achieved using a Luna® 3U column (100A, 150 mm x 4.6 mm), packed with C-18 
(Phenomenex, Hurdsfield, UK) and maintained at 40°C using a column heater.  The 
mobile phase was a mixture of methanol- 0.6% w/v aqueous ammonium acetate solution 
(75:25% v/v), filtered through a 0.2 µm nylon membrane (Whatman International Ltd, 
Maidstone, UK) and with a flow rate of 0.5 mL min-1.  The injection volume was 60 µL 
and samples were analysed in duplicate with a run time of 7 min.  Detection was at 240 
nm, where the detection wavelength was determined using Waters 2296 Photodiode 




2.3.3 Preliminary evaluation of the novel NGI particle collection method  
A Flixotide® 50 µg Evohaler was actuated 10 times to produce a loading dose of 
500 µg in the NGI.  The filter paper was removed from the filter holder and small sections 
of the filter were pierced out in the centre and outer skirts of the paper, as well as in the 
middle of the sections.  These sections were dissolved into 1 mL methanol and then 
injected into the RP-HPLC-UV for quantification of FP.  
 
2.3.4 Deposition and dissolution of FP by NGI and USP2 Rotating Paddle system 
The NGI was used to collect particles for evaluation of the rotating paddle 
dissolution system, using apparatus provided by Copley Scientific Ltd (Nottingham, UK).  
It was adapted for collection of particle using a filter-holding device, which is primarily 
designed for the archival calibration of the NGI (Marple et al., 2003).  The method is 
presented in Figure 2.1.  The fine particle fraction of the inhaler was collected using the 
next generation impactor (NGI).  The NGI lid was replaced with a ‘Flow Access’ lid 
provided by Copley Scientific Ltd.  After stage 2, the cover on the access port was 
removed and a filter holder, retaining a 47-mm diameter of GF/A glass microfibre filter 
paper, was attached via the O-ring. The Flixotide 50 µg Evohaler was connected to the 
NGI via a mouthpiece adaptor and actuated into the NGI 10 times to produce a mass 
loading of 500 µg.  Deposition was carried out at a constant air flow of 48 L/min, produced 
by a vacuum pump (Copley Scientific Limited, Nottingham, UK).  Following deposition, 
the filter paper was removed carefully, sealed onto a circular glass tile and immediately 
transferred into a vessel containing 900 mL of the dissolution medium (50% v/v MeOH: 
H2O). The paddle was set to rotate at 50 rpm, and 1 mL sample at each time point (2, 5, 
10, 15, 30, 45, 60 min) was removed using a syringe and placed into a HPLC vial for 
analysis. At 60 min, the filter paper was removed and placed into a glass beaker 
containing 50 mL of pure methanol to recover the deposited amount of FP. The beaker 
was sonicated for 20 min and then left aside until at 180 min, when 1 mL of sample was 
removed for analysis by HPLC.  The tests were performed at ambient temperature and 

















2.3.5 Deposition and dissolution of FP by TSI and Transwell® dissolution system 
The twin stage impinger was used to deposit respirable particles onto the surface 
of the Transwell insert, which was adapted as described by Arora et al (Arora et al., 2010) 
and is presented in Figure 2.2.  A Transwell® insert (Corning, UK) with a 0.45 µm pore 
polyester membrane was placed into the lower impingement chamber of a TSI to collect 
the fine particle fraction of the inhaler (particles < 6.4 µm).  The upper bulb of the TSI 
was filled with 7 mL of the dissolution medium. The Flixotide® inhaler was connected to 
the TSI inlet via a silicone rubber mouthpiece adaptor and actuated into the TSI, to emit 
a total mass of 500 µg. Deposition was carried out at a constant air flow of 60 ± 1 L/min, 
produced by a vacuum pump (Copley Scientific Ltd).  Following deposition, the Transwell 
donor chamber was filled with 100 µL solvent system (50% v/v MeOH:H2O) and 
transferred immediately into a well of a 24-well plate containing 600 µL of the dissolution 
medium. At each sample time point (2, 5, 10, 15, 30, 45 and 60 min), the Transwell insert 
was moved to a new well containing 600 µL of fresh medium, to ensure sink conditions 
were maintained and 175 L of each sample was collected into a HPLC vial for analysis. 
At 60 min, the total amount of FP particles deposited on the membrane was recovered 
by removing the 100 L on the membrane and adding it to the 600 µL medium in the 180 
min well, placing the Transwell insert into the well and adding 100 L of pure methanol 
on top of the membrane before leaving it until 180 min was reached. At 180 min, the 100 
L on the membrane was removed and mixed into the well and 175 L of sample was 
removed for analysis.  
Various types, strengths and batch of Flixotide® inhalers were assessed.  The 
dissolution media utilised in this study were 25%, 50%, 75% and 90% v/v MeOH in water 
as well as 0.5% w/v SDS in PBS.  To quantify FP in 0.5% w/v SDS in PBS, 100 µL 
sample was removed and diluted with 100 µL MeOH prior to injection into HPLC.  The 














2.3.6 Deposition and dissolution of FP by TSI and fluid-capacity limited 
Transwell® dissolution system 
The dissolution method followed section 2.3.4.  However, instead of filling the 
Transwell donor chamber with 100 µL of the solvent system following FP deposition on 
the polyester membrane, the insert membrane was pre-wetted with 100 µL solvent prior 
to its addition to the TSI.   
 
2.3.7 Deposition and dissolution of FP by modified TSI and fluid-capacity limited 
Transwell® dissolution system 
The dissolution method followed section 2.3.5, except that the Transwell 
membrane was modified, using an adapted method in Rohrschneider et al., study 
(Rohrschneider et al., 2015).  The polyester membrane was removed from the Transwell 

















2.4.1 Validation of RP-HPLC-UV for assay of FP 
The RP-HPLC-UV chromatogram of FP is shown in Figure 2.3.  There was no 
interference of the matrix and good separation peaks were observed.  A distinctive FP 
peak appeared at a retention time of approximately 9.5 min.  Validation of the assay and 
instrument performance, in terms of graph linearity and data precision are shown in 
Figure 2.4 and Table 2.1, respectively.  The curves of the three calibration sets prepared 
on the same day overlapped perfectly (Figure 2.4a) but the inter-day curves did not.  
However, each calibration curve displayed very good linearity (R2 > 0.999).  Excellent 
linearity was also highlighted in the combined inter-day data of the three calibration curve 
sets.  The SD value for six replicate injections were very low for all FP concentrations, 
highlighted by the absence of error bars (Figure 2.4).  Accuracy of data generated fell 
within the accepted range of 85-115% (ICH, 1996), except for FP concentration below 




Figure 2. 3. RP-HPLC-UV chromatogram of 10 µg mL-1 fluticasone propionate (FP) 
solution, where the FP peak corresponds to the retention time of approximately 9.5 




Figure 2. 4. Validation of RP-HPLC-UV for analysis of fluticasone propionate (FP) 
based on linearity of a) intra-day FP calibration curve sets (3 batches) and b) inter-
day FP calibration curve sets. Data obtained expressed as the mean area of FP 
peak (n=6) ± SD. 
 
Intra- and inter-day variation (Table 2.1) were determined at eight concentration 
levels (n=6).  The %CV for the intra-day and inter-day calibration sets ranged from 0.29 
to 2.54 % and 1.94 to 31.65 % respectively, with the %CV exceeding 2% once the FP 






Table 2. 1. Validation of RP-HPLC-UV for analysis of fluticasone propionate (FP) 




The limit of detection and limit of quantification calculated using equations (18) and 
(19) were in the ranges of 0.04 to 0.07 µg mL-1 and 0.13 to 0.20 µg mL-1 respectively 
(Table 2.2). 
 
Table 2. 2. Limits of detection (LOD) and quantification (LOQ) for the RP-HPLC-UV 












2.4.2 Preliminary evaluation of the novel NGI particle collection method  
The outer regions of the filter paper contained less FP particles in comparison to 
the middle region, with values being 6.49 ± 0.57 µg and 7.17 ± 0.47 respectively.  
However, differences in the result was statistically insignificant (p>0.05). 
 
2.4.3 Novel NGI/Rotating paddle system as a suitable dissolution method for 
OIPs 
The novel NGI/Rotating Paddle technique was evaluated as a suitable method to 
assess dissolution of inhaled products.  The dissolution of FP from Flixotide® 50, 125 
and 250 µg pMDIs, using this method, is shown in Figure 2.5.  Regardless of the strength 
of inhaler, it appeared the dissolution profile of FP was the same, with insignificant 
differences seen between them.  A high percentage of FP dissolved over time, reaching 
close to 100% by the end of the 60 min experiments.  The dissolution of FP from the 
same batch and different batch of Flixotide® Evohalers/pMDIs is shown in Figure 2.6.  
Again, it was evident that regardless of the batch the inhaler was selected from, the 
dissolution of FP was the same.  The experiments appeared to be well repeatable, as 








Figure 2. 5. Dissolution profiles of fluticasone propionate from Flixotide® 50, 125 
and 250 µg Evohalers (pMDIs) in 50% v/v methanol: water. Profiles obtained from 




Figure 2. 6. Dissolution profiles of fluticasone propionate from the same and 
different batch of Flixotide® 50 µg Evohalers (pMDIs), in 50% v/v methanol: water.  
Profiles obtained from the NGI/Rotating Paddle dissolution method.  Data 





2.4.4 Preliminary evaluation of the TSI/Transwell® dissolution method for OIPs 
To evaluate the performance of the TSI/Transwell dissolution method, experiments 
were conducted on the unmodified system, to assess its ease of handling and the 
reproducibility of results, when assessing the dissolution profiles of FP from varied 
strengths and types of Flixotide® inhalers.  The dissolution of FP from Flixotide® 50, 125 
and 250 µg pMDIs and Flixotide® 50, 100 and 250 µg DPIs are shown in Figure 2.7.  It 
appeared that the dissolution of FP from Flixotide same strength pMDI and DPI was very 
close, with some dissolution points overlapping.  Dissolution of FP from different 
strengths of Evohalers and from different strengths of Accuhalers, was also very similar.  
Insignificant differences were seen between all the FP dissolution profiles, as indicated 
by the overlap of the error bars associated with each time point. 
 
 
Figure 2. 7. Dissolution profiles of fluticasone propionate from Flixotide® 50, 125 
and 250 µg Evohalers (pMDIs) and 50, 100 and 250 µg Accuhalers (Powder/DPIs), 
in 50% v/v methanol: water.  Profiles obtained from the TSI/Transwell® dissolution 
method.  Data expressed as mean ± SD (n=3). 
 
Consequently, the system was evaluated in terms of its ability to identify for any 
batch-batch differences in inhalers.  The dissolution of FP from same batch and different 
batch of Flixotide pMDIs is shown in Figure 2.8.  There was evidently no difference in 





Figure 2. 8. Dissolution profiles of fluticasone propionate from same and different batch 
of Flixotide® 50 µg Evohalers (pMDIs), in 50% v/v methanol: water.  Profiles obtained 
from the TSI/Transwell® dissolution method.  Data expressed as mean ± SD (n=3). 
 
2.4.5 Optimisation of the TSI/Transwell® dissolution method 
2.4.5.1 Limiting the fluid capacity on the Transwell® insert 
To develop or optimise the TSI/Transwell dissolution method, the fluid in the donor 
chamber of the Transwell, initially added to mediate FP dissolution, was first limited, in 
attempt to more closely mimic the in vivo environment. Comparisons of dissolution 
profiles obtained from the unmodified Transwell® dissolution method with the fluid-
capacity limited method, is shown in Figure 2.9.  The dissolution profiles generated from 
the Flixotide® inhaler were very low, with a mean % FP dissolved reaching approximately 
8% for both the Evohaler® and Accuhaler®, in the original Transwell dissolution method.  
However, in the fluid-capacity limited method, the % FP dissolved by 60 min reached ≈ 
11%.  The small-sized and similarity in error bars at each time point, for both methods, 
indicated that both methods provided relatively reproducible dissolution profiles.  
However, at all time points, the mean % FP dissolved was significantly higher with the 
fluid-capacity limited method.  Dissolution of FP seemed to follow the same kinetics 
regardless of the method.  The general pattern was, within the first 15 min, the rate of 
FP dissolution is high, highlighted by the steepness of the curve, after which the rate of 




Figure 2. 9. Dissolution of fluticasone propionate from Flixotide® 50 µg Evohaler 
(pMDI) and 50 µg Accuhaler (powder/DPI), in 50% v/v methanol: water, obtained 
from the unmodified TSI/Transwell® method and the TSI/Fluid-capacity limited 
Transwell® method.  Data expressed as mean ± SD (n=3). 
 
2.4.5.2 Modification of the Transwell® insert membrane 
To develop the TSI/Fluid-capacity limited Transwell system further, the aerosol 
particle collection surface was modified, such that the Transwell insert collection surface 
was a GF/A microfibre filter as oppose to the original polyester membrane.  The 
dissolution of FP from Flixotide® Evohalers and Flixotide® Accuhalers, using the TSI/ 
fluid-capacity limited Transwell method versus the modified TSI/ fluid-capacity limited 
Transwell method is shown in Figures 2.10a and 2.10b.  It was evident that regardless 
of the inhaler type or the inhaler strength, there was a significantly higher % FP dissolved 





Figure 2. 10. Dissolution of fluticasone propionate from Flixotide® a) 50, 125 and 250 µg 
Evohalers (pMDIs) and b) 50, 100 and 250 µg Accuhalers (DPIs), obtained from the TSI/Fluid-
capacity limited Transwell® method (utilising the polyester membrane) versus the Modified 
TSI/Fluid-capacity limited Transwell® method (utilising the GF/A microfiber filter). Dissolution 
media was 50% v/v methanol: water. Data expressed as mean ± SD (n=3). 
 
2.4.6 Comparison of NGI/Rotating paddle and TSI/Transwell dissolution methods 
The dissolution of FP from the various strength of Flixotide Evohalers and via the 
TSI/fluid-capacity limited Transwell method, the modified TSI/ Transwell method and the 
NGI/Rotating Paddle method is shown in Figure 2.11.  It was evident that the % FP 
dissolved at each time point was highest when dissolution testing was carried out using 
the NGI/Rotating Paddle apparatus and lowest when using the TSI/fluid-capacity limited 
Transwell method.  Both Transwell systems exhibited a slow and incomplete dissolution 
of FP in the medium over the investigated time, whereas the rotating paddle enabled a 
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more complete dissolution, reaching up to 98-99% of the deposited amount. The profiles 
seemed to be relatively repeatable and reproducible for all methods used. 
Comparison of the deposited amount of FP from various Flixotide inhalers, on the 
filter, when using the TSI and the NGI aerosol collection techniques, was also made.  
This is shown in Table 2.3.  A significantly higher amount of FP was deposited on the 
GF/A filter paper from the NGI than from the TSI.  Consequently, the amount of FP 
deposited when using the NGI appeared to be a lot more repeatable than from the TSI. 
 
 
Figure 2. 11. Dissolution of fluticasone propionate from Flixotide® 50, 125 and 250 
µg Evohalers (pMDIs), obtained from the TSI/Fluid-capacity limited Transwell® 
method versus the Modified TSI/Fluid-capacity limited Transwell® method versus 
the NGI/Rotating paddle method.  Dissolution media was 50% v/v methanol: water. 
Data expressed as mean ± SD. 
 
Table 2. 3. Amount of fluticasone propionate (FP) particles deposited from 
different strength Flixotide® Evohalers, when collected via the twin stage impinger 






The dissolution methods were also compared in terms of their sensitivity to 
differences in the dissolution media applied and their discriminatory ability.  FP 
dissolution profiles in the TSI/fluid-capacity limited, modified TSI/fluid-capacity limited 
and the NGI/Rotating Paddle systems is shown in Figure 2.12.  Difference in dissolution 
profiles of FP were evident when the dissolution medium composition was changed.  
Regardless of the dissolution method, an increase in the percentage of methanol in the 
medium, from 25 to 90% v/v. resulted in an increase in the dissolution rate of FP.  0.5% 
w/v SDS in PBS was also applied as the dissolution media.  In the Transwell system. 
The dissolution profile of FP in 0.5% w/v SDS in PBS laid between the dissolution profile 
of FP in 75% and 90% v/v methanol in water.  However, in the rotating paddle system, 
the dissolution profile of FP laid between the profiles obtained using 50% and 75% v/v 
methanol in water.  There was no overlap in the dissolution profiles.  There was a clearer 
discrimination of the dissolution kinetics of FP over time, in the media of different 
solubilising capacity, when the rotating paddle system was used than in the Transwell 




Figure 2. 12. Dissolution of fluticasone propionate from Flixotide® 50 µg Evohaler, 
in 25%, 50%, 75%, 90% v/v methanol: water and 0.5% w/v SDS:  PBS from a) 
TSI/Fluid-capacity limited Transwell® dissolution system, b) Modified TSI/Fluid-
capacity limited Transwell® dissolution system and c) NGI/Rotating paddle 




The varied propositions of dissolution methodologies for OIPs have continuously 
been developed and refined, both in terms of the practicalities of use and applicability.  
The uses and advantages of developing a potential dissolution test, as mentioned 
previously, underlines the need to obtain sensitive and reliable data from the in vitro test 
utilised.  Taking this into consideration, my PhD prioritised evaluating the performance 
of two dissolution methods, considered to be the most appropriate for OIPs, the 
TSI/Transwell system and the NGI/Rotating Paddle system, as suitable dissolution 
methods for OIPs.  However, this initially required validation of a HPLC assay to be able 
to quantify the FP in the dissolution medium applied to these systems. 
 
2.5.1 Validation of RP-HPLC-UV for assay of FP 
The suitability of an analytical method to quantify the drug released in a dissolution 
assay is based on the chemical properties of the drug to be analysed and on its 
compatibility with the dissolution media, ensuring minimal analytical interference.  
However, the sensitivity of the method tends to be the predominant limiting factor to the 
design of dissolution assays.  The RP-HPLC-UV detection analysis used in this study is 
most suitable for microgram quantities of the fine drug particles deposited.  For the 
validation of an analytical method, factors that needed to be explored include accuracy, 
precision, reproducibility, linearity and robustness.  In this study, the RP-HPLC-UV 
instrument was validated based on methods adapted from to Murnane et al (Murnane et 
al., 2006) and was generally shown to be suitable for the assay of FP. 
The calibration standard series prepared were within the limits of detection.  The 
excellent linearity shown in all calibration curves produced, highlighted the good 
correlation between FP peak area at 240 nm and the concentration of FP in the sample. 
The intra-day validation data showed good repeatability and instrument precision, with 
%CV being < 2.54% at all concentration levels.  It indicated that only one set of calibration 
curve was needed to be prepared on the day of analysing the dissolution samples, since 
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all three calibration curve sets overlapped perfectly.  The reproducibility of the assay, 
indicated by the data derived for all three calibration curves produced on different days 
was not as good, producing higher %CV values.  This reflected the influence of 
instrument conditions, which changes from day to day, on quantifying FP and hence, 
confirmed the need of a new calibration set to be prepared on the day of sample analysis.  
In comparison to the validation evaluation carried out by Murnane et al, their inter-day 
data for FP indicated excellent assay reproducibility since the %CV was <2% for all 
standard concentrations.  However, they validated within a concentration range of 2 to 
50 µg mL-1 and according to the data generated in this study, between 3.5 and 10 µg mL-
1, the %CV proved to be equally good (< 2.54%).  Therefore, the assay was considered 
fit for the purpose of this study. 
 
2.5.2 NGI/Rotating paddle system as a suitable dissolution method for OIPs 
The novelty of the NGI/Rotating Paddle dissolution method lied with the respirable 
fraction collection method, whereby the NGI was adapted for collection of particles using 
a filter-holding device, which is primarily designed for the archival calibration of the NGI.  
The system presented the advantage of utilising a well-recognised and well-accepted 
Regulatory standard USP 2 apparatus for dissolution, a rotating paddle.  This advantage 
draws some initial reliability to the potential data obtained.  The attempts that have been 
made to modify the NGI to date have not proven to overcome the key limitation, in which 
the deposited aerosol particles is very likely to clump within the central region of the filter 
paper, affecting the reliability of the dissolution results.  This novel system was designed 
to overcome this recognised limitation and potentially allow for an evenly distributed layer 
of particles to deposit, ensuring adequate repeatable dissolution data for OIPs.   
During experimentation, it was recognised that the shape of the filter holder in 
which the aerosol particles travel through to deposit onto the filter, may not be sufficient 
to eliminate the associated risk of particle clumping.  This is because the filter holder 
cone is designed at an angle of 30°, which can predispose the particles to travel in a 
linear direction and not smoothly along the inner walls of the cone.  Therefore, this can 
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cause risk of particle channelling, in which the particles focus their deposition in the 
central region of the filter.  However, in the preliminary experiments carried out to validate 
the particle collection technique and assess particle deposition, it was evident that the 
FP particles were evenly distributed on the filter paper.  According to the cut-off 
calculations, attachment of the filter holder to Stage 2 of the NGI and conducting the 
experiment at a constant air flow of 48 L/min, ensured that only the fine particle fraction 
(FPF) i.e. particles <5 µm in diameter, deposited on the filter for dissolution.  Taking 
these into consideration, it can be concluded that the novel particle collection technique 
used here was efficient for the evaluation of the dissolution of OIPs. 
To evaluate the performance of the NGI/Rotating Paddle dissolution system 
overall, various strengths of Evohalers were applied.  The results obtained showed 
excellent repeatability and demonstrated batch-to-batch consistency.  This was as 
anticipated because the variations in the strength and type of inhaler was made for 
patient suitability or for the improved treatment of lung diseases and should not affect 
the PK of an inhaled drug in vivo.   Overall, the system was simple to follow and easy to 
conduct.   
 
2.5.3 TSI/Transwell® as a suitable dissolution method for OIPs 
A challenge towards developing a suitable system to assess the dissolution of 
OIPs, is the ability of the in vitro system to replicate the in vivo conditions.  For example, 
to accurately collect the respirable fraction of the drug particles that deposit into the lung, 
to utilise a limited volume of dissolution media to simulate the limited volume of lung fluid 
available in vivo and replicate the systemic circulation which act as a sink for poor water-
soluble drugs, even though the entire respired dose is not soluble in the limited volume.  
The TSI captures a suitably representative sample of inhaled drugs, allowing only the 
aerosol particles that are < 6.4 µm in size to deposit on the surface of the filter paper.  
The Transwell dissolution assay consequently uses a limited volume of dissolution 
media, the filter paper for deposition was prewetted and 600 µL was used in the receptor 
chamber.  Movement of the transwell insert across the well, containing fresh solvent 
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system, simplifies the sampling and suggests that sink conditions can be maintained in 
the receptor chamber.  The fact that the dissolution profiles of Flixotide® MDIs and DPIs 
overlapped and appeared to be identical, with similar kinetics visualised, may be 
indicative that sink conditions was not reached, with this system, as suggested by the 
works of Rohrshneider (Rohrschneider, 2012).  However, in his studies, only 
approximately 2% of the deposited amount of drug had dissolved after 5 hours, whereas, 
in this study, considering a slightly different TSI/Transwell system was used, dissolution 
reached up to 8% within 1 h of testing, suggesting that my system slightly improved the 
non-sink condition exhibited by the Transwell.  Consequently, the overlap in profiles 
between the pMDI and DPI, supported the overlap seen in Arora et al., study (Arora et 
al., 2010) and was suggested to be in fact consistent with the in vivo pharmacokinetic 
evidence of no real difference between the pMDI and DPI inhalation in humans (Brindley 
et al., 2000).  These replicating characteristics suggested that the TSI/Transwell method 
has the potential to be developed as both a QC tool and an IVIVC tool, potentially 
reaching the overarching aim to the study.  Hence, it was selected to be evaluated as a 
suitable system for OIPs.  
From the perspective of QC, the dissolution system demonstrated its ability to show 
batch-to-batch consistency between inhalers and showed that dissolution of FP is 
independent of the strength and type of inhaler used, similar to the NGI/rotating paddle 
method.  The profile kinetics for FP also very closely matched the FP dissolution profiles 
obtained from previously reported Transwell dissolution studies (May et al., 2012; 
Rohrschneider et al., 2015).  
 
2.5.4 Optimisation of the TSI/Transwell® dissolution system 
With regards to development of the system, the original TSI/Transwell method 
required the addition of 100 µL of the solvent system onto the Transwell polyester 
membrane prior to its introduction to the Transwell dissolution plate.  This is because it 
was originally hypothesised that the addition of a dissolution layer on the membrane 
would generate better dissolution profiles, with respect to profile reproducibility and 
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acceleration of the dissolution process (Arora et al., 2010).  This is because in the 
Transwell dissolution system, a diffusion barrier is separating the donor compartment, in 
which dissolution occurs, from the receptor compartment, in which sampling of the 
dissolved drug occurs.  The fine particles dissolve in the donor chamber fluid before 
crossing the polyester membrane via gradient diffusion, according to Fick’s law (May et 
al., 2014) so with more fluid available for dissolution in the donor chamber, means the 
drug particles are exposed to more medium and so the condition presented by the 
Transwell are less non-sink, in comparison to the more limited volume available for 
dissolution.  Therefore, there would be a faster dissolution rate However, this expected 
benefit was not given here and a greater dissolution rate was identified in the fluid-
capacity limited Transwell system, in which the 100 µl of fluid on the transwell surface 
was absent.  This opposing effect may be attributed to the fact that an extremely limited 
volume of fluid available for the FP drug particles to dissolve into, results in an even 
higher concentration of FP in the donor chamber in comparison to the receptor chamber.  
There is an amplified difference in FP concentration between the donor and receptor 
chambers, providing a stronger driving force for the diffusion of FP particles in one 
direction, into the receptor chamber for quantification.  The result obtained here was 
similar to those observed by May et al (May et al., 2014), who recognised that impact of 
the diffusion barrier is substance dependent.   
The TSI/fluid-capacity limited Transwell method was therefore selected to be taken 
forward for further developments.  However, omitting the small volume of dissolution 
medium in the donor compartment and since there is no stirring of the medium in the 
receptor compartment, this increases the likelihood of a concentration gradient-based 
diffusion effect, as described above.  Hence, the Transwell membrane was modified in 
attempt to reduce this effect.  The results indicated that the modified Transwell insert 
caused a significantly higher percent of FP to dissolve in the dissolution medium 
compared to the unmodified insert membrane.  This is because in the Transwell 
dissolution system, where the insert retained its polyester membrane, both dissolution 
and diffusion processes were the limiting steps to the transfer of the FP particles from 
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the donor compartment to the receptor compartment.  However, in the modified 
Transwell system, the filter paper reduced the extent of the rate-limiting diffusion step.  
The glass microfibre filter was more permeable than the polyester membrane and 
allowed for faster diffusion of the dissolved drug through to the receptor compartment.  
Although this diffusion barrier is not always the principle limiting factor (Arora et al., 
2010), similar faster rates of dissolution in the modified system have been observed for 
other poorly soluble corticosteroids (Rohrschneider et al., 2015).  In terms of the 
dissolution kinetics, the modified Transwell system seemed to be well optimised in that 
the dissolution kinetics of FP from inhalers was a lot clearer, with the profile steeping 
upwards as oppose to closely reaching a plateau.  Regardless of the system used, the 
dissolution kinetics appeared to approximate to zero-order, whereby a constant amount 
of drug was eliminated per unit time.  However, to understand the kinetics or dissolution 
mechanism better, the in vitro dissolution data need to be fitted to kinetic models, which 
was performed and is described in Chapter 5. 
Overall, modifying the Transwell in this manner proved to not cause any extra 
difficulty in operation or make it any less user-friendly.  It remained an economic 
procedure since the Whatmann GF/A filter was not considered expensive.  Regardless 
of the TSI/Transwell dissolution system used, the system was simple to use, experiments 
were easy to conduct, and the results produced were reproducible.  
 
2.5.5 Comparison of the dissolution methods 
Comparisons of the two dissolution systems was made in terms of their simplicity, 
ease of handling, robustness and discriminatory power.  These characteristics were 
evaluated in experiments which obtained QC-like data on commercially available 
Flixotide® inhalers, and experiments which measured the influence of the dissolution 
medium on the dissolution of FP.  The comparisons are simplified in Table 2.4.   
In terms of using the systems investigated, even those prior to optimisation, all 
systems proved to be simple to use and relatively easy to handle and operate.  However, 
the NGI/Rotating Paddle apparatus appeared to be more time-consuming to set-up 
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prepare the particles for dissolution.  Preliminary investigations showed that the TSI set-
up can be used three times for the same strength inhaler without the need to wash in 
between, and two 24-well plates would be sufficient to investigate the dissolution of an 
inhaler in triplicates, in a simultaneous manner.  Whereas, in the case of the NGI, 
preliminary investigations showed poor reproducibility when three vessels and three 
paddles were used to conduct experiments in triplicate.  Therefore, a single vessel was 
used and required thorough washing in between experiments.  Consequently, attaching 
the filter to the filter holder and securely introducing the filter holder to the NGI apparatus 
at stage 2 was quite time-consuming and made the method slightly less user-friendly.  
From an economic point of view, the NGI/Rotating Paddle system was less economic in 
comparison to the TSI/Transwell system since it required huge amount of solvent system 
or dissolution media, up to at least 600 mL is required per experiment. 
With regards to the deposition and collection of the aerosol particles for dissolution, 
the NGI allowed for significantly higher and repeatable deposition compared to the TSI.  
This was because the 47-mm diameter filter paper used in the NGI provided a larger 
surface area than the Transwell insert, facilitating the capture of up to 40-45% of the 
loading dose and ensuring the particles were evenly distributed, and hence, a consistent 
amount deposited.  The NGI system was also optimised such that it ensures the FPF is 
collected, increasing the reliability of the results obtained from the system.  In contrast, 
it is presumed the Transwell insert captures the sub-deposited amount of particles 
(particles <6.4 µm) and not specifically the FPF, and the amount of particles deposited 
was significantly lower, ranging between 7 and 14 µg.  The inconsistency in the amount 
deposited is likely attributed to the very small confined surface offered by the Transwell 
insert filter, increasing the likelihood for particle aggregation.  However, it is important to 
acknowledge that yet, the dissolution profiles obtained from the TSI/Transwell system 
did not seem to be significantly influenced by this.  The large amount of FP deposited via 
NGI meant that once the filter was placed into a vessel containing a large volume of 
medium, the particles would dissolve a lot more readily than in the small volume provided 
by the Transwell hence why the dissolution profiles from the NGI appeared to be clearer 
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and allowed better understanding of the FP dissolution kinetics.  On the contrary, the 
dissolution profiles from the Transwell method appeared to almost plateau at an early 
stage, leading to a poor understanding of the dissolution kinetics. Consequently, 
although modifications to the TSI/Transwell system provided less non-sink conditions 
and reduced the diffusion effects that occurred simultaneously with the dissolution 
process, the large volumes of media provided by the Rotating Paddle apparatus and the 
constant stirring of the medium over the deposited particles, meant that the NGI/Rotating 
Paddle dissolution system provided efficient sink conditions for the dissolution of OIPs, 
and provided more reliable in vitro dissolution data, since the deposited particles were 
immediately exposed to the medium and were not influenced by the process of diffusion. 
With regards to system sensitivity, regardless of the dissolution method, changes 
in the medium composition led to changes in the dissolution profile.  An increase in the 
percentage of methanol in the medium from 25 to 90% v/v, resulted in an increase in the 
dissolution rate of FP and this was due to the greater solubilising capacity of methanol 
for FP, which has poor aqueous solubility, approximately 0.1 µg/mL in water (Hastedt et 
al., 2016).  However, the rotating paddle arrangement was more sensitive to changes to 
the dissolution media since the dissolution profiles for FP were more distinct, also 
suggesting that the system has stronger discriminatory power.  The profiles obtained 
from this system was slightly more reproducible. 
Dissolution was initially carried out in different proportions of methanol to water, 
because it is a simple aqueous solvent that can be used to evaluate the dissolution of 
both aqueous soluble and poorly-aqueous soluble inhaled drug compounds.  
Consequently, for QC purposes, using a simple dissolution media is preferred over 
complex medium due to their general high reproducibility, lower costs and ease of 
preparation (Fotaki and Vertzoni, 2010). However, the experiments also evaluated the 
effect of 0.5% w/v SDS in PBS on the dissolution of FP, since many studies have utilised 
a surfactant to obtain rank order of dissolution rates for poorly soluble hydrophobic drugs, 
and 0.5% w/v SDS in PBS has been shown to differentiate between different dosage 
forms of OIPs (Amidon et al., 1995; Thorsson et al., 2001).  It was hypothesised that 
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since surfactants significantly increases the wetting of deposited particles and improve 
drug solubility, they have a major impact on the dissolution rate of FP in comparison to 
a simple aqueous system (Coowanitwong et al., 2008).  However, the results suggested 
that it did not impact the dissolution rate enough to overcome the high dissolution 
profile/rate exhibited for FP in 90% v/v methanol in water.  The fact that the profile in 
0.5% w/v SDS in PBS did not overlap the profiles in simple aqueous solutions, provided 
some indication that physiological surfactants and an overall more biorelevant medium 
consisting of a range of surfactants found in lung lining fluid may be useful to study the 
dissolution of OIPs, under conditions that mimic those found in the lung in health and 
disease. 
From an IVIVC perspective, the TSI/Transwell system exhibited better potential.  
This is because it is fluid-capacity limited, mimicking the limited volume of fluid in the 
lungs in vivo.  Due to this, it allows for application of physiologically-relevant fluids such 
as Survanta® or proposed simulated lung fluids.  However, the NGI/Rotating Paddle 
system requires a large volume of fluid, meaning it is less representative of the in vivo 
environment and it would be too expensive and inappropriate to study dissolution in such 
biorelevant fluids. 
 








Summary and conclusions 
The study explored, evaluated and compared prototype dissolution systems for 
inhaled products, by investigation the dissolution of FP delivered by various Flixotide 
inhalers and by varying the dissolution medium.  The dissolution systems compared were 
the TSI/Transwell and the NGI/Rotating Paddle.  The study showed that overall, it was 
difficult to have a single standardised dissolution test that can be utilised for both QC and 
IVIVC purposes.  The modified Transwell system with a higher permeability membrane 
provided a superior system to the unmodified Transwell for studying dissolution of 
inhaled products.  However, the rotating paddle dissolution method not only had the 
advantage of using standard USP 2 dissolution apparatus but collected the emitted fine 
particle fraction with greater efficiency using an adaptation of standard aerosol 
characterisation apparatus.  It also provided greater discrimination between dissolution 
profiles when experimental variables were modified. 
Therefore, the NGI particle collection, together with the rotating paddle dissolution 
system represents a good starting point for QC purposes and to evaluate batch-batch 
consistency during drug formulation R&D.  However, the modified TSI/Fluid-capacity 
limited Transwell dissolution method is advantageous in that it provides the best 
representation of lung geology; allows for application of physiologically-relevant fluids 
and hence, can be developed further and utilised as a potential tool to establish IVIVC 
or develop/model PK data of inhaled drugs.  Hence, this TSI/Transwell dissolution 












Development of a biorelevant simulant 
 
3.1 Introduction 
It was recognised in Chapter 1 that the dissolution media currently available and 
that have been applied to dissolution tests for OIPs, do not fully simulate the epithelial 
lung fluid in vivo, suggesting a need for a more biorelevant simulant to be developed and 
applied to such systems.  Consequently, it is widely recognised that drug solubility is key 
in the development of inhaled medicines, including drug design/discovery (Edwards et 
al., 2016), formulation (Hastedt et al., 2016) and toxicokinetics (Jones and Neef, 2012).  
The importance of both solubility and dissolution in predicting the pharmacokinetics of 
OIPs has been demonstrated convincingly (Bhagwat et al., 2017) and from the 
perspective of the FDA and EMA, application of in vitro test methods to assess these 
behaviour of OIPs in vivo is important.  Consequently, identifications of ways to modify 
the in vitro tests beyond a standard test developed primarily for QC, towards giving more 
improved IVIVC that are useful for bioequivalent studies, is a key focus to the industry.  
This requires more biorelevant fluids, in which to make meaningful in vitro experimental 
measurements.  
Since the first biological destination of inhaled medicinal aerosols in the RTLF in 
which they deposit, it was surprising how little is published about models of RTLF in 
which to study interactions with particles, e.g. requirements for fluid composition or 
critical attributes.  In contrast to intestinal fluid in which drug solubility and dissolution has 
been investigated extensively (Lennernäs et al., 2014), the development of lung fluid 
simulants appeared to be in its infancy.  Human intestinal fluids have been characterised 
thoroughly in terms of their composition and structure (Wuyts et al., 2015; Riethorst et 
al., 2016).  Simulants have been designed to represent fed and fasted conditions 
(Marques et al., 2011; Wuyts et al., 2015), studied for their biocompatibilities with human 
in vitro cell lines (Patel et al., 2006) and made available as commercial products (Klein, 
2010).  A variety of approaches have been adopted practically, to simulate the RTLF, 
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ranging from simple solutions to surfactant-containing solutions, and the tendency to 
refer to such solutions as ‘simulated lung fluid’ reflects a confusion regarding how best 
to simulate RTLF in vitro.  Based on this, in a PhD study conducted by Bicer (Bicer, 
2015), the key lipids and proteins that constitutes the RTLF was identified accurately, 
and a protocol for the preparation of SLF was established.  It provides a ‘base’ SLF that 
reflects human lung fluid composition and can be incorporated into in vitro experimental 
models and be supplemented for specific applications, e.g. if particular surfactant 
proteins, specific metabolic activities or model inflammatory disease states are of 
interest.  However, there remains a need to standardise the SLF and develop a quality 
specification for the simulant.  Also, for maximum utility, such a simulant should be 
biocompatible with respiratory cells so that it can be used in models to study lung-particle 
interactions in vitro. 
Consequently, if a simulant is to prove useful, it must be readily available, 
convenient, economic and well-defined conditions for storage and use.  For a complex 
aqueous fluid with components susceptible to chemical degradation, physical instability 
or microbial spoilage, freeze-drying provides an excellent means of preservation.  
Desiccation will protect the SLF since it minimises chemical reactions, e.g. the rate of 
lipid hydrolysis during storage (Nounou and El-Khordagui, 2005), and deters microbial 
growth.  Accordingly, freeze-drying the SLF would allow batch manufacture in a form that 
has extended use-by date and is easily handled and transported for reconstitution at its 
place and time of use (Tang and Pikal, 2004; Lee et al., 2007). 
 
Aim: 
Therefore, in this chapter, the aim was to develop the biorelevant SLF that can be 
made readily available for in vitro experimentations such as dissolution testing of OIPs 
or to contribute to inhalation biopharmaceutics studies, where it can be used as the 
medium to assess and rank the solubility of inhaled drug compounds.  The application 
of SLF in this manner will contribute to the development of a biorelevant dissolution 
system that can potentially be utilised beyond just QC purposes, moving towards 
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To reach this aim, the objectives were to, (i) optimise the manufacture of SLF, (ii) 
characterise the physiochemical properties of SLF (iii) carry out stability assessment of 
SLF under different conditions for different lengths of time, to determine or define its 
storage conditions, (iv) freeze-dry SLF and assess its stability, (v) asses the 
biocompatibility of SLF with A549 lung epithelial cells and (vi) investigate a range of 





















3.2 Materials  
The 25 mg/mL stock solutions of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC) and 1,2-dipalmitoyl-sn-glycero-3-phospho-(1’-rac-glycerol) sodium salt 
(DPPG), both >99% purity, were obtained from Avanti Polar Lipids, Inc. (Alabama, 
USA). Reagent-grade purified human immunoglobulin (IgG), lyophilized human serum 
albumin, Bioreagent-grade transferrin, cholesterol, ascorbate, urate, certified reference 
material-grade glutathione was supplied by Sigma-Aldrich Company Limited (Dorset, 
UK).  Hanks’ Balanced Salt Solution (HBSS), phenol red-free, was also supplied by 
Sigma-Aldrich and consisted of: 0.19 g/L calcium chloride dihydrate, 0.09 g/L 
magnesium sulphate anhydrous, 0.40 g/L potassium chloride, 0.06 g/L potassium 
phosphate, 0.35 g/L sodium bicarbonate, 8.00 g/L sodium chloride, 0.05 g/L sodium 
phosphate dibasic, and 1.00 g/L D-Glucose.  HPLC-grade chloroform and methanol 
were supplied by Fischer Chemicals (Loughborough, UK). 25% ammonium hydroxide, 
sodium chloride and 2 M hydrochloric acid solutions were obtained from Sigma-Aldrich 
Company Limited (Dorset, UK).  For biocompatibility experiments, all ingredients were 
also purchased from Sigma-Aldrich Company Limited (Dorset, UK).  The ingredients 
used for the manufacture of Gamble’s solution (Appendix A Table A.2) were all 
analytical grade and purchased from Sigma-Aldrich Company Limited (Dorset, UK).  
Sodium Dodecyl Sulphate Lauryl (SDS) was obtained from Thermo Fisher Scientific 
(Paisley, UK) and phosphate buffered saline (PBS) was purchased from Sigma-Aldrich 
Ltd (Dorset, UK).  Survanta® was purchased from AbbVie Ltd (Maidenhead, UK).  
Fluticasone propionate (FP), mometasone furoate (MF) and budesonide were 
purchased from Adooq Bioscience (Irwin, CA).  Beclometasone dipropionate was 






3.3.1 Preparation of SLF 
Preparation of SLF is shown in Figure 3.1.  SLF consisted of the key components 
found in healthy human RTLF, the major soluble proteins, the abundant lipids and the 
antioxidants that were identified in the study by Bicer (Bicer, 2015).  The proteins were 
albumin, IgG and transferrin, and the lipids were DPPC, DPPG and cholesterol.  The 
preparation method was optimised into two stages, with the manufacture of a liposomal 
dispersion followed by addition of the proteins (Table 3.1).  To prepare the liposomal 
component, 1.92 mL DPPC and 0.1 mL DPPG, from 25 mg/mL stock solutions in 
chloroform were combined in a bijou bottle, with 5 µL of cholesterol from a 200 mg/mL 
stock solution in chloroform also added.  The mixture was stirred gently, and the 
chloroform evaporated under a stream of nitrogen gas for 30 min (sufficient to ensure 
that the lipid film was solvent free) to produce a thin film of lipids.  The proteins were 
added to the lipid film in aliquots of aqueous stock solutions: 4 mL of albumin (88 mg/mL), 
4 mL of IgG (26 mg/mL) and 1 mL of transferrin (15 mg/mL).  To represent lung 
antioxidant levels, 88.5 µL of the following antioxidant stock solutions were added: 10 
mM ascorbate, 10 mM glutathione, and 5 mM urate in HPLC-grade water.  The mixture 
was vortexed for 5 min.  Using an ultrasonicator/ probe for 10 min at a pulse of 10 
amplitude, the lipids were dispersed into the solution, in the form of polydisperse multi-
sized liposomes.  Finally, 10 µL of 50 mg/mL gentamicin was added to minimise microbial 
growth followed by 775 µL of HBSS, under gently agitation, to make up to 10 mL volume. 
 
Figure 3. 1. A schematic diagram on the manufacture of simulated lung fluid (SLF). 
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3.3.2 Characterisation of fresh aqueous SLF  
The SLF was characterised in this study in terms of its appearance, pH, particle 
morphology, particle size distribution, conductivity, viscosity, density, surface tension 
and monolayer behaviour.  The appearance and colour were analysed visually and via 
measurements of the mean grey value, using the Image J software (Java 1.8.0-25, 
version 1.51p).  Using the software, the images captured were first converted to ‘8-bit’ 
prior to obtaining the mean grey value.  The pH was measured using a pH probe (Ph 
level 2 InoLab, WTW, Germany).  Particle structure and morphology was characterised 
via Cryo-transmission electron microscopy (cryo-TEM), using a Zeiss Libra 120 
Transmission Electron Microscope (Carl Zeiss NTS, Oberkochen, Germany).  The 
microscope was operated at 80 kV in zero loss bright-field mode under cryo conditions 
and the digital images were recorded under low dose conditions, with a slow-scan CCD 
camera (TRS GmbH, Moorenweis, Germany) and iTEM software (Olympus Soft Imaging 
System GmbH, Munster, Germany).  An under focus of 1-2 µm was used to enhance the 
image contrast.  Samples were spread thinly and prepared in a 100% humidity chamber 
to avoid dehydration, then quickly vitrified in liquid ethane held at a temperature just 
above its freezing point (-182°C).  The sample were then transferred to the microscope, 
using a Gatan CT3500 cryo-transfer (Gatan, Oxon, UK) to maintain samples below -
165°C.  To measure the hydrodynamic diameter of structures in SLF, photon correlation 
spectroscopy (Nanosizer, Malvern Instruments, UK) at a scattered angle of 173° was 
used.  Suspensions of SLF, 1 mL, was analysed using instrument parameter: reflective 
index 1.330, temperature 25°C, dynamic viscosity 0.8882 x 10-3 Pa s.  Zetasizer software 
6.20 was used to analyse data. 
The conductivity of SLF was measured using a conductivity probe and meter 
(Jenway A520, Cole-Parmer, UK), calibrated using 0.01 M potassium chloride solution, 
providing a value of 1413 ± 1 µS/cm.  The density of SLF was measured using a density 
meter (DMA 35, Anton Paar, UK) whereby the inverted capillary cell was filled with 
approximately 5 mL of SLF.  Distilled water was used as the reference.  The viscosity 
was measured using the Automated Micro Viscometer (AMVn 320, Anton Paar, UK).  A 
104 
 
1.6 mm capillary, containing a 1.5 mm ball was filled with 400 µL SLF, sealed with a luer 
cap and measurements made with the capillary tilted at 50°, 60° and 70°.  The surface 
tension of SLF was measured using a torsion balance (Model OS, TBS, UK), using 
distilled water as the reference sample which gave a surface tension value of 72.5 ± 0.5 
mN/m.  A 4 cm circumference platinum ring was immersed approximately 0.5 cm into 
SLF ring and the force required for withdrawal of the platinum ring from the surface of 
the fluid was recorded as the surface tension. All measurements were conducted in 
triplicate at ambient temperature. 
A Langmuir trough (Model 602A; Nima Technologies Ltd., Coventry, UK) was used 
to evaluate the monolayer behaviour or make surface pressure-area measurements at 
23°C, using a PS4 surface pressure microbalance (0-240 mN/m range, 0.1 mN/m 
resolution) fitted with a Wilhelmy plate (1 cm width Whatman Grade 1 chromatographic 
paper, GE Healthcare life sciences, Little Chalfont, UK) and controlled by Nima IU4 
computer interface unit software.  Suspensions of freeze-dried SLF, 1 mg/mL, were 
prepared in chloroform, vortexed for 10 min, then bath sonicated at 37 kHz, 25°C, for 10 
min.  For each isotherm, the test fluid was deposited dropwise onto a 0.9% w/v NaCl 
sub-phase surface using a Hamilton syringe and spreads rapidly to cover the available 
area of the trough until the surface pressure reached 20 mN/m, with the barriers open at 
their maximum.  The solvent was allowed to evaporate for 10 min before the barriers 
were compressed at 35 cm2/min.  The mean molecular weights of the surface-active 
components of SLF (38,760.9 g/mol) were calculated from their defined compositions 
and together with the known masses of the deposited monolayers, were used to 
determine the molecular area of SLF.  The isotonic saline subphase was used to simulate 
the influence of normal lung fluid counter-ions on the behaviours of the monolayer 
components (Scarpelli et al., 1965).  Individual compressions were used to determine 
the collapse pressure of SLF, which was 50 mN/m.  Subsequently, each film was 
compressed to a surface pressure 5 mN/m below its collapse pressure and then 
expanded to reach the initial surface pressure, 20 mN/m.  Triplicate experiments of ten 
isotherm cycles was performed, without an equilibration period between the expansion 
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and re-compression.  Each individual compression-expression cycle took 10-25 min to 
complete.  The degree of hysteresis was determined from differences between the 
compression and expansion isotherms for each cycle.  The surface compressional 
modulus (K) (Vollhardt and Fainerman, 2006), was calculated using equation (20): 
 
K = I / C = -A x (dπ/dA)T                                                                                                                                                 (20) 
 
Where C is compressibility, A is the mean area per molecule and (dπ/dA)T  is the slope 
of the isotherm at a defined surface pressure.  Compressibility is characterised by high 
surface elasticity and low interfacial stiffness (Choi et al., 2014). K ranges between 12.5 
and 50 mN/m for the liquid expanded phase, 50 – 100 mN/m liquid intermediate phase 
and 100-250 mN/m for the liquid condensed phase (Dynarowicz-ŁA̧tka and Ha̧c-Wydro, 
2004), whilst the condensed state has K values > 250 mN/m. 
 
3.3.3 Standardisation of SLF 
SLF was prepared three times on day 1 and prepared once on day 2 and day 3.  
The SLF was also manufactured once in the absence of the protein components and in 
the absence of the lipid components.  The solutions were then characterised in terms of 
their appearance and their physicochemical properties: appearance, pH, conductivity, 
viscosity and surface tension, using the methods described in section 3.3.2. 
 
3.3.4 Freeze-drying of SLF 
SLF, 10 mL solution, was prepared in SCHOTT tubular glass freeze drying vials.  
The samples were frozen overnight at 20°C and then placed into a vacuum freeze-drying 
system (Lyotrap, LTE Scientific Ltd, UK) with condenser temperature -45°C and a 
vacuum of 0.060 millibars for 48 h.  The samples were covered in a thin layer of parafilm 
with a couple of piercings to allow for vapor to escape during sublimation.  
Thermogravimetric analysis (Discovery TGA, TA Instruments, UK) was used to analyse 
the residual moisture content in the freeze-dried SLF powder, heating the sample at a 
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heating rate of 10°C/min to a maximum of 200°C.  The powder was reconstituted with 
10 mL de-ionised water and compared to fresh SLF using the physicochemical 
parameters described in section 3.3.3. 
 
3.3.5 Stability assessment of fresh aqueous SLF and freeze-dried SLF 
Fresh and freeze-dried SLF study was determined for samples stored in the fridge 
(4°C) and at room temperature (20°C) and at human physiological temperature (37°C).  
The stability was assessed by analysis pH, viscosity, conductivity and surface tension 
after their storage for 1, 2, 3, 4, 7, 14 and 28 days for the aqueous SLF and for 7 days, 
28 days, 3, 6 and 9 months for freeze-dried SLF, using the methods described in section 
3.3.3.   
Lipid degradation was evaluated using one-dimension thin layer chromatography 
(TLC).  The lipid components were extracted from the SLF fluid, using an adapted 
version of the method detailed by Bligh and Dyer (Bligh and Dyer., 1959).  Briefly, 1 mL 
SLF sample was ultracentrifuged at 13, 000 rpm for 10 min to sediment out the lipids and 
proteins.  To the pellet obtained, 1 mL of a mix consisting of chloroform: methanol [2:1] 
and 0.26 mL, was added and mixed to form a single phase.  The sample was left to 
incubate with gentle agitation for 90 min at 37°C.  Acidified saline (150 mM sodium 
chloride adjusted to pH 2 with hydrochloric acid), 0.5 mL was added, and vortex mixed 
for 5 min followed by centrifugation at 2000 rpm for 15 min (Biofuge, Pico, Jencons-PLS 
Scientific, UK).  The aqueous phase was removed, and 0.25 mL methanol and 0.25 mL 
acidified saline was added to the remaining organic phase.  This was vortex mixed and 
centrifuged again at 2000 rpm for 15 min, then the aqueous layer was removed, and the 
organic solvent evaporated to concentrate the lipids. 
To analyse the isolated lipids by TLC, the sample was spotted approximately 1 cm 
from the bottom of a plain silica gel 60 TLC plate.  The plate was transferred to a glass 
TLC tank containing 1 cm of the mobile phase, consisting of chloroform, methanol and 
25% ammonium hydroxide solution at a ratio of 65:25:10.  When the mobile phase 
reached three-quarters way up the plate the lipids were visualised as yellow spots using 
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potassium permanganate stain.  The retardation factor (RF) was calculated as the 
distance travelled by centre of the spot divided by the distance travelled by the solvent 
front.  A calibration between spot intensity (using the mean grey value) and concentration 
of DPPC and DPPG was established and used to estimate the content of lipid in the SLF. 
 
3.3.6 Biocompatibility of SLF with Human A549 cell line 
The biocompatibility of both fresh SLF (SLF stored at 4°C for one week) and 
degraded SLF (SLF stored at 37°C for one week), with human alveolar epithelial A549 
cells was carried out.  The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay was used to assess the effects of exogenously applied compounds on the 
cell layer metabolism.  The cells were cultured in a humidified atmosphere at 37°C, 5% 
CO2 using a cell culture medium (CCM) composed of RPMI-1640 medium supplemented 
with 10% v/v fetal bovine serum (FBS), 1% v/v L-glutamine and 0.1% v/v gentamicin.  
For the MTT assay, A549 cells were seeded in 96-well plates at 20,000 cells/cm2 using 
reduced serum (2% FBS) CCM before exposure to SLF for 24 h.  After 24 h, cells were 
washed with PBS and 100 µL of fresh CCM containing 25 µL of MTT solution (5 mg/mL 
in PBS) was added to each well and the plate was incubated for 4 h in a humidified 
incubator.  After 4 h this medium was removed by gentle inversion and tapping onto 
paper.  The cells were lysed, and any formazan crystals formed within the adherent cell 
layers were solubilised with 100 µL of a surfactant solution, 10% v/v SDS in 
dimethylformamide: water [1:1].  Cells were incubated with lysis solution overnight at 
37°C before the absorbance of solubilised formazan was measured at 570 nm using a 
SpectraMax microplate reader (Molecular Devices, UK).  The relative cell proliferation 
(% cell viability) was calculated using equation (21): 
 
Cell viability (%) = [T-N/P-N] X 100                                                                                 (21) 
 
Where T is the absorbance obtained for each concentration of the test substance, N is 
the absorbance obtained for the negative control (SDS solution/ no viability) and P is the 
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positive control (the medium/ absolute viability).  The measurements were corrected for 
background absorbance, using a wavelength of 650 nm.  Experiment was carried out in 
triplicate. 
 
3.3.7 Solubility of inhaled drug compounds in SLF 
The solubility of fluticasone propionate, beclomethasone dipropionate, 
mometasone furoate and budesonide were measured in SLF and compared with 
Gamble’s solution, Survanta and 0.5% w/v SDS in PBS.  It was done by mixing excess 
drug powder (approximately 0.5 mg) with 0.5 mL of the solvent in a microcentrifuge tube.  
The sealed tubes were vortex mixed for 5 min before sonication at 37°C for 30 min before 
transfer to a shaking water-bath at 37°C.  After 48 h, the drug suspensions were 
centrifuged at 13000 rpm for 10 min, then the supernatant (0.2 mL) was centrifuged for 
a second time before 0.1 ml of supernatant was diluted 10 times with methanol.  This 
sample was analysed for drug concentration by RP-HPLC-UV, using similar method 
described in Chapter 2, section 2.3.2, with mobile phases specific to the compound 
(Table 3.2). Solubility of FP was also carried out in degraded SLF/ SLF stored in poor 
conditions and compared with its solubility in SLF stored under appropriate conditions.  
All measurements were carried out in triplicates.  
 
3.3.8 Dissolution of inhaled compounds in SLF 
The dissolution of a couple of inhaled compounds, FP and BDP was carried in SLF 
and compared with Gamble’s solution, Survanta® and 0.5% w/v SDS in PBS.  For these 
experiments, Flixotide® 50 µg Evohaler or QVAR® 50 µg pMDI was used and the 
dissolution method was as described in Chapter 2, section 2.3.5.  Dissolution of FP was 
Table 3. 2. List of inhaled drug compounds and the mobile phases used in the RP-HPLC-UV 
system for quantification in simulated lung fluid (SLF). 
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also carried out in degraded SLF and compared to its dissolution in SLF stored under 
appropriate conditions.  To quantify FP in samples dissolved in Gamble’s solution, 175 
µL of sample was removed from the well plate at each time point and placed into a HPLC 
vial for analysis.  To quantify FP in samples dissolved in 0.5% SDS in PBS, 100 µL 
sample was removed and diluted with 100 µL MeOH prior to injection into HPLC.  For 
samples dissolved in Survanta® or SLF, 200 µL sample was removed and placed into a 
microcentrifuge tube and centrifuged at 13,000 rpm for 10 min.  The supernatant, 100 
µL was removed and diluted with 100 µL MeOH prior to injection into HPLC.  The tests 
were carried out at ambient temperature and in triplicates. 
 
3.3.9 Statistical analysis 
The physicochemical properties were derived from three independent batches of 
SLF; the data for the stability study was for 3 vials from a single batch of SLF.  Data 
comparing the freeze-dried SLF with the non-freeze-dried material were normally 
distributed (Histogram; Skewness and Kurtosis).  Therefore, the non-parametric paired 
sample T-test was applied.  However, for biocompatibility assessment, comparing the 
SLF stored at 37°C with the SLF stored at 4°C and at variable SLF concentrations, Two-
Way ANOVA was applied. Stability data were also normally-distributed (Histogram; 
Skewness and Kurtosis) and One-way ANOVA was applied.  All statistical analyses were 
performed using the IBM SPSS software, version 24, (SPSS, Armonk, NY, USA).  Data 












3.4.1 Composition and characterisation of SLF 
The physicochemical characteristics of SLF is listed in Table 3.3.  The freshly 
prepared SLF was peach in colour due to the presence of transferrin and very frothy as 
a result of the albumin.  In terms of mean grey value, it gave a value 165.5 ± 0.3.  The 
pH of SLF was neutral, pH 7.2, due to the buffering provided by the HBSS as a base 
medium, maintaining the physiological pH range of 7.2-7.6, according to the product 
specification.  Uni-, bi- and oligolamellar liposomes were visualised in the SLF, using the 
Cryo-TEM.  Irregular electron-dense structures could also be seen, which may have 
been indicative of protein aggregates.  Dynamic light scattering also detected structures 
in SLF, with a strong signal for structures with a size of 57 nm and a weaker signal for 
946 nm.  However, there were a lot of background scattering.  The density of SLF was 
closer to that of water, which approximates to 1 g/cm3.  The surface tension of SLF was 
lower than that of water, which is typically 72.0 ± 0.5 mN/m.  Langmuir isotherms 
(pressure-area relationships) was explored to determine the physicochemical behaviour 
of monolayers formed on water.  The mean molecular area of SLF was 668-800 Å2, over 
the 10 cycles.  SLF seemed to form a stable monolayer after the first compression-
expansion cycle.  During compression, it underwent transitions from a liquid expanded 
to intermediate phase, followed by a liquid condensed phase.  A large hysteresis loop 
and shift towards lower molecular area was observed between the first and second 
compression cycle.  The remaining cycles were identical, indicating the formation of a 
stable monolayer.  The same physicochemical properties were maintained for all SLF 
samples, prepared on the same or alternative days.  There were no significant 
differences in the properties between 3 separate batches of SLF (Table 3.4). 
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Table 3. 3. Physicochemical characteristics of simulated lung fluid (SLF).  All 




Table 3. 4. Physicochemical properties of three batches of simulated lung fluid 
(SLF) prepared on day 1, 2 and 3. All measurements made at 25°C and data 
represent mean ± SD (n=3). 
 
 
3.4.2 Stability of fresh SLF 
Preliminary studies showed that appearance and four physiochemical properties 
were stability-indicating; these were used to evaluate SLF over 28 days at three 
temperatures, 4, 20 and 37°C (Figure 3.2).  In terms of appearance, SLF was peach 
coloured when freshly made.  This was quantified using Image J as a mean grey value 
on a scale where 0 corresponds to black and a value of 225 corresponds to white (Figure 
3.2.a).  SLF lightened in colour visibly, becoming white by day 2, with the mean grey 
value rising from 168.5 ± 0.4 to 174.5 ± 0.1 at 20°C and 169.7 ± 0.3 to 175.3 ± 0.3 at 
37°C.  At 4°C, the mean grey value was unchanged at day 14 and only increased from 
168.9 ± 0.3 to 175.9 ± 0.3 at day 28.  The pH and viscosity of the SLF samples stored at 
20 and 37°C also began to decrease after day 2 of storage (Figure 3.2.b and 3.2.c).  
Conductivity and surface tension were affected similarly (Figure 3.2.d and 3.2.e), at 37°C 
there was a reduction of surface tension from 54.6 ± 0.5 mN/m to 53.0 ± 0.2 mN/m at 
day 2, which continued to decrease until 28 days (One-way ANOVA, p ≤ 0.05). 
TLC analysis was used to probe lipid stability further.  Potassium permanganate 
was used to detect phospholipids by oxidising the phosphorus groups, giving a distinctive 
colour change from pink to yellow.  At day 0, TLC of SLF revealed two spots with RF 
values of 0.66 ± 0.01 and 0.85 ± 0.01, which were identified as DPPC and DPPG, 
respectively, by comparison to reference standards (Appendix A Figure A.2).  From day 
3 and day 2, SLF stored at 20°C and 37°C exhibited an additional spot with RF value of 
0.48 ± 0.01, indicating presence of a lipid hydrolysis product. The TLC was also used for 
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quantitative determination, where spot intensity can be correlated to the concentration of 
DPPC or DPPG (see Appendix A Figure A.3).  For SLF stored at 20°C, DPPC 
concentration fell by approximately 15% and DPPG concentration fell by 25% by day 3.  
For SLF stored at 37°C, both DPPC and DPPG concentrations decreased by 
approximately 20% by day 2.  In contrast, less than 10% loss of DPPC and DPPG was 
measured in SLF stored at 4°C. 
 
 
Figure 3. 2. Stability assessment of simulated lung fluid (SLF) after its storage at 
4, 20 and 37°C for 0, 1, 2, 3, 4, 7, 14 and 28 days based on changes in a) colour, b) 
pH, c) viscosity, d) conductivity and e) surface tension. All measurements made 




It was evident that the appearance, pH, viscosity, conductivity and surface tension 
remained constant for 14 days at 4°C, and significant changes in SLF characteristic do 
not become evident until day 28 (One-Way ANOVA, p ≤ 0.05) (Table 3.5).  This indicated 
that SLF can be stored in a refrigerator for 2 weeks.  At 20°C, changes in the SLF 
characteristics only became significant after 3-4 days of storage, indicating that SLF is 
stable for 48 h.  At 37°C, changes in SLF characteristics became significant at day 2, 
indicating that its use is only restricted to 24 h. 
 
Table 3. 5. The day at which the simulated lung fluid (SLF) changes with regards 
to its appearance and physicochemical properties (tested at days 1, 2, 3, 4, 7, 14, 














3.4.3 Freeze-dried SLF 
Images of the freshly prepared SLF, freeze-dried powder and reconstituted SLF is 
shown in Figure 3.3.  The powder appeared to be very lyophilised and of small quantity 
at the base of the vial.  The reconstituted SLF exhibited a similar peach colour and frothy 
solution, to the original SLF.  The same physicochemical chemicals used to assess 
stability, were also used to compare the freeze-dried material with the original SLF.  The 
appearance and physicochemical properties of SLF was restored successfully after 
rehydration with de-ionised water, except for a higher pH (Table 3.6).  TGA indicated that 
4.42 ± 0.15% moisture was retained in the powder (Appendix A Figure A.2). 
 
Figure 3. 3. Images captured of a) Freshly prepared simulated lung fluid (SLF), b) 




Table 3. 6. Physicochemical properties of simulated lung fluid (SLF) when freshly 
manufactured and when reconstituted after freeze-drying.  All measurements 
made at 25°C and data represent mean ± SD (n=3). 
 
 
3.4.4 Stability of freeze-dried SLF 
The appearance, pH, viscosity, conductivity and surface tension were also used 
as indicators to assess the stability of the freeze-dried SLF (Figure 3.4).  For the freeze-
dried powder, the stability was assessed for a longer period, up to 168 days, as oppose 
to 28 days for the aqueous SLF.  It appeared that the appearance and all 
physicochemical properties of the re-constituted powder remained consistent over the 
course of 168 days.  TLC analysis showed no extra spots, apart from the two spots 




Figure 3. 4. Stability assessment of freeze-dried simulated lung fluid (SLF) after its 
storage at 4, 20 and 37°C for 0, 7, 28 days and at 3 and 6 months, based on changes 
in a) colour, b) pH, c) viscosity, d) conductivity and e) surface tension. All 










3.4.5 Biocompatibility of fresh and degraded SLF with A549 cells 
The MTT assay, a colorimetric assay, is used to measure the metabolic activity of 
the cells, whereby the mitochondrial reductase enzyme reduces the yellow MTT salt to 
formazan dye which has a purple colour.  This allows the investigator to assess the 
viability and proliferation of the cells, where the darker the intensity of the purple colour 
means there were more living cells and hence represents a higher % cell viability.  The 
% cell viability and thus the biocompatibility of SLF stored under the correct condition 
versus SLF stored under poor condition, at different concentrations, with human alveolar 
epithelial A549 cells is shown in Figure 3.5.  Exposure of the cells to SLF after 24 h, 
immediately dropped the % cell viability from 100% to approximately 60%.  There were 
evidently yet some mitochondrial activity and cellular metabolism occurring in the cells.  
The % cell viability remained consistent regardless of the concentration of SLF applied, 
with insignificant differences seen at all concentrations (Two-Way ANOVA, p≤0.05).  
Insignificant differences were observed between the effects of SLF stored at 37°C and 
SLF stored at 4°C on % cell viability, at all concentrations (Two-Way ANOVA, p≤0.05). 
 
 
Figure 3. 5. MTT assay to assess the biocompatibility of different concentrations 
of good quality and degraded simulated lung fluid (SLF) with human alveolar 
epithelial A549 cells.  Good SLF was described as SLF stored at 4°C  for 1 week 
and degraded SLF was described as SLF stored at 37°C for 1 week.  Data represent 
mean ± SD (n=3). * Represents significant difference ( p ≤ 0.05). 
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3.4.6 Solubility and dissolution of FP in fresh and degraded SLF 
SLF stored under poor conditions had a significant impact on the solubility of FP, 
as seen in Table 3.7.  Solubility of FP in the degraded solution was approximately three 
times higher than in the good SLF.  The dissolution rate of FP in degraded SLF appeared 
to also be significantly higher than in SLF stored under appropriate conditions, since the 
% dissolved at each time was much higher and the SD associated with them did not 
overlap (Figure 3.6). 
 
Table 3. 7. Solubility of fluticasone propionate in fresh/good simulated lung fluid 




Figure 3. 6. Dissolution of fluticasone propionate in fresh/good simulated lung 
fluid (SLF) and in degraded SLF, carried out using the TSI/Transwell® dissolution 







3.4.7 Solubility and dissolution of inhaled compounds in simulated fluids 
The solubility of a few inhaled drug compounds: Beclometasone dipropionate 
(BDP), Budesonide, Fluticasone propionate (FP) and Mometasone furoate (MF) in SLF 
was identified and compared to other reported versions of simulated fluids (Table 3.7).  
For all drugs, the solubility in Gamble’s solution was the lowest.  Solubility of the drugs 
in 0.5% w/v SDS in PBS was the highest, except for solubility of FP, which seemed to 
be influenced greatly by the components in Survanta®.  For BDP and Budesonide, their 
solubility in SLF was closest to their solubility in Survanta, in comparison to the other 
fluids. However, unexpectedly FP and MF solubility in SLF were much closer to Gamble’s 
solution than Survanta.  The dissolution of FP and BDP from licensed inhaler products 
correlated with drug solubility in the dissolution medium (Figure 3.8).  BDP appeared to 
dissolve more readily than FP and for both drugs, the dissolution rate in SLF was greater 
than in Gamble’s solution, but lower than the rate in 0.5% w/v SDS in PBS. 
 
Table 3. 8. Solubility of inhaled compounds in Gamble's solution, Simulated Lung 





Figure 3. 7. Dissolution of A) fluticasone propionate and B) Beclometasone 
dipropionate in Gamble’s solution, simulated lung fluid (SLF), 0.5% w/v SDS in 












3.5.1 Manufacture and characterisation of SLF 
The SLF was designed to provide a simulant that trades off the biorelevance of 
featuring the full complexity of lung lining fluid with the pragmatic need for a simulant that 
can be manufactured economically, reproducibly and is fit for the majority of applications 
in inhaled medicines biopharmaceutics.  It consisted of key components found in healthy 
human RTLF, the major soluble proteins, the abundant lipids and the antioxidants that 
were identified in a study by Bicer (Bicer, 2015).  The lipid components were DPPC and 
DPPG to represent the surfactant phospholipids in the lungs and cholesterol, a neutral 
steroid lipid.  Although DPPC, which contributed approximately 80% w/v of the surfactant 
phospholipids, is often used as a sole representative phospholipid component in model 
lung fluids, for physiological relevance other lipid components were included.  DPPG was 
included since it represents approximately 10% of total phospholipids and cholesterol, 
which accounts for 5-10% surfactant, was included since it has been shown to have a 
stabilising role in the bilayer structures.  Urea corrected total protein concentration 
measured in human lavage samples is in the range 17.9 ± 8.6 mg/mL (Bicer, 2015), but 
due to the limited commercial availability and consistency of some human protein 
components, e.g. the surfactant proteins: SP-A, SP-B, SP-C and IgA and A1TA, the total 
proteins used in the preparation of SLF was 12.9 mg/mL  Biorelevant concentrations of 
antioxidants were included to promote biocompatibility of SLF with respiratory epithelial 
cells. 
The preparation method in this study was optimised to counteract few theoretical 
limitations associated with the method reported in Bicer’s study.  For example, the main 
two steps are the preparation of the liposomal components and the preparation of the 
protein components.  This means SLF could be prepared more simply with fewer steps, 
taking only 20 min to prepare.  Also, stock solutions of the ingredients were prepared 
prior to this, whereby the lipid components were prepared in chloroform, protein 
components were prepared in HBSS and antioxidants in deionised water.  Taking 
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samples immediately from the stock solutions, minimised the complexity and transfer 
errors associated with weighing out powders.  Consequently, the method for the re-
submersion of the surfactant bilayers within the fluid was chosen to ensure minimal 
damage to the structures created in SLF.  The manufacturing process was a robust 
method since the SLF appeared to be the same and present the same properties 
regardless of the time and day prepared. 
In terms of the characterisation of SLF, the physicochemical properties and the 
characterisation techniques to identify them, were selected based on previous studies 
that focused on characterisation of physiological fluids such as saliva or simulated 
intestinal fluids (Boni et al., 2009; Gittings et al., 2015).  SLF appeared peach in colour 
and when converted to a mean grey value, it gave a value closer to white than black on 
the 0 to 225 scale on Image J (0 corresponds to back and 225 corresponds to white).  
SLF exhibited a neutral pH, buffered by the HBSS and closely matched the pH of in vivo 
lung, although subject to some variability.  For example, the pH in the nasal cavity is 
approximately 6.3 (range 5.2-8.1) (Washington et al., 2000), pH is 6.9-9.0 in the trachea 
(Karnad et al., 1990) and suggested to be more acidic in inflammation and infection 
(Karnad et al., 1990).  The buffering effect provided by HBSS was evidently not 
influenced by the addition of multiple protein and lipid components.  The HBSS not only 
provides a buffering effect, but the essential inorganic ions present provide a 
physiological salt composition, tonicity (280 mOsM) and are responsible for the high 
conductivity of SLF in comparison to de-ionised water, matching the properties of lung 
lining fluid in healthy subjects (Effros et al., 2005).  Consequently. the ions present in 
HBSS are a mix of polydisperse ions, large and small.  The larger ions tend to act as 
chaotropes and cause the HBSS solution to have a higher density than pure water, and 
the smaller ions or macromolecules compensates for the chaotrope content and presents 
a counter-acting effect (Hribar et al., 2002).  As a result, the SLF exhibited a similar 
density to water. 
The particle structure and size were analysed via Cryo-TEM and DLS respectively.  
Initially optical microscopy was used to study the particle structures involved in SLF.  The 
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technique confirmed the presence of particles, that appeared predominantly 
agglomerated.  Agglomeration was an expected observation since SLF consisted of high 
protein content, which can cluster together forming bimolecular protein agglomerates 
(Filipe et al., 2010).  However, the exact identification of the agglomerate composition 
could not be fully established via this method.  Cryo-TEM imaging better confirmed 
presence of lipids, that were too small to be identified by optical microscopy.  The use of 
cryo-TEM technique originated from a study by Almgren et al and the method was 
adapted to their study (Almgren et al., 2000).  Although it has been reported that HBSS, 
due to its high salt content, may interfere with TEM imaging (Bicer, 2015), the images 
captured in this study proved the technique to be powerful in characterising the liposome 
morphology and allowed for visualisation of the fine detail of surfactant structure in SLF.  
There were varied sizes of undamaged liposomes present and this emphasised the 
benefit of the optimised preparation technique for SLF.  The polydispersity in bilayer 
structures was like the polydispersity exhibited by the human RTLF (Appendix A Table 
A.1).  It has been suggested that cholesterol, present in both, is responsible for 
increasing bilayer stiffness and cohesive strength, producing defined circular structures 
(Almgren et al., 2000).  However, the slightly more cohesive lamellar array observed in 
RTLF, is likely due to the additional presence of SP-A, which promoted the formation of 
surfactant films (Bernardino de la Serna et al., 2013).  The presence of the smaller 
irregular structures is likely reflective of protein aggregates, and DLS supported the 
detection of these structures, since the stronger signal for structures with a size of 57 nm 
corresponded to the size of the liposomes, and the weaker signal for 946 nm likely 
corresponded to the proteins and protein aggregates.  However, further interpretation of 
the DLS result was not possible, due to background scattering by the multi-molecular 
protein agglomerates.  This is a recognised limitation of dynamic light scattering size 
analysis in media with high protein content (Filipe et al., 2010).  
The lower surface tension exhibited by SLF, in comparison to the reference 
water, was due to the surfactants in SLF.  DPPC is the most surface-active molecule in 
the pulmonary surfactant mix and hence, was responsible for the significantly reduced 
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surface tension (Pérez-Gil and Keough, 1998).  Proper pulmonary function requires low 
surface tensions during expiration to minimise the work of breathing (Schürch et al., 
1976).  The pulmonary surfactants in human RTLF form a lipid-rich film with a 
significantly reduced surface tension from 70 mN/m at the upper airways, to near 0 
mN/m at the alveoli (Siebert and Rugonyi, 2008; Ikegami et al., 2009).  It has been 
reported that DPPC forms a semi-crystalline monolayer capable of surface tensions 
reaching near zero when fully compressed (Ding et al., 2001).  However, in this study, 
although SLF consisted of a relatively high concentration of DPPC, it appeared to 
exhibit a higher surface tension than would otherwise be anticipated. This is likely due 
to the absence surfactant proteins, particularly of SP-B, a small hydrophobic protein.  In 
a study conducted by Ikegami et al (Ikegami et al., 2009), they found that removal or 
reduction of SP-B, increases the surfactant surface tension, demonstrating its 
important role in regulating the surface tension-lowering properties of surfactants.  
Surfactant proteins also play a role in fluid viscosity, whereby SP-C interacts with lipids 
to produce high surface viscosity (Alonso et al., 2005).  However, despite the absence 
of SP-C in SLF, the viscosity of SLF was higher than that of simple aqueous solutions 
and this was attributed to the presence of protein macromolecules and complex lipids 
in their physiological concentrations.   
The Langmuir trough experiment characterises both the structural and 
mechanical properties of SLF.  The phase behaviour of surfactants in two dimensions 
is determined by the pressure-area isotherms.  It appeared that SLF formed a stable 
lipid monolayer on water surface, after the first compression-expansion cycle.  For the 
lungs to function effectively, it would require the lung surfactants to form a rigid 
monolayer of low surface tension upon compression, but also be fluid enough to 
spread rapidly during the expansion of the interface that accompanies inspiration 
(Bastacky et al., 1995).  DPPC is reported to be responsible for the semi-crystalline 
monolayer rigidity and stability, whereas proteins are responsible for fluidising the 
monolayer (Ding et al., 2001).  This contradictory requirement of the lung surfactant 
monolayer has led to the ‘squeeze-out’ theory of lung surfactant function, whereby it is 
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thought that any unsaturated lipids and proteins present in lung surfactants in vivo are 
selectively removed or ‘squeezed-out’ from the monolayer during compression, leading 
to a DPPC-enriched stable monolayer (Schürch et al., 1976; Ding et al., 2001).  The 
surfactant proteins in SLF, especially SP-B and SP-C, are thought to interact with the 
lipids to create a localised monolayer-to-multilayer transitions that provide low surface 
pressures on compression and rapid and repeatable re-spreading on expansion 
(Schürch et al., 1976; Ding et al., 2001).  However, although surfactant proteins are 
absent in SLF, this theory seemed to yet be supported by the in vitro results reported 
from the Langmuir.  Results indicated that SLF is a simple stable colloidal system, that 
required a composition-refining process during the first isotherm cycle, in which excess 
material such as the incorporated albumin or transferring proteins, is removed from the 
interface before the stability of the DPPC-enriched monolayer is maintained with the 
remaining compression-expansion cycles.  The absence of specialist surfactant 
proteins in general, limits the application of the SLF for some specialist immunological 
applications, e.g. where SP A and D are important in host-defence or biological studies. 
 
3.5.2 Stability of SLF and its significance 
SLF is predominantly a liposomal formulation and liposomes in aqueous 
dispersions tend to be relatively unstable, where hydrolysis and oxidation degradation 
often occur over time and are accelerated when exposed to heat (Nawar, 1969; Reis and 
Spickett, 2012; Mahdy and Yang, 2014).  More specifically, the ester functionality 
connecting the fatty acid and glycerol backbone is susceptible to hydrolysis resulting in 
free fatty acids, lysophospholipids and/or glycerophospho compounds (Aveldaño and 
Horrocks, 1983; GRIT et al., 1993).  It has been shown that hydrolytic degradation 
influences liposome size and bilayer rigidity (Zhang et al., 2004).  Peroxidation, which 
involves the removal of a hydrogen atom from the fatty acid constituents to produce the 
free radical, is a serious concern with liposomal formulations.  The lipid radical may react 
with oxygen in the air to produce a peroxyl radical (Reis and Spickett, 2012) and 
additional reactions can occur such as cyclization, fragmentation and rearrangement 
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(Payton et al., 2014).  These reactivity processes have shown to alter the physical 
properties of the liposome bilayers such as the fluidity and hence, the physicochemical 
properties of the whole liposomal formulation (Payton et al., 2014).  This provided motive 
to study the stability of SLF. 
In this study, the stability of SLF was carried out according to the recommended 
ICH guidelines (ICH EMEA, 1993).  The assays chosen to assess stability were simple 
approaches, the apparatus used are relatively cheap to purchase and easily accessible 
and can be carried out in all labs.  Consequently, these methods are sensitive in 
identifying the physical changes that occur in solutions and in this study, they were 
congruous in detecting conditions and time at which SLF began to degrade and in 
profiling temporal stability at each storage temperature.  The background scattering seen 
in the DLS results complicated interpretation of the results and thus was not suitable as 
a stability test.  The results were consistent with changes that occur to lipids at elevated 
temperature or over periods of time, as mentioned above.  Although antioxidants are 
present in SLF in small quantities, they are not fully protective, and it has been reported 
that ascorbate may even catalyse the oxidation of phospholipids in solvent systems 
(Deutsch et al., 1941).  Degradation of the phospholipids can reduce pH as lipid 
dissociate into their constituent fatty acids (Abramson et al., 1968).  Metal cations, such 
as the sodium ion present in DPPG and the quaternary ammonium ion in DPPC, can 
participate in reactions that produce a sharp decrease in viscosity (Abramson et al., 
1968).  Hydrolysis of phospholipids produces two main lysoforms, with the 1-acyl 
lysoform being predominant (Jeschek et al., 2016).  The higher levels of lipids tend to 
reduce the surface tension of protein-containing solutions (Xu et al., 2013) and the 
electrical conductivity of aqueous solutions (McClements, 2005).   
TLC analysis identified more spots of different RF values on the plate after it was 
stained with potassium permanganate, further supporting the concept of lipid hydrolysis 
at higher temperatures to its constituent fatty acids.  It can also be used for quantitative 
determination (Askal et al., 2008), thus in this study, image analysis was used to provide 
a semi-quantitative measure of spot intensity for DPPC and DPPG, whereby the mean 
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grey value of the spot was plotted as a function of lipid concentration (Appendix A Figure 
A.3).  There was a strong positive correlation between the two factors, which meant the 
percent degradation of the lipids could be estimated.  The results suggested that DPPG 
was more vulnerable to degradation, since its concentration fell more than DPPC in the 
SLF stored at room temperature. 
Identifying the conditions in which SLF must be stored under is important, as 
results in this study indicated that SLF stored in poor conditions affects the solubility of 
FP significantly, by a factor of three.  This was likely attributed to the increase in the 
hydrophobic fatty acid content in SLF, a result of phospholipid hydrolysis, when SLF was 
stored at 37°C for 1 week.  With more hydrophobic tails present in SLF, although not 
tightly packed, they provide more regions or reservoirs for FP to adhere to, and thus 
increases its solubility and its dissolution rate as a response.  However, poor storage of 
SLF did not seem to have a significant impact on its biocompatibility with lung A549 cells.  
The MTT assay was applied in this study to determine the cytotoxicity of poorly-stored 
SLF, since it was thought that its degradation products would interfere with cell viability 
and growth.  However, the results suggested that although the physicochemical 
properties of SLF changes with poor storage conditions, the fatty acids do not present 
any further toxicity to the cells.  The antioxidants seemed to maintain this good 
biocompatibility.  Regardless of the SLF concentration the cells were exposed to, the % 
cell viability remained relatively constant, indicating that the fluids may have a synergistic 
effect on the cells.  However, the SLF did not provide any nutrients to the cells to allow 
for sufficient metabolism in comparison to the medium, since the % cell viability 
immediately dropped from 100% viability in the presence of only medium to 
approximately 60%, in the presence of pure SLF.  This means that the medium is the 
dominant provider of nutrients to the cells to allow for cell growth and proliferation, 
whereas the components of SLF provides some form of protection to the cells.  Although 
it has been shown that presence of antioxidants can stimulate the proliferation of cultured 
endothelial cells (Kuzuya et al., 1991), the antioxidant components in the fluid did not 
seem to do so to a large extent, but provided limited protection to the available cells from 
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oxidant-induced apoptosis for example and thus allowed for up 50% cell growth. 
Consequently, it has been shown previously that A549 cells benefit from cholesterol and 
DPPC, which exhibits anti-inflammatory effects to the cells (Morris et al., 2008).  
Therefore, it may be that incubation of the cells with SLF has an immunomodulatory 
protective role, as oppose to detrimental effects.  Consequently, although the 
degradation products of SLF caused the pH to decrease, it was not substantially far from 
physiological pH (6.5-7.6) and the HBSS present provided the physiologically relevant 
electrolytes and glucose concentrations which further protected the cells. Overall, the 
data suggested that there was no adverse impact of the physiologically relevant protein, 
liposome and their fatty acid constituent concentrations within the simulant, on the 
proliferation of A549 cell monolayers and hence, the simulants were biocompatible with 
this human epithelial cell line. 
 
3.5.3 Freeze-dried SLF and assessment of its stability 
Freeze-drying is a unique drying process used particularly for heat-sensitive 
materials or to improve the stability of lipids that are susceptible to chemical degradation 
(Hua et al., 2010).  Water in the dilute aqueous solution is usually removed, leaving 
behind a dried product that can be packaged and stored under various conditions, 
without its stability being affected (Hua et al., 2010).  The stability of freeze-dried SLF 
powder was studied here and compared to the aqueous form of SLF.  Stability was 
carried out in a similar manner to the aqueous solution, and in accordance to the ICH 
guidelines; however, for a longer time.  Although freeze-dried material could be prepared 
as a single large batch of powder, with each opening and closing of the batch to carry 
out the stability tests, it is likely air and humidity would be introduced to the powder, 
affecting the stability measurements.  To prevent this, separate disposable samples of 
SLF was freeze-dried and stored for analysis.  Part of the freeze-drying technique, 
involved the sample bottles being huddled in the centre of the stand and surrounded by 
empty bottles on the outside.  This is because preliminary studies showed that samples 
placed at the periphery of the stand is likely to be exposed to a different temperature 
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profile to the samples in the centre.  Hence, this technique ensured the samples were 
freeze-dried in a more uniform and consistent manner.  All samples were placed on the 
same cooling shelf level.  Where possible, SCHOTT freeze-drying vials were used with 
a tight-sealing lid to eliminate the influence of relative humidity of the storage conditions, 
on the stability of the powder.  In some cases, this was eliminated by sealing the glass 
bijou bottles tightly with parafilm.  Consequently, the sample were removed from the 
freeze-drier under the presence of nitrogen gas, again to ensure no oxygen, air humidity 
or water was introduced upon removal of the samples, which would otherwise 
compromise SLF sample stability.  Moisture has been reported to significantly influence 
the stability of lyophilised powder (Wang et al., 2012). 
For freeze-drying to be determined as successful, a dry fluffy lyophilised powder 
should be produced which can be easily reconstituted to possess physicochemical 
properties that match the original sample (Hua et al., 2010).  This is because the direct 
transition of water from solid to vapour via sublimation, without a liquid phase, helps to 
preserve the initial raw material’s properties.  Studies have shown that lyophilised 
powder of liposomes without addition of cryoprotectants is likely to be compact, clumpy 
and difficult to reconstitute and thus cryoprotectants have been considered as a critical 
processing parameter to consider when undergoing freeze-drying (Nounou and El-
Khordagui, 2005; El-Nesr et al., 2010; Soares et al., 2013).  However, in this study, the 
SLF was successfully freeze-dried without the need for additional formulation 
components to act as cryoprotectants; the powder produced was very fluffy and easy to 
reconstitute with water to restore the appearance and physicochemical properties of the 
SLF.  The results indicated that freeze-drying did not compromise the stability of the 
liposomal structures present in the fluid.  The reconstituted freeze-dried formulation was 
identical to the freshly made solution, except for a small statistically significant increase 
in pH, which can be readily corrected.  Although water is predominantly neutral in pH, 
the use of different grades for reconstitution e.g. distilled water, de-ionised water, HPLC-
grade water or ultrapure water, may result in variations in pH (Kulthanan et al., 2013).   
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Freeze-drying is effectively a drying operation, in which the water is removed by 
sublimation and a vacuum chamber is used to increase the speed of this process 
(Mujumdar and Devahastin, 2008).  While freeze-drying can improve the storage of 
liposomal formulations, it has been recognised that the process can also cause damage 
to the liposome structures which are exposed to stress conditions, such as excessive 
dryness, upon long periods of sublimation, which can pierce the liposomes or predispose 
them to aggregation (Nounou and El-Khordagui, 2005; Ingvarsson et al., 2011).  
However, the TGA results indicated that sufficient moisture was retained in the powder, 
so the liposomes were not subjected to excessive dryness and the process did not seem 
to induce destabilising stress factors to SLF solution.  Hence, the freeze-drying process 
parameters such as the freezing rate, freezing temperature and processing time can be 
considered optimal for this study.  The process evidently prolonged the stability of SLF, 
regardless of its storage conditions to up to 6 months so far, yielding a product with an 
extended shelf-life.  This is because due to the absence of water in the solid material, 
the degradation pathways or reactivity processes such as hydrolysis and oxidation, 
which becomes profound at higher temperatures, is far less pronounced than in the 
aqueous state.   
 
3.5.4 Recommendations for use of SLF 
The results from the stability study indicated that SLF can be stored in the 
refrigerator for 2 weeks and remain stable, with its physicochemical properties preserved 
well.  SLF is only stable for 2 days on the shelf, where it can be utilised for laboratory 
experiments such as, for solubility or dissolution testing which are often carried out at 
room temperature.  If SLF was required for in vitro experiments which involve cell culture 
or the use of physiological temperature, based on the results when SLF was stored at 
37°C, these experimentations should be restricted to 24 h. 
The appearance and physiochemical properties of the reconstituted lyophilised 
SLF powder remained unchanged after 6 months of storage, regardless of the storage 
temperature and there was no degradation of or chemical changes to the lipids detected 
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by TLC, indicating an improved stability of the lyophilised liposomal formulations in 
contrast to the aqueous formulation, and hence allowing for longer-term storage of 
material.  Lyophilisation clearly increases the shelf-life of liposomes, preserving it in a 
dry form that can easily be reconstituted with water immediately prior to use. 
 
3.5.5 Solubility and dissolution of inhaled compounds in SLF 
Drug solubility in lung fluid is an important determinant of the fate of inhaled aerosol 
medicines hence, studies have focused attention on the need to measure drug solubility 
in mediums that is representative of human RTLF (Riley et al., 2012).  The components 
and physicochemical properties of SLF very likely influences the solubility of inhaled 
compounds.  For example, results from the Langmuir suggested very stable colloidal 
structures in SLF, which may make them less likely to sequester poorly soluble drugs in 
its micelles.  In this context, the FP, BDP provide excellent references since they are 
considered as very poorly water-soluble drugs, reported to have concentrations of 
approximately 0.1-2 µg/mL in water (Appendix Table A.4,Murnane et al., 2008; Sahib et 
al., 2012; Hastedt et al., 2016).  In simple aqueous media, such as gambles, which is 
only composed of a variety of salts (Appendix A Table A.2), it was expected for the 
inhaled drugs to exhibit low solubility.  However, in the remaining surfactant-containing 
media, the solubility of the drugs increased hugely particularly in the 0.5% w/v SDS in 
PBS, which was expected and reflective of in vivo conditions.  In vivo, lung surfactants 
tend to enhance the solubility of small, lipophilic drug molecules, such as corticosteroids 
and cationic compounds, because they form structures with lipid domains (Wiedmann et 
al., 2000; Liao and Wiedmann, 2003).  However, some results were unexpected.  For 
example, Budesonide exhibits much better aqueous solubility, reported to be 
approximately 45 µg/mL yet its solubility increased significantly in surfactant-containing 
media but MF and FP, with low aqueous solubility, presented a solubility in SLF that was 
much closer to Gamble’s solution than the remaining surfactant-containing solutions.  
This suggested that solubilisation may be determined not only by lipid content but also 
the interaction of the components, including the drug, which affect liposomal structures.  
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For example, cholesterol may form tight nanodomain complexes with DPPC stabilising 
the lamellar structures formed (Kim et al., 2013) and forcing the retention of drugs within, 
whereas albumin may solubilise the cholesterol (Kim, 2007) and reduce the stability of 
the lamellar phase and the extent to which drug is solubilised in these structures.  
Consequently, the difference in solubilities across the range of compounds is influenced 
by the difference in the compounds’ intrinsic lipophilicity and pKa, influencing the 
compound partitioning into the lipid compositions of the fluid versus the aqueous 
composition (Fan and de Lannoy, 2014),  
However, an estimate for the solubility of FP in the lungs using mechanistic 
modelling (Boger et al., 2016) appears to support the value obtained with SLF.  Since 
the aqueous solubility of poorly soluble compounds tends to underpredict the in vivo 
dissolution rate, the parameter Cs, which defines the solubility of a drug according to 
Nernst-Brunner equation, should be estimated from observations of total drug 
concentrations in the lung made in an inhalation study The estimated Cs of FP, obtained 
following incorporation of parameters into a developed mechanistic physiologically 
based pharmacokinetic model, was 4530 nM and when converting the solubilities of FP 
in the fluids used in this study to nM, the value of FP in SLF was 4400 nM, which most 
closely correlated to the predicted Cs.  This finding supported the hypothesis that the 
salt solution is likely to underestimate the dissolution of hydrophobic drugs, while 0.5% 
SDS may overestimate solubility and hence dissolution in the lungs.  For the dissolution 
experiment, FP and BDP were selected to represent inhaled drugs that have poor 
aqueous solubility and likely to be dissolution limited, accounting for their relatively low 
dissolution profiles.  The solubility of BDP in all fluids, was significantly higher than the 
solubility values of FP, indicating that the impact of the lipid or surfactants present to 
solubilise FP was much greater than expected for BDP.  These results emphasised that 






Summary and conclusions 
A SLF of biorelevant composition was characterised and shown to possess 
physicochemical properties comparable to those of RTLF.  The simulant was determined 
to be stable for 24 and 48 h at 37 and 20°C, respectively (in-use stability) and for 14 days 
when stored in a refrigerator (storage stability).  Colour, surface tension and conductivity 
were the most sensitive indicators of product deterioration.  The SLF can be freeze-dried 
which provides a means of prolonged storage, for up to 6 months, with studies ongoing.  
This means it can be manufactured in large batches, in a form that has an extended use-
by date and is easily handled and transported for reconstitution at its place and time of 
use.  Overall, the study presented and provides a readily available, biorelevant and 
biocompatible SLF that can be used for in vitro investigations in the field of inhalation 
biopharmaceutics, e.g. the solubility of inhaled compounds, the dissolution of inhaled 
medicines and the interaction of aerosol drugs or particles with lung cells.  Relative to 
this thesis, it can now be applied to dissolution tests, in attempt to develop a biorelevant 
















Biorelevant in vitro/in silico modelling of inhaled drug 
dissolution in the lungs 
 
4.1 Introduction 
The next key step to the study was to evaluate the applicability and assess the 
necessity of SLF in the development of an in vitro biorelevant dissolution system, for 
discerning the quality attributes of inhaled medicines or for predicting the in vivo 
performance of inhaled products.  To do this, a recently-developed integrated apparatus, 
comprising the PreciseInhale® and DissolvIt® systems, will be used since it simulates the 
physiological conditions in the lung and mimics the pharmacokinetic data of inhaled 
particles.  Although this means the DissolvIt® dissolution system addresses various 
limitation exhibited by the other proposed dissolution tests for OIPs, the dissolution 
vessel requires 5.7 µl of a polyethylene oxide (PEO) gel as the dissolution matrix rather 
than a biorelevant medium.  This provides motive to apply the SLF, developed in Chapter 
3, to enhance the bio-relevance of the dissolution system and investigate the impact it 
has on the dissolution of FP, by comparing it to the other version of simulated fluids.  
Since the system is very novel, there is already very little reported data on the 
performance of the system in predicting dissolution, and hence, using this system in this 
study proves to be particularly useful. 
Consequently, delivery of FP to the DissolvIt® with different biorelevant media in 
the chamber, permits comparison to FP dissolution-absorption profiles in other systems, 
such as Isolated Perfused Lung (IPL).  This allows for IVIVC.  To perform such 
experiments however, requires accurate quantification of sub-micromolar concentrations 
of FP using a sensitive assay and an efficient extraction method (Krishnaswami et al., 
2000; US FDA CDER, 2011; Lombardi, 2015).  It has been reported that the liquid-
chromatography with tandem mass spectrometric detection (LC-MS/MS) technique 
provides selective and sensitive analysis of glucocorticoids in biological fluids (Li et al., 
1997; Krishnaswami et al., 2000; Matuszewski et al., 2003).  However, conducting many 
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of the reported liquid-liquid phase or solid phase extraction methods during my 
preliminary experiments, proved to be difficult to replicate and showed very poor 
repeatability.  This required the development of a solid phase extraction (SPE) method, 
which was easy to conduct, well validated, repeatable and reliable, requiring minimal 
sample preparations. 
The main value of in vitro systems is in providing decision-making data e.g. 
dissolution measurements for predicting and modelling impacts on drug PK in the early 
stages of the drug development process.  This can expedite drug development and 
prevent unexpected toxicokinetics and ultimately avoid the costly end-stage failures (Di 
et al., 2013).  The current PK and PD studies not only add in time and cost but may also 
introduce additional risk, with poor IVIVC data complicating the demonstration of 
bioequivalence (BE) between OIPs.  Therefore, improving the in vitro dissolution test to 
access better IVIVC and enable the greater reliance on in vitro methods for BE testing 
for example, has become an important goal in industry (Copley and Sipitanou, 2018).  
The ideal model should be able to reflect in vivo predictability.  Good predictive models 
for pharmacokinetics depends strongly on selecting appropriate mathematical 
approaches, and more current studies tend to utilise in silico techniques (Chen et al., 
2012; Gaohua et al., 2015; Fröhlich et al., 2016).  For modelling dissolution, Backman et 
al have described how recent advances in mechanistic models may aid in getting a better 
understanding of dissolution which can be used to predict systemic exposure (AUC) and 
hence its influence on drug therapeutic effect (Bäckman et al., 2014).  Therefore, for this 
study, it required a mechanistic model to be developed and utilised to evaluate the 




In this chapter, the predominant aim was to take the first steps into developing 
dissolution as a biorelevant system, that can potentially be used as an in vitro in vivo 
correlation tool for OIPs, by applying the developed SLF to DissolvIt® system and 
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comparing the dissolution performance of FP with other proposed dissolution medium.  
In doing this, it provides an indication into the significance and necessity for SLF, if we 
wish to develop a dissolution system that provides profiles that truly mimic the dissolution 
of aerosol particles in vivo. 
 
Objectives: 
To reach this aim, the objectives were to, (i) validate a novel LC-MS/MS method 
for the measurement of low FP drug concentrations in lung fluid samples, (ii) apply 
different examples of dissolution/ bio-relevant medium to the DissolvIt system: a) 1.5% 
w/v PEO + 0.4% w/v L-alphaphosphatidyl choline, b) Survanta® and c) SLF and 
investigate the effect of the dissolution medium on FP aerosol particle dissolution, 
evaluating for significance of SLF application and (iii) compare the dissolution profiles 
obtained from the DissolvIt® system with the profiles obtained from rat IPL and (iv) 
apply a developed in-silico model to the data, to explore the impact of the dissolution 
















4.2 Materials  
Flixotide® 50µg Evohaler was provided by GSK.  Polyethylene oxide (PEO) and L-
alphaphosphatidyl choline were supplied by Sigma Aldrich Limited (Dorset, UK) whereas 
Survanta® was obtained from AbbVie Ltd (Maidenhead, UK).  The materials required for 
the aerosolisation, deposition and dissolution of FP were provided by Inhalation 
Sciences, Sweden.  For FP dissolution in rat IPL, female CD IGS (Sprague Dawley) rat 
were obtained from Charles River (Sulzfeld, Germany) and the necessary equipment 
were provided by Inhalation Sciences, Sweden.  The Chemicals required for the 
manufacture of SLF were as listed in Chapter 3. For solid phase extraction validation, 
the chemicals included were micronized FP (USP grade, purity 98%) supplied by LGM 
Pharma Inc (Boca Raton, USA), FP-d5 (USP grade, purity 97%) by Insight Biotechnology 
Limited (Wembley, UK) and rabbit serum, purchased from Sigma-Aldrich Company 
Limited (Dorset, UK).  Chemicals required for the extraction procedure were zinc 
sulphate powder, supplied by VWR International Limited (Lutterworth, UK), HPLC-
gradient grade acetonitrile, 35% v/v ammonium hydroxide solution and Analytical-
Reagent grade dichloromethane, which were all purchased from Fischer Chemical 
(Loughborough, UK).   
 
4.3 Methods 
4.3.1 Validation of the SPE and LC-MS/MS assay for quantification of FP 
Validation of the assay required preparation of calibration curves.  Primary stock 
solutions of FP and FP-d5 (I.S.) were prepared by adding 1mg of FP or FP-d5 into a 10-
mL volumetric flask and filled to the volume with pure acetonitrile, producing 100 µg/mL 
solutions, and stored at -20°C.  A 1 µg/mL FP working solution was prepared by the 
appropriate dilution of the stock with pure acetonitrile.  The calibration standards (156, 
313, 625, 1250, 2500, 5000 and 10,000 pg/mL) were prepared from serial dilution of the 
working solution with pure acetonitrile.  The QC samples (470, 1880 and 7500 pg/mL) 
were prepared by mixing the appropriate FP standard solutions to achieve the desired 
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concentrations.  Working I.S. plasma solution (0.1 µg/mL) was prepared by adding 50 
µL of an intermediates FP-d5 solution (10 µg/ml in pure acetonitrile) to 5 mL rabbit 
plasma. 
Solid phase extraction was used for sample extraction of the calibration and quality 
control samples. 1225 µL of rabbit plasma was placed into 10 Eppendorf micro-centrifuge 
tubes, labelled C1 to C7 and LQC, MQC, HQC, respectively.  25 µL of each FP standard 
and QC samples were placed into the tubes and vortexed for 5 min.  The remaining steps 
were as described in section 4.3.4.   
Partial method validation was conducted in terms of linearity, precision (intra-day 
and inter-day), accuracy, limit of detection and limit of quantification, following the 
specific recommendations stated by the US FDA industrial Bioanalytical Method 
Validation Guidance (US FDA CDER, 2001).  Linearity was evaluated by plotting a 
calibration curve of mean peak area ratio of FP/FP-d5 (n=9) against the concentrations 
of 7 standards, using a weighted (1/x) linear regression model.  The relative standard 
deviation (%CV) provided information on assay and instrument precision.  For intra-day 
precision, the %CV values across 3 calibration sets prepared on the same day were 
looked at however, for inter-day precision, another 3 fresh series of calibration standards 
prepared on days 2 and 3 were analysed.  Accuracy of the data was evaluated across 9 
determinants of each standard, ensuring it was within ±15% of the theoretical standard 
concentration.  The limit of detection (LOD) and limit of quantification (LOQ) were 
calculated based on equations (18) and (19), in Chapter 2.3.1.       
Evaluation of the extraction recovery was done in accordance to a paper by 
Matuszewski et al (Matuszewski et al., 2003) on the LQC, MQC and HQC, whereby a 
set of those QC samples were prepared in plasma extract and spiked before extraction, 
and a fresh set of samples prepared in plasma extract and spiked after extraction.  The 




Extraction recovery % = [Mean peak area ratio from extracted LQC, MQC or HQC / Mean 
peak area ratio from post extraction blank plasma-spiked with neat standard] X 100                        
(19) 
 
4.3.2 Deposition and dissolution of FP in the DissolvIt® system 
The aerosolisation of Flixotide® was carried out using the PreciseInhale® aerosol 
system (Inhalation Sciences, Stockholm), whereby the Flixotide pMDI canister was 
connected to the US Pharmacopeia Induction Port No 1 (standardised simulation of the 
throat) of the aerosol system, (Figure 4.1). The aerosol particles were deposited on 9 
circular microscope glass cover slips, 13 mm in diameter and the dissolution of the 
deposited particles was investigated on the DissolvIt® system (Inhalation Sciences, 
Stockholm), thermostatted to 37°C.  The prepared perfusate consisted of 0.1 M 
phosphate buffer plus 4% albumin solution, mixed thoroughly using a magnetic stirrer.  
Helium was bubbled through the perfusate to remove excess bubbles. The SLF was 
prepared via the method described in Chapter 3, section 3.3.1.  The Survanta was diluted 
with PBS to provide a lipid concentration of 4.0 mg/mL.  The composition of the three 
mucus simulants investigated, PEO, SLF and Survanta®, are listed in Table 4.1.  Pre-
warmed mucus simulant, 5.7 µL, was applied on one side of the polycarbonate 
membrane of a single-use cell, with the perfusate buffer streaming on the other side.  
The dissolved particles were absorbed at a perfusate flow rate of 0.4 mL/min over a 
period of 4 h and the perfusate samples were collected by an automated controlled 




Figure 4. 1. A schematic of a) fluticasone propionate aerosolisation and particle 
deposition and b) the dissolution system. 
 
Table 4. 1. The protein and lipid compositions of the three mucus simulants/ bio-
relevant dissolution media: 1.5% w/v Polyethylene oxide + 0.4% w/v L-








4.3.3 Dissolution of FP in rat isolated perfused lung 
This work was carried out by scientists in Inhalation Sciences.  Female CD IGS, 
with body weight of 279 ± 20 g, were euthanised with phenobarbital sodium (100 mg/kg, 
i.p.) and their whole lung prepared as described in other reports (Kroll et al., 1986; 
Sundstrom et al., 2003).  The lungs were placed in the artificial thoracic chamber.  They 
were ventilated with room air at 75 breaths/min by creating an alternating negative 
pressure (-0.2 to -0.8 kPa)3 inside the chamber, using an Ugo Basile model 7025 animal 
respirator (Varese, Italy), with a stroke volume of 6 mL, superimposed on a constant 
vacuum source connected to the chamber.  The tracheal air flow velocity and pressure 
inside the chamber were measured with a heated 8430 series pneumotachograph 
(Kansas City, MO, USA) at 0-3 L/min and a differential pressure transducer (EMKA 
Technologies, Paris, France) respectively.  The physiological lung-function variables: 
tidal volume (Vt), dynamic lung compliance (Cdyn)3 and lung conductance (Gaw), which is 
inversely proportional to lung resistance (RL)3 were calculated from each breath in real 
time and logged by a data acquisition system using the software IOX v. 6.1a (EMKA 
Technologies). The lungs were perfused via the pulmonary artery in a single-pass mode, 
at a constant hydrostatic pressure of approx. 12 cm H2O and the perfusate reservoir was 
continually overflowing into a recirculation drain pipe, to keep a constant liquid pressure 
head.  Throughout the experiments, the perfusate flow rate after the passage through 
the lung (Qperf) was measured gravimetrically using a custom-made fraction collector with 
a scale. The perfusion medium consisted of Krebs-Henseleit buffer, 5.5 mM glucose, 
12.6 mM HEPES and 4% bovine serum albumin.  The temperature of the perfusate and 
the artificial thoracic chamber was maintained at 37°C.  The lungs were left to stabilize 
for 30 min prior to aerosol exposures and only the lung preparations with stable baseline 
values for Vt, Cdyn, Gaw and Qperf during at least a 15-min period were used. The measured 
values were: Vt: 1.8 ± 0.2 mL, Cdyn: 6.6 ± 1.0 mL/kPa; Gaw: 279 ± 20 ml/s/kPa, and Qperf: 
32 ± 2 mL/min (n=6).  For the exposure of the IPL to the Flixotide® aerosol, this was 
carried out using the PreciseInhale® as described above, where the aerosol was 
delivered to the lung by the active dosing system and the system automatically 
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terminated the exposure when the inhaled target dose was reached.  The perfusate was 
repeatedly sampled in an automatic fraction collector during a 2-h period from the start 
of the aerosol exposure and the sampling intervals were 4.5, 6, 7.5, 9, 12, 15, 30, 60 and 
120 min.  After the end of the perfusion period, the lungs and trachea were harvested for 
analysis of the amount of FP retained in the tissues after the perfusion period.  The 
experiments were approved by a local ethical review board in Stockholm.   
 
4.3.4 Sample extraction by SPE 
Samples were prepared for analysis following the new, validated solid phase 
extraction method.  325 µL of each sample was loaded into a deep-well sample plate 
(Thermo-Scientific, Surrey, UK) followed by 50 µL of working I.S. solution (0.1ug/mL FP-
D5).  300 µL of 0.1 M zinc sulphate followed by 75 µL of 10% ammonium hydroxide were 
added and mixed using a multichannel pipette.  The SPE plate was placed on an orbital 
shaker (Stuart-Scientific, UK) for 30 min followed by centrifugation at 3700 rpm for 5 min.  
The samples were then transferred to a pre-conditioned Evolute® Express ABN 10mg 
SPE 96-well plate (Biotage, Sweden). With little vacuum applied (< 5 mm Hg pressure), 
they were washed with 200 µL HPLC-grade water followed by 200 µL of 25% v/v 
methanol in water.  The analytes were eluted twice with 200 µL of pure acetonitrile 
followed by once with 100µL dichloromethane and vacuum centrifuged (Genevec EZ-2, 
UK) to dryness.  Samples were reconstituted with 30 µL of 55% v/v acetonitrile in water 
and sonicated rapidly for 10 min.  The MS plate was then covered with a transparent 
seal film (Thermo-Scientific, Surrey, UK), ready for analysis.  An aliquot of the final 
sample solution (20 µL) was injected into the LC-MS/MS system. 
 
4.3.5 FP quantification by LC-MS/MS 
Quantification of FP was carried out by Waters® Xevo TQ tandem quadrupole 
mass spectrometer (Waters, Elstree, UK) equipped with an ESI interface, corporate with 
an Ultra Performance LC system (Waters, Eltree, UK), equipped with a binary solvent 
delivery system and an Acquity auto-sampler.  Chromatographic separations were 
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carried out on a 100A Acquity BEH (2.1 x 50 mm) analytical HPLC column, packed with 
1.7 µm C-18 (Waters, Eltree, UK).  The mobile phase was a mix of mobile phase A and 
mobile phase B, which were 0.1% ammonium hydroxide in water and 1:1 v/v acetonitrile 
in water respectively.  The chromatograms of FP and FP-d5 from the plasma extract 
were obtained from a mobile phase flow rate of 0.2 mL/min with a 2-min gradient flow 
from 50% to 95% B.  Argon was used as the collision gas and the collision energy was 
set at 12 V. The LC-MS/MS operations were controlled by the computer software, 
MassLynx 4.1 and analyte quantification was done with the following parameters: m/z 
501.4 > 313.1 for FP and m/z 506.5 > 313.1 for FP-d5.   
 
4.3.6 Data analysis 
For the validation process, peak integrations and data analysis were performed 
using the MassLynx 4.1 computer software.  The relationship between peak area ratio 
(y) and analyte concentration (x, pg/mL), was performed and calculated using the 
LINEST function in Microsoft Excel.  Data was expressed as the mean ± SD of replicate 
determinations, whereby n ≥ 3.  The acceptance criteria for the calibration standards and 
the QCs were identified from the US FDA industrial Bioanalytical Method Validation 
Guidance (US FDA CDER, 2001).  For the FP dissolution graph, the %FP in the 
perfusate was expressed as a percent of the deposited amount on the glass slide.   
 
4.3.7 Statistical analysis 
Data were normally distributed (Histogram, Skewness and Kurtosis).  Therefore, 
One-Way ANOVA was applied to the data followed by Tukey POST-HOC analysis.  
Statistical analysis was performed using the IBM SPS software, version 24, (SPSS, 
Armonk, NY, USA).  Data was regarded statistically significant when p ≤ 0.05.   
 
4.3.8 Dissolution PBPK modelling 
A mechanistic physiologically based pharmacokinetic (PBPK) model for predicting 
the fate of inhaled FP (Figure 4.2) was developed by Sumit Arora and collaborators at 
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University of Graz, in Austria.  The model was carried out using Java (Version 1.8.0_111, 
Oracle, Redwood City, US). The integration of the system of ordinary differential 
equations was performed via the 8(5,3) Dormand-Prince integrator (Hairer and Wanner, 
1991) as realized in the Apache Commons Math library (Version 3.6.1, Apache Software 
Foundation, Forest Hill, U.S.).  The model was adapted from recently published paper 
by Boger et al (Boger et al., 2016).  Briefly, the model was based on the respiratory 
physiology divided into three compartments; extra-thoracic, tracheobronchial (central 
lung) and alveolar (peripheral lung) region (Figure 4.2).  The particles deposited in the 
extra thoracic region were swallowed and transferred to gut, where they were subjected 
to systemic absorption, based on their bioavailable fraction (F).  Particles deposited in 
central and peripheral lung were modelled for their dissolution, using input from the in 
vitro dissolution experiments in DissolvIt® system, in epithelial lung lining fluid followed 
by their permeation in lung tissues and considering that the particles deposited in the 
central lung were also subjected to mucociliary clearance, as described by Boger et al.  
The central and peripheral lung areas were perfused by the bronchial blood flow 
(Q_central lung) and entire cardiac output (Q_cardiac output) respectively. Perfusion-
rate limited distribution was assumed to apply for all tissues. System-specific input 
parameters for central lung, peripheral lung, blood flows and volume of the tissue 
compartments included are presented under supporting information (Appendix B Tables 
B.1 and B.2). 
 For regional lung deposition modelling, the particle size distribution of the tested 
formulations was determined using next generation impactor (NGI), resulting in a 
discrete distribution of seven particle sizes with corresponding mass fraction deposited 
(f0,….f6). Multiple-Path Particle Dosimetry model (MPPD V2.11, Applied Research 
Associates Inc., Albuquerque, N.M, US, 2009) was used to calculate the regional 
deposition of particles from the tested formulations. A breathing pattern with 2 s 
inspiration, 1 s expiration, 10 s breath hold, and a tidal volume of 625 mL was used. The 
Yeh-Shum 5-lobe lung model was chosen for the calculations of regional deposition 
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fraction (Yeh and Schum, 1980).  The drug and formulation specific parameters for FP 




Figure 4. 2. A schematic representing the whole body physiologically based 
pharmacokinetic (PBPK) model. 
 
4.3.9 Sensitvity analysis of disoslution kinetics 
A sensitivity analysis of the pharmacokinetic parameters to the in vitro dissolution 
kinetics of FP was performed using the mechanistic PBPK model (described in section 
4.3.8).  Hypothetical in vitro dissolution profiles of FP were created by means of 
numerical approximation with maximum cumulative percent dissolved fixed to mimic the 
cumulative percent of FP in SLF.  The numerical approximations were selected in order 
to probe three different possible in vitro dissolution scenarios: a profile where release 
greatly exceeded that observed experimentally in SLF (case 1) and two profiles that are 







4.4.1 Validation of the SPE and LC-MS/MS assay for quantification of FP 
The SPE and LC-MS/MS methodologies required for the quantification of FP in 
bio-relevant media were very easy to conduct and with good sensitivity to low 
concentrations of FP.  LC-MS/MS provided sharp distinctive peaks in the mass spectra 
representative of FP and FP-d5, with minimal background noise, as shown in Figure 4.3.  
Good data repeatability and excellent linearity between the mean peak area ratio of 
FP/FP-d5 and the concentration of FP in the samples was observed (most R2 values = 
0.999) (Figure 4.4). 
 
Figure 4. 3. Daughter scan mass spectra of a) FP and b) FP-d5, obtained from LC-




Figure 4. 4. Validation of solid phase extraction and LC-MS/MS for analysis of 
fluticasone propionate (FP) based on linearity of a) intra-day FP calibration curve 
sets (3 batches) and b) inter-day FP calibration curve sets.  Data represent mean 
± SD (n=3). 
 
 
The inter-day and intra-day precision data complied with the validation guidance, 
with all CV being < 20%, except for 156 pg/mL which had a CV of 35.5% (Table 4.2).  
The accuracy data for all FP standard concentrations passed the accepted criteria of 85-
115% (Table 4.3).  Furthermore, both the precision and the accuracy of the QC standards 
successfully met the validation criteria (Table 4.4).  The LOD and LOQ were 106 pg/mL 
and 312 pg/mL respectively. 
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Table 4. 2. Inter- and intra-day precision (CV, %) of the data obtained for each 
fluticasone propionate (FP) standard concentrations, using the LC-MS/MS.  Data 
represent mean ± SD (n=3). 
 
 
Table 4. 3. Accuracy of the data obtained for each fluticasone propionate (FP) 
standard concentration, using the LC-MS/MS.  Data represent mean ± SD (n=9). 
 
 
Table 4. 4. Precision (CV, %) and accuracy of the fluticasone propionate (FP) 





The % extraction recovery was low, between 20-30% for all FP QC standards 
(Table 4.4) however, the values were consistent overall when evaluating the intra-day 
and inter-day % recovery.   
 
Table 4. 5. Extraction recovery (%) of fluticasone propionate (FP) quality control 
standard concentrations.  Data represent mean ± SD (n=9). 
 
 
4.4.2 Application of bio-relevant media in the DissolvIt® system 
The PEO medium used as the standard solvent in the DissolvIt® system possessed 
a lipid content of 4 mg/mL, which was lower than the lipid content of SLF, 5.4 mg/mL 
(Table 4.1).  The FP concentration in the perfusate was highest at all time points when 
FP dissolved in PEO and lowest in SLF (Figure 4.5).  However, the overall difference in 
the FP concentration values in all three lung fluids at most time points, were not 
statistically significant (One-Way ANOVA, p ≥ 0.05).  This is except the difference in FP 
concentration in PEO and SLF at 20 min.  The FP concentration profile in perfusate was 
very similar between PEO and Survanta®, both reaching a Cmax at approximately 20 





Figure 4. 5. Concentration of fluticasone propionate (FP) in the perfusate over 
time, following dissolution in 1.5% w/v Polyethylene oxide + 0.4% w/v L-
alphaphosphatidyl choline (PEO), simulated lung lining fluid (SLF) and diluted 
Survanta®.  Concentration normalised to mass deposited on the glass cover slips. 
**Difference in FP concentration in PEO and SLF is statistically significant (One-
Way ANOVA, p ≤ 0.05). Data represent mean ± SD (n=3). 
 
4.4.3 Evaluation of the dissolution of FP in DissolvIt® versus in IPL 
The concentration of FP and the cumulative percent of FP transferred into the 
perfusate over time is shown in Figure 4.6.  There were similar profiles in each medium 
reflecting the ranking observed in the perfusate in Figure 4.5.  The concentration of FP 
and cumulative % FP in the perfusate was significantly highest, at nearly all time points, 
following its dissolution in rat IPL in comparison to all the bio-relevant medium applied to 
the DissolvIt® system (One-Way ANOVA, p ≤ 0.05).  However, with regards to the FP 
concentration profile shape over 120 min, the shape for IPL most closely matched that 
of SLF, whereby the graph seemed to plateau after approximately 10 min and there was 




Figure 4. 6. a) Concentration of fluticasone propionate (FP) in the perfusate over 
time following dissolution in 1.5% w/v Polyethylene oxide + 0.4% w/v L-
alphaphosphatidyl choline (PEO), simulated lung lining fluid (SLF), diluted 
Survanta® and rat isolated perfused lung (IPL). *Difference in FP concentration in 
IPL and SLF is statistically significant (One-Way ANOVA, p ≤ 0.05). **Difference in 
FP concentration in IPL and the remaining three lung fluid is statistically 
significant (One-Way ANOVA, p ≤ 0.05), and b) Cumulative % of FP transferred into 
the perfusate over time, following its dissolution in PEO, SLF, Survanta and IPL. 







4.4.4 In silico modelling of FP dissolution 
Development of the in-silico model and data collection was done by Sumit and 
collaborators at University of Graz, in Austria.  The in vitro data collected were fitted to a 
Weibull function to extract the shape and time scale parameters, that were then used to 
model the dissolution of particles in the developed model (Figure 4.7).  Pharmacokinetic 
parameters (Cmax, Tmax and AUC0-∞) calculated from the simulated profiles for the 
different lung fluid simulants, all seemed to reasonably well predict (within two folds) the 
pharmacokinetic parameters of inhaled FP (1000 µg dose) administered via Flixotide 
Evohaler® 250 µg strength inhaler, obtained from a study by Mackie et al (Mackie et al., 
2000) (Table 4.6).  No significant difference was found between the clinically observed 
and simulated pharmacokinetic parameters when in vitro dissolution input from PEO and 
Survanta was used in the developed PBPK model (One-Way ANOVA, p ≥ 0.05).  On the 
contrary, statistically significant differences in Cmax and AUC0-∞ were found when the 
slower in vitro dissolution of FP in SLF was modelled compared to dissolution in PEO.  
The AUC0-∞ predicted by the model in all three bio-relevant mediums were slightly 
underestimated, in comparison to the in vivo profile.  However, it appeared that the 
pharmacokinetic parameters from the in vivo profile most closely matched the values 
obtained from PEO than from the other bio-relevant medium. 
To gain a better understanding of the sensitivity of the predicted PK parameters 
towards the dissolution profiles of FP, different hypothetical dissolution profiles were 
created (Figure 4.8) and the data was fitted to the Weibull function to extract the shape 
and time parameters of these profiles (Table 4.7).  The parameters were obtained using 
a rearranged version of the Weibull equation (equation 13, stated in Chapter 1); it was 
applied to describe various hypothetical dissolution curves and used as an input to the 
PBPK model.  The exact equation used in this context was equation (23): 
M = 1 – exp [-(t-Ti)b / α]                                                                                      (23) 
The location parameter (Ti) in all the investigated cases was zero.  In the cases where 
the dissolution-time curves differed from the SLF profile only in terms of faster or slower 
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initial rate (cases 2 and 3), a similar shape parameter described the exponential curves 
(b~1).  Fitting of an immediate release type hypothetical dissolution profile (case 1) 
resulted in a value describing a sigmoidal curve (b>>1).  Calculated values of AUC for 
the cases were similar to the values generated for SLF, reflecting the fixing of the 
cumulative percentage of dissolved FP to 9.34% in 4 h.  However, major differences 
were observed in terms of Cmax and Tmax with profiles when drug dissolution was 
faster/slower than in vitro dissolution profile of FP in SLF.  Dissolution profiles mimicking 
the faster dissolution rates (case 1 and case 2) predicted higher values of Cmax (6- and 
2- folds), and lower values of Tmax (6- and 4- folds) compared to the values observed in 
SLF.  In case 3, where the initial rate of in vitro dissolution was lower than that in SLF, a 





Figure 4. 7. In-silico modelling. A) Simulated plasma concentration of fluticasone 
propionate (FP) over time, following its dissolution in 1.5% w/v Polyethylene oxide 
+ 0.4% w/v L-alphaphosphatidyl choline (PEO), simulated lung lining fluid (SLF), 
diluted Survanta®. B) The median plasma FP concentrations in healthy volunteers 
after administration of FP 1000 µg via a chlorofluorocarbon (CFC) and a 
hydrofluoroalkane (HFA) metered-dose inhaler (MDI) and administration of FP 250 






Table 4. 6. Pharmacokinetic data of fluticasone propionate (FP) absorbed in 
plasma from healthy volunteers, after inhalation of FP pMDI (In-vivo) and of FP 
absorbed in perfusate, following its dissolution in 1.5% w/v Polyethylene oxide + 
0.4% w/v L-alphaphosphatidyl choline (PEO), simulated lung lining fluid (SLF), 




Figure 4. 8. Sensitivity testing using numerical approximation to derive three 
dissolution profiles that vary from the experimental observations for dissolution 
of fluticasone in simulated lung fluid (SLF) (observed): a profile where release 
greatly exceeded that observed experimentally in SLF (case 1) and two profiles 






Table 4. 7. Fitted Weibull shape factor (b) together with pharmacokinetic data of 
FP following its dissolution in simulated lung fluid (SLF) and artificial dissolution 



























4.5.1 Solid phase extraction and LC-MS/MS validation for assay of FP 
It is well known that SPE offers an improved extraction method over liquid phase 
extraction.  Although liquid-liquid extraction is more cost-effective, SPE is less time-
consuming and requires minimal sample preparation and solvent use (Zwir-Ferene and 
Biziuk, 2006).  Initially, a couple of liquid-liquid extraction methods were attempted to 
extract the FP from the biological fluids (Guan et al., 2003; Byrro et al., 2012).  However, 
the methods proved to be non-repeatable since when attempting to validate the liquid-
liquid extraction and LC-MS.MS assay, the calibration curves were not always linear and 
the %CV were very inconsistent.  Therefore, for this study, SPE was chosen as the 
preferred extraction method.  However, it was found that there are currently little reports 
of SPE methods or simplified easy to follow methodologies.  Consequently, the methods 
that are published for FP analysis (Krishnaswami et al., 2000; Matuszewski et al., 2003) 
proved to be difficult to replicate with adequate reproducibility and sensitivity.  Hence, 
this study first prioritised developing and validating a newly-modified SPE, LC-MS/MS 
method for quantification of low concentrations of FP in biological fluids.   
The SPE conditions for sample preparation initially required optimisation.  SPE 
preconditioning, washing with water, low percentage organic solution and elution solvent 
were optimised with different volumes and different percent of organic solution. For 
example, for preconditioning the SPE columns, water was added followed by 50% v/v 
methanol in water, to ensure adequate wash and preparation of the column.  However, 
at this step, a small peak corresponding to the FP analyte was detected.  Therefore, 
conditioning with 25% v/v methanol in water was a better option since no peaks were 
detected, indicating no FP was lost in the wash step.  For the extraction procedure, zinc 
sulphate was added first to the samples to allow for FP drug to detach from the albumin 
in the rat plasma and this was mixed well, before addition of ammonium hydroxide to 
resuspend the detached FP into the solution.  However, this produced very poor 
extraction with smaller peak areas for FP and FP-d5, in comparison to when zinc 
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sulphate and ammonium hydroxide were added simultaneously prior to the adequate 
mixing.  For elution of FP, eluting with acetonitrile alone also produced very little peak 
areas in comparison to eluting with acetonitrile and dichloromethane.  However, when 
using high volumes of each chemical, this produced an extra peak in the chromatograms 
indicating that too much organic solvent was added.  Therefore, both chemicals were 
used, whereby FP was eluted twice with 200 µL of pure acetonitrile followed by once 
with 100µL dichloromethane, enhancing material recovery and quantification. 
It can be concluded that the final assay for quantification of FP in rat plasma was 
developed well and validated successfully.  The sensitivity of an assay is dependent 
upon the efficiency of the extraction method and the sharpness of the chromatographic 
peak (US FDA CDER, 2011).  This method appeared to be highly selective and sensitive, 
and effectively eliminated the interference by endogenous impurities, as clear distinctive 
peaks corresponding to the analyte of interest were seen in all chromatograms 
generated, at all standard concentrations.  Most of the validation data fell within the 
accepted criteria or ranges, except for the lowest standard concentration, at 156 pg/mL. 
This is most likely attributed to the concentration of the drug being so close to the 
reported LOD, causing more noise signal interference and affecting the precision and 
repeatability of the result.  However, since the FP concentrations in all dissolution 
experiments predominantly fell within the upper concentration range of the calibration 
curve, the method was deemed as fit for purpose.  The method was suitable for this study 
and can be applied to biological fluids such as the lung lining mucus, to allow for accurate 
pharmacokinetic analysis of compounds following their inhaled administration.   
With respect to the percent analyte recovered, a very low percent was recovered 
from the SPE extraction method.  This is likely due to the inevitable high binding-affinity 
FP tends to have to plastic, binding to the extraction plates (Otero et al., 2001).  To 
minimise this and further optimise SPE, low-binding deep-well plates were used for the 




It is important to note that to complete the validation process, an assessment of 
the matrix effect is often required, particularly if one wishes to validate an entirely novel 
SPE, LC-MS/MS quantitative method, since the full validation recommendations must 
ideally be followed.  This matrix effect allows for the assessment of any ion suppression 
or ion enhancement caused by the plasma media used and if this interferes with the 
results.  However, assessment of the matrix effect has been reported to be only critical 
when homologues, rather than stable, isotope-labelled analytes are utilized as internal 
standards (Matuszewski et al., 2003).  The internal standard used in this study was FP-
d5, which is a stable isotope labelled deuterated FP and hence, assessment of the matrix 
effect was not a necessity for the study.  Again, this indicated that the novel SPE/LC-
MS/MS technique developed here was fit for purpose. 
 
4.5.2 Application of bio-relevant media in the DissolvIt® system 
Applying different versions of proposed lung fluid to the DissolvIt® system was a 
first step towards developing dissolution as a biorelevant system, as it allows for the 
assessment on the necessity for the application of SLF, if we truly wish to mimic the 
dissolution of aerosol particles that occur in the lungs.  
The Survanta used in this study was diluted with PBS in attempt to normalise the 
data generated to lipid concentration, however, the SLF yet exhibited slightly higher lipid 
concentration to the others.  It was hypothesised, based on this, that dissolution in SLF 
would be enhanced as the greater lipid content may facilitate the lipophilic FP drug 
solubilisation via encapsulation into the lipid lamellar structures.  However, the results 
showed differently; FP concentration in the perfusate was lowest when FP dissolved in 
SLF compared to when FP dissolved in the other media.  This is likely attributed to the 
characteristics of SLF as identified and described in Chapter 3.  It was made evident in 
Chapter 3 that the FP exhibited solubility in SLF that was very close to its solubility in 
Gambles, even though SLF is predominantly a liposomal formulation and Gambles in a 
simple aqueous solution.  This may be attributed to SLF liposomes forming stable 
colloidal structures, making them less likely to sequester such poorly soluble drugs.  
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However, solubilisation and hence dissolution may not only be influenced by the lipid 
content but also by the interaction of the extra components present in SLF.  For example, 
the albumin present in the media may solubilise the cholesterol that contributes to the 
formation of tight lamellar structures (Kim et al., 2013) and thus reduce their stability and 
the extent to which drug is solubilised within them.  However, such influence in FP 
dissolution may not be regarded as substantial since the overall difference in the FP 
concentration values in all three lung fluids at most time points, were not statistically 
significant.  The FP concentration profile in perfusate was very similar between PEO and 
Survanta as expected, since both have the same lipid concentration of 4 mg/mL, 
influencing the dissolution of FP in the same manner.  
 
4.5.3 Evaluation of the dissolution of FP in DissolvIt® versus in IPL 
The next clear step to this study was to undergo some pre-clinical investigations 
using rat IPL.  The concentration of FP in the perfusate profiles, obtained following FP 
dissolution in the different proposed media, can be compared directly with the profile 
obtained following FP dissolution in rat lung.  This allows for a better understanding on 
how close the dissolution profiles and dissolution kinetics of FP obtained from a 
developing in vitro system, is, to the true dissolution of FP that occurs in vivo in mammals. 
It was evident that the concentration of FP and cumulative % of FP in the perfusate 
was significantly highest at nearly all time points following its dissolution in rat IPL, and 
this is likely attributed to the IPL possessing a comparatively rapid peripheral (alveolar) 
dissolution and permeation as well as a slower central (airway) dissolution and 
permeation, compared to what the DissolvIt® system models.  In the central regions of 
the lungs, non-sink conditions may be expected as the dose is distributed over a small 
area compared to the alveolar region and dissolved FP particles are required to diffuse 
across the 5-20 µm pseudostratified epithelium compared to 1-2 µm in the alveoli of the 
lungs, to reach the perfusate.  However, the DissolvIt® system possess an area of 1.3 
cm2 and the penetration distance is approximately 60 µm (Gerde et al., 2017).  However, 
visually, the overall perfusate concentration profile of FP following its dissolution in rat 
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IPL most closely mimicked the profile from SLF, in comparison to the remaining applied 
fluids.  This suggested that there is a potential similarity in the FP pharmacokinetics 
following its dissolution in SLF and its dissolution in vivo, providing an indication that SLF 
may be necessary if we truly wish to mimic the dissolution that occurs in vivo. 
 
4.5.4 In silico modelling of FP dissolution 
Since FP has been reported in literature to exhibit dissolution rate-limited 
absorption (Edsbäcker and Johansson, 2006; Boger et al., 2016) it is important to 
mechanistically understand the dissolution process of this molecule, to then accurately 
predict its deposition and absorption in the lungs.  Hence, modelling was carried out to 
rationalise the in vitro dissolution data generated from the DissolvIt® and identify the 
effect of using different lung fluid simulants on the simulated plasma concentration time 
profiles of inhaled FP.   
Although comparison with rat IPL data suggested that SLF may be a necessary 
dissolution media, if we wish to predict what occurs in vivo obtain reliable IVIVC data, in 
silico modelling suggested differently.  The data indicated that pharmacokinetics of 
inhaled FP can be much closely predicted following its dissolution in PEO, then in the 
other fluids, since the Cmax, Tmax and AUC0-∞ most closely resembled the FP 
pharmacokinetics in the in vivo plasma.  However, the AUC0-∞ predicted by the model in 
all three cases appeared to be significantly low in comparison to the in vivo data.  It is 
likely the values are underestimated due to the underestimation of terminal time points 
of plasma concentration time profile of inhaled FP, as reported in the literature. This leads 
to the speculation that FP is retained for longer in the airways, which if incorporated into 
the model would improve further the quality of the simulation.  Consequently, it was 
recognised that the model developed exhibited some intrinsic limitations.  This is 
because the in vitro dissolution data incorporated into the model, to obtain PK data, was 
in fact a combination of both dissolution and diffusion of the FP, both processes that 
inevitably and simultaneously occurred when analysing the dissolution of FP using the 
Transwell® dissolution method.  Eliminating the diffusion process entirely from the 
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Transwell® dissolution system, would further improve the quality and reliability of the 
model.  
However, the model proved to be sensitive to differences in in vitro dissolution 
profiles and translate the differences effectively to the respective PK parameters.  When 
evaluating the sensitivity of the predicted PK parameters towards the different 
hypothetical dissolution profiles of FP, the similarity in AUC in all three cases and SLF 
was expected.  This is because AUC differences would only be likely if there were 
different extent of in vivo dissolution of the drug over the period of 4 h.  The differences 
in Cmax and Tmax observed for the dissolution profiles mimicking faster dissolution rates 
(cases 1 and 2) was as expected, considering that these dissolution profiles provided 
higher drug concentration in solution during the early stages of dissolution process.  The 
results illustrated how dissolution profiles can have significant impact on the PK 
parameters of a poorly soluble inhaled drug, and the application of biorelevant in vitro 
assays together with PBPK modelling to study the impact of dissolution. 
 
Summary and conclusions 
A novel and sensitive solid phase extraction and LC-MS/MS technique for the 
assay of FP was established and validated successfully, where it can quantify FP at low 
concentration levels, in biological lung fluids.  With respect to application of various 
dissolution media to the DissolvIt® system, the overall insignificant differences in the 
concentration of FP in perfusate/time and the FP dissolution profiles seen between the 
SLF, PEO and Survanta®, suggested that SLF is not a necessary medium if we truly wish 
to mimic the dissolution behaviour of inhaled pharmaceuticals in vivo.   
The developed in silico model was successful in translating the differences 
observed in the in vitro dissolution of FP to physiologically relevant simulated in vivo 
plasma concentration time profiles, leading to an enhanced understanding on how 
dissolution of FP may influence absorption in the lung.  It appeared that using PEO as 
the dissolution media in the DissolvIt® system provided the best approximation for 
dissolution in vivo so far, and thus provides better correlation and bioequivalence. 
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The study suggested overall that although SLF consists of the key components 
that constitutes the in vivo lung lining fluid and hence contributes to making a dissolution 
system to most closely mimic the in vivo lung environment, in comparison to other 
proposed fluids, it does not provide any added significance in terms of obtaining more 
predictive or reliable IVIVC data or profiles.  Therefore, in taking this further, a simpler 
surfactant-based solution, seems to be reasonable for application in dissolution systems 
























Development of a biorelevant dissolution test using 
Experimental Design methodology 
 
5.1 Introduction 
In addition to the DissolvIt® system, the Transwell® system developed in Chapter 
2, was found to be another convenient starting point towards the development of a 
biorelevant dissolution system.  It was concluded that the Transwell dissolution method 
provides the best representation of lung geology, with the transwell insert allowing for 
applications of physiologically-relevant fluids, at little volumes.  Hence, this system can 
be developed further to potentially become a tool to establish IVIVC and model PK data.  
In this context, for the in vitro test to be biorelevant, i.e. reflective of the in vivo lung 
environment, and to be used for the purpose of describing the in vivo situation, it requires 
conditions that reflect those encountered in vivo to be utilised.  Hence, it was necessary 
to consider factors that potentially influence dissolution in vivo and apply these to the in 
vitro system, evaluating their significance and effects.  This would help identify the ideal 
physiologically-relevant factors that must necessarily be controlled, if we wish to obtain 
dissolution data that is predictive of what occurs in vivo.  Key influential factors include 
dissolution medium concentration, the temperature at which dissolution occurs at and 
the stirring rate at which dissolution is exposed to.  
 With regards to the dissolution medium concentration, there has been a general 
lack of understanding of the true composition of the lung lining fluid at which dissolution 
of particles occur and as a result, the application of previously proposed fluids has led to 
the overestimation and underestimation of the dissolution rate of inhaled drugs.  To 
improve this, part of this PhD considered developing a SLF, which consists of the 
components of healthy human alveolar RTLF (described in Chapter 2).  However, when 
SLF was applied to the DissolvIt® system as an initial step towards identifying its 
necessity in developing a biorelevant system (described in Chapter 4), it was concluded 
that the PK data of FP obtained from the in-silico model did not correlate significantly 
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with the in vivo profile, in comparison to the other proposed media.  Therefore, for this 
part of the study, the dissolution medium used was a simple surfactant solution, SDS in 
PBS, as utilised by many studies previously (Arora et al., 2010; Son et al., 2010; 
Rohrschneider et al., 2015).  With regards to the temperature, dissolution experiments 
may be conducted at room temperature, 21°C, for practical reasons of convenience or 
performed at 37°C to mimic normal human body temperature (Martins et al., 2010; 
Huang et al., 2016).  The impact of conducting the experiment under different 
temperatures has not been evaluated, to date, nor has the necessity to conduct the 
experiment under physiological temperatures to obtain accurate dissolution profiles been 
addressed.  Consequently, with respect to the stirring rate, although implications of this 
has not been studied extensively, a study conducted by Rohrschneider et al, found that 
a stirred Ciclesonide solution versus an unstirred solution, produces a higher dissolution 
rate (Rohrschneider et al., 2015).  In the lungs, the lining fluid is not stirred and is often 
described as ‘stagnant’.  However, the fluid is exposed to dynamic changes during 
breathing and the implications of this on dissolution and the biorelevant level of agitation 
required in vitro, are unclear.  Hence, for this study, there was clear rationale to assess 
the impact of these three factors on dissolution. 
An aspect of system development and improvement, and to obtain valuable 
information on the influences of factors on a system, statistical Design of Experiment 
approach (DOE) can be employed (Dean, 2000).  DOE allows variables to be changed 
together, permitting the assessment of the effects of the individual variable on the system 
as well as the evaluation for any variable-variable interactions.  Consequently, it ensures 
efficiency, whereby meaningful and multiple conclusions can be drawn from small 
number of experiments (Lakeram et al., 2008). This approach has been applied to many 
previous studies, evaluating and optimising physiologically-relevant experimental 
conditions on an in vitro assay (Lakeram et al., 2008; Jivani et al., 2012; Mogal and Derle, 
2017).  However, it has not yet be applied to dissolution systems for OIPs and hence 
presents a novel opportunity that can be exploited in this study. 
167 
 
The development of dissolution tests to be utilised in drug research and 
development, must allow for adequate comparison between the dissolution profiles 
obtained.  To compare dissolution profiles between different pharmaceutical products or 
dissolution profiles from the same product but under different conditions, mathematical 
models can be applied (Dash et al., 2010; Lokhandwala et al., 2013; Caccavo et al., 
2017).  Many studies have modelled drug dissolution or drug-release profiles 
quantitatively, using the model-dependent approach (Patel et al., 2008; Gonjari et al., 
2009; Simionato et al., 2018).  However, this has been widely applied to solid and semi-
solid dosage forms, with very little reports on the modelling of dissolution profiles 
obtained from OIPs specifically.  In a single previous study, Weibull modelling  has 
however been applied on the dissolution profiles of FP obtained from the Transwell® 
method (Kippax et al., 2016).  Application of the model provided a description of the 
dissolution process in more detail in comparison to other models and provided time 
parameters that allows for quantitative comparisons between the dissolution profiles, 
such as T25 or Td, which represent the time taken for 25% and 63.2% of the drug to 
dissolve, respectively (Langenbucher, 1972).  To use a suitable ‘Response’ parameter 
for the DOE analysis, identification of the most convenient time parameter to use, is 
required.  Generally, modelling such profiles is a relatively novel approach and using 
such parameters to constitute the ‘Response’ of the DOE, can help provide an indication 
of the factors that need to be controlled and the optimal, physiological dissolution 
conditions required, to produce the desired dissolution rate for an inhaled product.   
 
Aim: 
In this chapter, the aim was to take an alternative route into developing dissolution 
as a biorelevant system, that can potentially be used as an IVIVC tool for OIPs.  This will 
be done by evaluating the influence of and the need for physiologically-relevant factors 
on the Transwell® dissolution system and optimising the system to exhibit conditions that 





To reach this aim, the objectives were to, (i) identify convenient factor levels of 
each factor studied via preliminary experimentations, (ii) use experimental design to 
conduct a suite of dissolution experiments under various physiological conditions, (iii) 
employ a model-dependent approach to quantitatively compare dissolution profiles (iv) 
use experimental design methodology to evaluate the influence of these physiological 
factors on dissolution and assess for factor-factor interactions and (v) identify the optimal 




















5.2 Materials  
Dissolution was carried out via the TSI/Transwell dissolution system, using the 
materials listed in Chapter 2, section 2.2. The equipment/glassware necessary for the 




5.3.1 Solubility of FP 
The solubility of FP in different concentrations of SDS in PBS: 0.02, 0.05, 0.10, 
0.15, 0.20, 0.25 and 0.50% w/v were carried out according to the method described in 
Chapter 3, section 3.3.7. 
 
5.3.2 Deposition and dissolution of FP  
The dissolution method used was as described in Chapter 2, section 2.3.6.  
However, the dissolution medium was either 0.02%, 0.1% or 0.5% w/v SDS in PBS.  
Following deposition and transfer of the Transwell insert into a well of 24-well plate 
containing 600 µL of the dissolution medium, the plate was placed on an orbital rotator, 
set to stir at either 15, 50 or 85 rev p min.  The tests were performed at either 21, 29 or 
37°C.  For the validation of the selected mathematical dissolution model, dissolution of 
FP was carried out over an 8 h period, were the time points were 2, 5, 10, 15, 30, 45, 60, 
120, 240, 360, 480 and 540 min.  To obtain the deposited amount of FP, the recovery of 
the filter at 540 min was carried out exactly as the recovery of sample 180 min, as 
described in section 2.3.6. 
 
5.3.3 Quantification of FP by RP-HPLC-UV  
Quantification of FP in the samples was carried out using the method described in 




5.3.4 Experimental Design 
A three-level three factorial Box-Behnken experimental design (constructed using 
Design-Expert 11) was used to evaluate the effects of selected independent variables 
on the response.  The selected response in this study was a dissolution rate parameter, 
T25, which represents the time taken for 25% of deposited drug to dissolve.  For the Box-
Behnken experimental design, a total of 45 experimental runs were used (Table 5.1).  
The design required three factors to be chosen with three levels of each factor evenly 
spaced.  The factors were coded for low, medium and high settings, as -1, 0 and +1 
respectively, as similarly set out in previous studies (Singh et al., 1996; Lakeram et al., 
2008).  The factors studied that constitutes the experimental design were the dissolution 
media concentration, stirring rate of the dissolution process and temperature at which 
dissolution was carried out (Table 5.2).  Each factor was set at limits determined via 















Table 5. 1. List of the 45 dissolution 
experiments, with factor levels 
presented as coded values for the 
Box-Behnken Experimental Design, 
where ‘a’ represents concentration of 
the dissolution media/concentration 
of SDS in PBS, ‘b’ represents 
temperature and ‘c’ represents the 
stirring rate. -1, 0 and +1 represent 




Table 5. 2. The factors and their factor levels investigated in the Box-Behnken 




5.3.5 Dissolution profile modelling 
To decide the response parameter for the Experimental Design, mathematical 
models were applied to the drug dissolution graphs obtained from the 45 experiments.  
The models applied describe the dissolution kinetics and provide a dissolution 
parameter, such as dissolution rate constant or time taken for an amount of drug to 
dissolve.  An excel add-in, DDSolver software, was used to facilitate the application and 
comparisons of the mathematical models (Zhang et al., 2010).  All models were applied 
to a random selection of a few dissolution experiments from the 45 runs, ranging from 
experiments that were carried out under low, medium and high factor conditions. The 
best fit model was selected based on the R2 values obtained, an approach taken by many 
other studies (Costa and Sousa Lobo, 2001; Patel et al., 2008; Cascone, 2017).  After 
comparison of the R2 values and via logical rational, Weibull was selected.  All dissolution 
data gathered were then fitted to the Weibull probability distribution model and Weibull 
parameters were calculated and compared.  The parameters were obtained using 
equation 13, as stated in Chapter 1: 
 
Log [-ln (1-m)] = β log (t – Ti) – log α                                                                               (10) 
 
Where m is the accumulated fraction of the drug, β is a shape parameter, α is a scale 
parameter and Ti is a location parameter.  Td can be calculated from the α and β 
parameters and represents the time taken for 63.2% of the drug to dissolve.  Other 
parameters included the T25, T50, T75 and T80 which corresponds to the time taken for 
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25%, 50%, 75% and 80% of the drug to dissolve.  The T25 was used as the ‘response’ 
values and inputted into the Experimental Design for data analysis.  
 
5.3.6 Data analysis 
Statistical data analyses were performed using analysis of variance (ANOVA), with 
the Design-Expert 11 software.  Data comparing the dissolution of FP in SLF and in 0.1% 
w/v SDS in PBS, the f2 similarity factor, equation (7), and the non-parametric paired 






















5.4.1 Preliminary investigations 
The preliminary solubility study carried out to identify the solution with the 
appropriate SDS concentration, in which the solubility of FP in it matches the solubility 
of FP in SLF, is shown in Table 5.3.  It was evident that the solubility of FP in 0.10% w/v 
SDS in PBS most closely matched the solubility of FP in SLF and thus was considered 
the biorelevant dissolution medium to be applied to the Transwell® dissolution system. 
Preliminary investigations to identify or confirm the three factors to select for DOE 
is shown in Figure 5.1.  The factors that have the potential to increase dissolution of FP 
were selected for this study, since significant differences were seen when the respective 
factor levels were altered (Figure 5.1).  The stirring rate was selected to be 15, 50 and 
85 rev p min.  They were considered appropriate and reflective of physiological stirring 
since they match the human breathing rate at rest, human breathing rate during exercise 
and the breathing rate of mice, respectively (European Lung Foundation, 2016; Johns 
Hopkins University, 2019).  The temperature ranged from 21 to 37°C since they reflect 
room to human body temperature.  To establish the influence of these factors, dissolution 
of FP was studied under the factor levels that created highest, medium, lowest, 
biorelevant and practical conditions for dissolution.  The highest conditions at which 
dissolution was carried out appeared to present a steeper dissolution profile, with greater 
% of FP dissolved at all time points in comparison to the other conditions and dissolution 
reached a maximum of 22% by 60 min.  The biorelevant conditions exhibited an FP 
dissolution profile that was in between the lowest and the medium conditions.  The 
conditions considered to be more ‘practical’ showed no significant difference in FP 




Table 5. 3. The solubility of fluticasone propionate in simulated lung fluid (SLF) 
and in different concentrations of sodium dodecyl sulphate (SDS) in phosphate 





Figure 5. 1. Dissolution of fluticasone propionate via the Transwell® method, under 












5.4.2 Dissolution profile modelling 
The dissolution profiles and tables of percent and amount of FP dissolved in each 
of the 45 experiments, are shown in (Appendix C, Tables C.1 and C.2). Parameters from 
the Weibull probability distribution model, that was applied to the 45 dissolution profiles, 
are listed in Table 5.4.  The co-efficient, R2, provides an indication on the correlation 
between the Weibull model profiles and the dissolution profiles.  For all dissolution 
profiles, the R2 was approximately 0.99.  The β value provides an indication of the 
dissolution kinetics and it appeared that for all profiles, the value was < 1.  A lower T25 
value indicated a higher dissolution rate, since it means that under set conditions, it takes 
less time for 25% of the FP drug to dissolve.  Experiment number 5, which represents 
the conditions: dissolution media of 0.5% w/v SDS in PBS, 37°C and 85 rev p min seem 
to exhibit the lowest T25 value of 73.29 min.  Experiment number 13, which represents 
the conditions: dissolution media of 0.02% w/v SDS in PBS, 21°C and 15 rev p min seem 








Table 5. 4. The parameters and 
determination co-efficient for 
the 45 dissolution experiments, 
obtained from the Weibull 
probability distribution model. 
β is a shape parameter, α is a 
scale parameter and T25 
represents the time interval 
necessary to dissolve 25% of 


























5.4.3 Validity of the Weibull model 
To validate the Weibull model that was selected to obtain a dissolution rate 
parameter for each experiment, a selection of the lowest, medium and highest factor 
conditions experiment was repeated.  This time, the dissolution process was prolonged 
for 8 h rather than for 1 h (Appendix C, Figure C.1).  This was to evaluate whether the 
T25 obtained from these experiments match the predicted T25 derived from the applied 
Weibull model.  The T25 values are shown that the in Table 5.5. It was evident T25 
values obtained directly from the dissolution curves fell within the predicted ranges from 
the Weibull model.   
 
Table 5. 5. Comparison of the T25 value obtained from the dissolution curve 
with the predicted T25 value derived from application of Weibull model.  
Experiment numbers 13, 25 and 35 corresponds to the dissolution 
experiments conducted under the lowest, medium and highest factor 
















5.4.4 Influence of the factors on dissolution 
To evaluate the influence the tested factors had on dissolution, Design-Expert 11 
software was used, whereby the T25 values were inputted and graphical presentations 
and table of results were obtained.  The data appeared to be normally distributed and 
according to the ‘Residuals vs. Predicted graph’, the variations in data seem to be well 
distributed overall, with no outstanding results.  It was evident that the concentration of 
the dissolution media and the temperature had very significant effects on the response, 
T25 (p<0.0001) (Table 5.6).  However, stirring rate did not have significant effects.  With 
respect to the quadratic terms for each factor, a2 and b2, which represent the 
concentration of the dissolution media and temperature respectively, were significant, 
although a2 was a lot more significant, with p value < 0.0001.  In terms of factor-factor 
interactions, it appeared that the interaction between concentration of dissolution media 
and the temperature was very significant (p<0.0001), and the interaction between the 
concentration of the dissolution media with the stirring rate was somewhat significant 
(p<0.05).  Interactions between the temperature and stirring rate factors were evidently 
insignificant. 
 
Table 5. 6. Significance of the effects of each factor on the response, T25, at their 





The co-efficient for each factor was a negative value, as highlighted in Table 5.7.  
This indicated that increases in the dissolution media concentration, temperature and 
stirring rate factors each caused a decrease in the T25 response.  Increase in the 
concentration of dissolution media caused the greatest drop in T25, where for every 
increase in 1% w/v SDS in PBS, there was a drop in T25 by 157.17 min.  Changes in 
stirring rate had the least influence on T25; for every increase in 1 rev p min, there was 
a decrease in T25 by 48.18 min. 
 
Table 5. 7. The co-efficient of each factor effect on the response, T25.  Data 
obtained from Design Expert 11 analysis. 
 
 
To assess the change of the response surface, 3 dimensional (3D) plots for the 
measured responses were constructed based on the model polynomial functions (Figure 
5.2).  Since there was no interaction between the temperature and stirring rate, and their 
effects on T25 were independent of each other, a 3D plot incorporating the two factors 
was not required for interpretation.  Figures 5.2a and 5.2b represented a Type I plot, an 
inverted dome shaped plot, in which they looked like parabolas opening upwards.  The 
plots featured a linear decrease in the T25 value along one axis (temperature in Figure 
5.2a or stirring rate in Figure 5.2b) while along the other axis (concentration of the 
dissolution media), there was a decrease in T25 value up to a minimum then an increase 
in the value thereafter.  The linearity of the temperature actor appeared to be a lot more 
profound and steep than the stirring rate, causing slight difference in plot shape between 





Figure 5. 2. Response surface plots (3D) showing the effects of the factors: 
dissolution media, temperature and stirring rate, on the response: T25. A) Fixed 
stirring rate of 15 rev p min, B) Fixed temperature of 37°C. 
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Figure 5.3 provides an insight into the individual effects of each factor on T25.  The 
dissolution media concentration curve was evidently parabolic, correlating to the huge 
significance of the a2 value in Table 5.5 (Figure 5.3a).  However, the temperature was 
somewhat parabolic closer to the end and stirring rate appeared to be relatively linear 
(Figure 5.3b and 5.3c).  This indicated that as the dissolution media concentration 
increases from 0.02% w/v to 0.1% w/v SDS in PBS, the T25 decreases to a minimal 
value, after which from 0.1% w/v to 0.5% w/v SDS in PBS, the T25 value increases.  
However, the effects of temperature and stirring rate on T25 were more proportional, 
whereby as they increase, the T25 decreases linearly.  The minimal T25 value for the 
temperature appears to be at 37°C, where after that value, the graph provides a visual 
indication that the T25 value will increase (Figure 5.3b).  Changes in stirring rate did not 




Figure 5. 3. 1D graphs showing the effects of A) Dissolution media, B) Temperature 




To develop the Transwell® dissolution system as a biorelevant system for OIPs to 
potentially obtain data that is predictive of what occurs in vivo, this study considered the 
interactions and impact of three variable, the dissolution media, temperature and stirring 
rate, on the dissolution rate of FP from a pMDI.  This helped identify the optimal 
conditions and condition levels at which dissolution testing should be carried out, if we 
wish to achieve the desired dissolution rate and obtain reliable QC and’ IVIVC-type data. 
 
5.5.1 Selection of factors and factors levels 
Whilst many studies select conditions to carry out their in vitro dissolution analysis 
for either practicality reasons, physiological relevance or to achieve the highest 
dissolution rate, the results from the preliminary investigations confirmed that changes 
in the composition of the dissolution media, the temperature and the stirring rate causes 
major differences in the dissolution profiles of inhaled FP.  Hence, they emerged to be 
key obvious factors to evaluate in this study. 
To truly predict the dissolution rate of an inhaled drug in vivo, this requires the 
determination of the solubility of the drug in the RTLF and this value is currently unknown.  
However, from my work on estimating the solubility of inhaled compounds in the SLF 
developed in Chapter 3, which is proposed to consist of the ingredients found in human 
respiratory tract lavage samples, it became evident that the solubility of those inhaled 
drugs in SLF were significantly different to their solubilities in other more simpler versions 
or simulations of RTLF, and more precisely, the estimated solubility of FP in the lungs 
using mechanistic models, strongly supported the value obtained in SLF in comparison 
to the other fluids (Boger et al., 2016).  Hence, it only seemed appropriate to apply the 
SLF to the Transwell® dissolution system.  However, since the DOE design required a 
set of 45 experiments and due to the expense of SLF, this could not be done.  Therefore, 
as part of the preliminary investigations, the study considered reversing back to simpler 
surfactant solutions and the match between the FP solubility in 0.1% w/v SDS in PBS 
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and in SLF meant that the medium (0.1% w/v SDS in PBS) factor level for dissolution 
media could represent biorelevance.  A dissolution medium concentration of 0.5% w/v 
SDS in PBS was selected as the highest factor level, since previous studies have utilised 
this concentration to obtain a rank order of dissolution rates for poorly soluble 
hydrophobic drugs such as FP, and 0.5% w/v SDS in PBS has shown to differentiate 
between different dosage forms of OIPs (Rohrschneider et al., 2015).  It was 
hypothesised that as the concentration of SDS in the dissolution media increases, the 
dissolution rate will significantly increase.  This is because surfactants increase the 
wetting of the deposited FP particles and improves its solubility in the receptor chamber 
of the Transwell®, causing a steeper concentration gradient and hence a faster 
dissolution rate (Coowanitwong et al., 2008; Rohrschneider et al., 2015). 
With regards to temperature, the temperature of the dissolution medium has shown 
to be an influential parameter, specifically in FP dissolution studies, whereby faster 
dissolution rates were seen at higher temperatures (Noriega, 2017).  Most studies carry 
out dissolution testing at 37°C, body temperature, to obtain reliable data predictive of in 
vivo situations.  However, the significance or necessity of condition has not been 
evaluated extensively and hence, it was considered an important factor to study.  
In terms of the stirring rate, implications of changes in stirring rate on dissolution of 
OIPs has not yet been evaluated although it was understood that dynamic movements 
caused by breathing could influence the dissolution of inhaled particles.  All three levels 
of stirring rate were selected based on physiological relevance, where the levels 
corresponded to the rested breathing rate of a human, the exercised breathing rate of a 
human and the breathing rate of mice which may.  It was hypothesised, that the stirring 
rate would have minimal effects on dissolution, because the drug particles that have 
deposited deeper into the lung have likely embedded into the surface of the lung fluid in 
vivo, and thus are not exposed to too much movement with each breath.  With such 
limited volume of fluid at the alveoli surface, it was likely that it remained relatively 




5.5.2 Dissolution profile modelling 
Rather than apply in-silico modelling to obtain some predictive PK data of FP, a 
model-dependent mathematical approach was applied in this study to obtain a 
quantitative value to allow for direct comparisons between the dissolution profiles and 
obtain a quantitative understanding of the dissolution rate i.e. a dissolution rate 
parameter.  Once a suitable model or function is selected, the dissolution profiles can be 
evaluated based on the chosen derived model parameter. 
To select the most appropriate model for and model the dissolution data, few of 
the lowest, medium and highest dissolution condition data were selected randomly.  
Initially, an attempt was made to model the data manually, plotting various graphs, 
following the methodologies stated in many studies that have attempted to model the 
dissolution or release kinetics of solid oral dosage forms (Maharjan, 2014).  The model 
graph that gave the highest R2 value was determined to be the best mathematical model 
to fit the data (Costa and Sousa Lobo, 2001; Cascone, 2017).  However, it appeared that 
either Higuchi or Weibull modelling was ranking as number 1 for the data that were 
selected to be evaluated.  Mechanistically, the Higuchi model did not seem entirely 
appropriate for the purpose of this study, since it is often applied to matrix-systems such 
as studying dissolution from a planar heterogenous matrix system, where the drug 
concentration in the matrix is lower than its solubility and the dissolution or release occurs 
through the pores in the matrix (Maharjan, 2014). However, it was not disregarded since 
it may be that wetting is a key mechanism for the dissolution of FP particles i.e. it may 
be that water must enter the pores of the FP particles before it can disintegrate and 
dissolve.  Otherwise, it may be that since the FP particles actuated from a pMDI, may 
land on the Transwell® insert, surrounded with some propellant, the propellant may act 
as a matrix and impact the dissolution of FP.  This provided some justifications to why 
this model ranked number 1. 
Since the data seemed to fit multiple models, it was decided to apply the DDSolver 
software to evaluate the selected dissolution data with all the possible mathematical 
models available, and potentially screen out the single most appropriate model to apply.  
187 
 
The software is very easy to use and fits nonlinear equations to drug release or drug 
dissolution data, facilitating modelling and is based on a built-in library containing at least 
forty dissolution models (Zhang et al., 2010; Zuo et al., 2014).  It presents a key 
advantage in speeding up calculations associated with the manual method, reducing 
user error and providing a convenient conclusive report of dissolution data. 
After ranking the R2 values, it was derived from the software and confirmed, that 
the two most appropriate models were Higuchi and Weibull as suggested via the manual 
application.  Although the Higuchi model could be somewhat justified, the Weibull model 
was eventually selected.  This was on the basis that this model holds more logical 
rationale for application to the data.  It is one of the most commonly used in varied 
dissolution and drug release studies and can be applied widely and successfully to all 
pharmaceutical dosage forms, and to almost all kinds of dissolution curves.  The Weibull 
model has also been applied in a previous study conducted on the dissolution of FP 
specifically via the Transwell® method (Kippax et al., 2016).  Consequently, Weibull 
presents the advantage of being an empirical mathematical equation, indicating it does 
not make any assumptions or characterisations on the kinetic property of the drug in vivo.  
To pharmaceutical dosage systems following this model, linearization of the dissolution 
rate curve is obtained from a plot of the logarithm of the dissolved amount of drug versus 
the logarithm of the time (Langenbucher, 1972).  Application of the model provides a 
description of the dissolution process in more detail to the other models, via parameters 
such β, the shape parameter that describes the dissolution curve or via time parameters 
that allows for quantitative comparisons between the dissolution profiles, such as T25, 
T50, Td, T75 and T80 which represent the time taken for 25%, 50%, 63.2%, 75% and 
80% of the drug to dissolve respectively (Langenbucher, 1972).  Validation experiments 
further proved Weibull modelling to be appropriate for this study. 
The β parameter characterises the curve as either exponential if β=1, s-shaped 
with upward curvature followed by a turning point if β>1 or as a parabolic curve with a 
steeper initial slope than is consistent with the exponential if β<1 (Langenbucher, 1972).  
The calculated β were all <1, which indicated the dissolution profiles’ kinetics were 
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parabolic.  In terms of the time parameter, Td can also be selected because few studies 
who have applied the Weibull model on their drug release or drug dissolution data, 
compared the Td values between them (Patel et al., 2008).  Consequently, since the 
validation experiments indicated a very close match between the actual T25 and the 
predicted T25, this allowed the presumption that the Td would not be overestimated.  
However, regardless, T25 was selected as the key response parameter in the DOE to 
ensure reliability of the analysis.  The preliminary studies indicated that by the end of 60 
min and even under the influence of the highest condition factors, only a maximum of 
22% of the deposited FP particles dissolved.  The conditions that exhibited the highest 
T25 value i.e. the lowest dissolution rate, was expected since they were the lowest levels 
of each factor.  An SDS concentration of 0.02% w/v was not enough to improve the 
wettability of the FP drug particles and increase its solubility and a temperature of 21°C 
and stirring rate of 15 rev p min did not provide sufficient heat or kinetic energy to the 
particles to enhance dissolution.  The condition that gave rise to the lowest T25 value, 
also supported our hypothesis since all the factor levels were at their highest. 
   
5.5.3 Design of Experiment 
The choice of an experimental design depends on the objectives of an experiment 
and on the number of factors the study hopes to investigate (LP and XL, 2012).  This 
study investigated the effects of three factors on a single response.  It aimed to estimate 
the interaction between the factors with each other and between each factor and the 
response and evaluate for any quadratic effects/quadratic relationships between the 
response and the factors, thus the study had a ‘Response Surface’ objective.  This study 
also aimed to identify the optimum factor levels or conditions required for a proposed 
response.  The combination of these reasonings meant that the Box-Behnken design 
was adequate for this investigation. 
When analysing the T25 values obtained for the 45 experiments at first glance and 
relative to the dissolution media concentrations, it was generally presumed that a higher 
concentration of surfactants would improve the solubility and hence the dissolution of 
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poorly soluble drugs like FP.  The results from Design-Expert highlighted that this occurs 
to a certain extent, after which presence of too much surfactant would limit the dissolution 
of FP rather than improve it.  Surfactants, such as SDS, tend to reduce the surface 
tension of an aqueous solution by accumulating at the air-liquid interface, whereby its 
hydrophobic tail is exposed to the air and its hydrophilic head remains incorporated into 
the solution, interfering with the water-water hydrogen bond (Hu et al., 2016).  Exposure 
of the hydrophobic tail attracts poorly soluble compounds into the solution, such as FP, 
increasing FP wettability.  The FP concentration in the medium increases and hence, its 
solubility and dissolution rate.  The effect evidently becomes profound as SDS 
concentration increased from 0.02% to 0.1% w/v in PBS.  The effect of SDS on 
increasing a hydrophobic drug’s solubility in aqueous solutions even below the Critical 
Micelle Concentration (CMC) has been reported previously (Madelung et al., 2014).  
However, once the SDS reaches above its CMC, it forms micelles.  These micelles 
further enhance FP solubility by incorporating and accumulating it into the hydrophobic 
core of the micelles (Rangel-Yagui et al., 2005; Marcolongo and Mirenda, 2011).  The 
CMC of SDS in PBS at ambient temperature,21°C is reported to be 1.1 mM (0.03 %w/v) 
(Sikorska et al., 2016). The CMC of SDS in PBS at higher temperatures has not been 
reported, however, it is expected to be of a higher value as the temperature increases 
since, the CMC of SDS in water for example, changed from 8 mM to 8,4 mM, when the 
temperature increased from 21 °C to 37 °C (Marcolongo and Mirenda, 2011). This 
indicated that at dissolution media concentrations of 0.02% w/v and 0.1% w/v, there were 
no micelles present but at 0.5% w/v, there was plenty since the concentration exceeds 
the CMC, regardless of the temperature at which the dissolution has occurred in.  
Although this was expected to cause a further linear decrease in T25, based on the 
theory above, this did not occur.  This may be a result of the interplay of factors and 
conditions the dissolution system was exposed to andhence it was key to evaluate the 
results further using 3D plots and significant tables, obtained from Design Expert. 
Results from Design-Expert highlighted that changes in dissolution media 
concentration and in temperature had the most statistically significant impact on the 
190 
 
dissolution rate, whereas changes in stirring rate did not.  This seemed to be truly 
reflective of what occurs in vivo since once the inhaled drug particles land and are 
attached or embedded within the lung lining fluid at the alveoli surface, they tend to not 
be exposed to too much movement/stirring with each breath.  Consequently, it has been 
reported that respiratory frequency has shown to be a contributing factor to the residence 
time of aerosol particles in the lungs and causes marked differences in the deposition 
pattern, affecting the probability of deposition by gravitational and diffusional forces, but 
does not affect the rate at which the particle dissolve (National Research Council, 1991). 
The influence of all factors assessed in general however, was negative to T25, in that for 
every increase in factor value, there was a decrease in T25.  With less time taken for 
25% of the deposited drug to dissolve, this meant that the dissolution process was faster 
and hence describes the dissolution rate well.  It appeared that the effect of dissolution 
media concentration is very quadratic, proving that the concentration of SDS in PBS 
must be at an optimum and more specific value if we wish to obtain a desired low T25 
value. 
There were clear interactions between the dissolution media concentration and 
temperature or the dissolution media concentration and stirring rate.  When evaluating 
the interaction between the dissolution media concentration and temperature, it was 
expected that as the temperature increases and at low SDS concentrations, the rate at 
which the SDS molecules settle at the air-liquid interface to attract and adsorb the FP 
drug particles increases, gradually increasing the solubility of FP and hence its 
dissolution rate, indicated by the smaller T25 value.  However, for the maximum SDS 
concentration of 0.5% w/v SDS in PBS, increases in temperature is expected to have 
caused the contradicting effect, as visualised in the graphs.  This is likely because the 
added kinetic energy increased the rate at which micelles were formed in the solution, 
yielding smaller micelles, which would inevitably reduce the extent of effectively 
entrapping and solubilising all the FP particles within (Hammouda, 2013).  Similar 
conclusions can be used to explain the interactions between the dissolution media 
concentration and the stirring rate.  Again, at high dissolution media concentration and 
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high stirring rate, the kinetic energy causes the water structure to become disrupted, so 
they cannot stabilise the hydrophobic head group of the surfactant well, and this 
disfavours micelle formation.  Hence, this decreases solubility of FP and increases the 
T25 value, indicative of a higher dissolution rate. Based on these explanations, both 3D 
interaction graphs gave rise to an inverted dome-shape.  Generally, it was clear that the 
factors analysed were co-dependent on each other, indicating that specific and controlled 
levels of each factor is necessary to provide a system in which one can obtain the desired 
T25 value or desired dissolution rate. 
 
5.5.4 Optimal Experimental Parameters 
The optimal experimental parameters suggested by this study were: 
• Dissolution media concentration of 0.1% w/v SDS in PBS 
• Temperature of 37°C 
• Stirring rate of 15 rev p min 
These were in fact representative of the in vivo physiological conditions, whereby the 
experiment is conducted at the correct body temperature, a dissolution media that 
exhibits the same solubilising capacity towards FP as the SLF and a stirring rate that is 
reflective of the average human breathing rate at rest.  Since changes in the stirring rate 
did not have a significant impact on the T25 value and hence did not need to be specified, 
it was appropriate to carry out dissolution at the lowest rate.  The conditions supported 
the hypothesis that if we wish to conduct an in vitro dissolution test for OIPs and obtain 
reliable dissolution data, reflective of the in vivo environment, we must do so under 
physiological relevant condition sets. 
To validate this further, a dissolution graph comparison between FP dissolution 
under the above set of optimum conditions, was made, with FP dissolution under the 
same conditions but with SLF applied as oppose to the 0.1% w/v SDS in PBS (Figure 
5.4a) and a comparison of the predicted T25 values was also made (Figure 5.4b).  
Insignificant differences in the FP dissolution profiles were seen overall in both 
dissolution medium, as expected, except for a slightly significant difference in the % FP 
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dissolved at 30 min (p ≤ 0.05).  The profiles were very similar, giving an f2 value of 
90.52%.  This was accounted by the similarity in the solubilising capacity both medium 
have towards FP. There were also insignificant differences in the predicted T25 values, 
obtained from the Weibull model (p > 0.05). 
 
Figure 5. 4. A) Dissolution profile of fluticasone propionate (FP) under the 
conditions: temperature of 37°C, stirring rate of 15 rev p min and dissolution 
media of 0.1% w/v SDS in PBS and dissolution profile of FP under the same 
conditions, except using SLF as the dissolution media.  B) T25 values 
predicted from Weibull modelling of the dissolution profiles of FP in the two 
different dissolution media.  Data obtained from the TSI/Transwell® system. 











Summary and conclusions 
The utility of using an experimental design such as Box-Behnken for the 
optimisation of in vitro assays and systems has been generally illustrated in this study.  
It can be concluded the experimental design guided the development of an optimal set 
of experimental conditions required for the evaluation of the dissolution rate of orally 
inhaled products.  The optimum conditions were to use a dissolution media composed 
of 0.1% w/v SDS in PBS and conduct the experiment under the temperature of 37°C and 
stirring rate of 15 rev p min.  These were all considered as physiologically relevant 
conditions and can be employed in the future, when using the Transwell® dissolution 
system.  The work also showed that a further step has been taken towards the 
establishment of a standardised, biorelevant dissolution system, that can be used for 
OIPs during drug research and development.  A future work here would be to potentially 
compare the dissolution of FP under the ideal set of conditions with dissolution of FP in 
rate IPL, to provide a further indication into how close the correlation is or how predictive 


















Dissolution of nebulised dosage forms 
 
6.1 Introduction 
The chapters in this thesis have looked at the dissolution of DPIs and pMDIs but 
have not considered applying or assessing the dissolution of nebulised formulations.  In 
principle, the FPF of suspensions aerosolised by nebulisation can be analysed using the 
same dissolution techniques proposed for DPIs and pMDIs, however, to date there 
seemed to be no examples of this reported in literature. Hence, this chapter focuses on 
assessing the dissolution of nebulised fluticasone propionate, using the opportunity to 
develop a novel nebulised prototype and comparing its performance with the reference 
commercially-available product.  The nebulised aerosol medicine developed in this 
study, is a fluticasone propionate microemulsion and the success of the formulation was 
envisaged via a variety of tests including application of the developed biorelevant 
dissolution system, to assess its dissolution, and compared with the commercially 
available Flixotide® suspension nebule. 
To develop a novel inhaled formulation, the benefits of the delivery device must be 
considered for the selection of the most appropriate for patients.  Although the pMDIs 
and DPIs have increasingly replaced the nebuliser over the years, the nebuliser has an 
advantage with respect to its universal ability to deliver treatment to all age groups of 
patients.  They are particularly useful for the elderly, the very young or very sick who may 
find it difficult to maintain good co-ordination when operating the inhalation device or to 
ensure they receive the adequate dose of drug during an exacerbation (Pritchard et al., 
2018).  Nebulisers also allow for the delivery of large doses or volumes of drugs and can 
produce small aerosol droplets, in the nanometre range, allowing the aerosolised drug 
to penetrate the lung more deeply (Rogueda and Traini, 2007; Amani et al., 2011; Amini 
et al., 2014). Of the available nebuliser technologies, jet nebulisers are generally more 
accommodating to a huge range of pulmonary drugs and more convenient to patients.  
They have numerous benefits such as they tend to be least expensive, the easiest to 
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clean, can be used for thermosensitive drugs and can deliver formulations with a huge 
range of surface tensions and viscosities (McCallion et al., 1996; Lavorini, 2013). 
When considering the nebulisation of poorly soluble drugs such as FP, there is 
currently only one type of formulation commercially available, which is the 
microsuspension.  However, these have shown to be less than optimal in the delivery of 
drugs to the respiratory tract (Nikander et al.,1999; Amani et al., 2011; O’Callaghan et 
al, 2014). For instance, there have been reports of large variations in dose, 
inconsistencies in droplet drug concentrations and due to the production of large droplet 
sizes, excessive impaction on the upper airways and subsequent ciliary clearance 
leading to loss of delivered dose (Cheng, 2014; O’Callaghan, White and Kantar, 2014). 
Consequently, there is a need for preservative when formulating nebuliser suspensions, 
which may be incompatible with the respiratory tract and for time-consuming aseptic 
preparation techniques to ensure minimum sterility assurance level for the API and/or 
excipients.  This is because filtration sterilisation would lead to a significant loss of drug 
from the suspension formulation.  Also, fluticasone suspensions specifically, have 
reportedly experienced the hygroscopic growth effect phenomenon, where the size of 
the aerosol droplet increases with increasing relative humidity from the oral cavity 
through to the lungs and this has negatively impacted on the therapeutic efficacy of the 
formulation in clinical use (Haddrell et al., 2014).  
This provided a rationale to look for alternative nebulisable formulations.  For 
example, colloidal systems, whereby the drug is entrapped in liposomes.  This has 
improved the aerosol output performance and aerodynamic particle size profile however, 
it has shown to have poor shelf life stability and requires a tight control of the lipid 
concentration as high concentrations can significantly decrease the aerosol output rate 
(Wagner et al., 2006).  Other formulations include polymeric nanoparticles, which have 
shown high-nebulisation ability and sufficient stability (Lim et al., 2016).  However, a 
major limitation to this nebulised preparation is the control of the aerodynamic particle 
size, to ensure adequate efficacy of delivery (Tashkin, 2016). Studies have also focused 
on cyclodextrin solutions as alternative formulations for poorly aqueous soluble drugs 
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(Le et al., 2006). Although they significantly enhance solubility and allow for large 
quantities of aerosol to be nebulised within acceptable nebulisation times, only a 
selection of pulmonary drugs can be complexed with the cyclodextrin thus not all 
categories of drugs are suitable substrates for the formulation (Tiwari et al., 2010). Other 
formulations include incorporation of steroids into micellar solutions and microemulsions 
(Malcolmson and Lawrence, 1993; Malcolmson et al., 1998).  However, micellar 
solutions have caused toxicity to cells.  Studies have shown that toxicity of drugs was 
significantly reduced when formulated as a microemulsion in comparison to their 
corresponding micellar solution (Warisnoicharoen et al., 2000). 
Microemulsion formulations have currently attracted most attention as an 
alternative nebulisable formulation.  They circumvent the limitations of other systems and 
potentially allow nebulisers to be utilised to their utmost advantage in clinical care 
(Lawrence and Rees, 2000; Smola et al., 2008; Amani et al., 2010; Fanun, 2012).  They 
present as thermodynamically-stable systems that enhance the solubility of hydrophobic 
drugs by incorporating the drug into the oil phase.  Microemulsions have been 
hypothesised to be better formulations for drug delivery because they behave, for the 
most part, like solutions meaning they allow for sterilisation via filtration, more uniform 
distribution of aerosol droplet size and greater reproducibility in droplet drug content 
(Fialho and da Silva-Cunha, 2004).  However, there are currently no commercially 
available microemulsion formulations for the inhaled delivery of glucocorticoids, due to 
the relatively small number of pharmaceutically acceptable excipients available for 
inhalation (Tiwari et al., 2012). Formulation of microemulsions for pulmonary route is 
particularly limited by the sensitivity of the respiratory tract to some of the surfactants 
and co-surfactants used to stabilise the formulations.  Taking this into account, the 
microemulsion prepared in this study used excipients which were reported to have good 
biocompatibility (Amani et al., 2010).   
      When carrying out in vitro investigations, for a microemulsion formulation to present 
as the better alternative to the corresponding suspension for nebulised delivery, it should 
ideally provide a high solubilising capacity for the hydrophobic drug and exhibit excellent 
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aerosol output performance, with a high fine particle fraction (FPF), as this indicates the 
likelihood for deeper deposition of particles into the alveolar in vivo. Following deposition, 
the interactions of the aerosol particles or drug in vivo, with the epithelial lung lining fluid 
and subsequent dissolution determines the drug bioavailability and the rate and extant 
of absorption to the systemic circulation (Bäckman et al., 2018). It was anticipated that 
the microemulsion exhibit a different dissolution profile to the suspension, hence why 
investigating the dissolution profiles of the formulations is of interest. 
      
Aim: 
The main aim of this chapter was to apply the biorelevant dissolution system 
established in the previous chapters, to a nebulised formulation and evaluate a novel 
formulation compared to a licensed suspension formulation.  Since there are no studies 
on the manufacture of an inhaled microemulsion formulation of FP, it was interesting to 
investigate the in vitro dissolution performance of such formulations. 
 
Objectives: 
The objectives were to (i) prepare a prototype microemulsion that solubilises 
fluticasone propionate (ii) characterise the physicochemical properties and test the 
potential for the microemulsion to be nebulised via a jet nebuliser and (iii) compare the 
properties of the emitted aerosol including its in-vitro dissolution with the commercially 








6.2 Materials  
      The fluticasone propionate was purchased from Generon (Slough, UK).  The 
Tween 80 BioChemica and sterile normal saline solution (0.9% NaCL) were purchased 
from VWR International Ltd (Lutterworth, UK). Medium chain trigyceride (Crodamol 
GTCC) was a sample provided by Croda International Plc (East Yorkshire, UK) and 
Flixotide® nebules 0.5 mg/2mL were purchased from GSK (Middlesex, UK).  HPLC-grade 
ethanol, methanol and water were supplied by Sigma-Aldrich Company Limited (Dorset, 
UK).  Dissolution was carried out using the Transwell dissolution method, using the 
materials as listed in Chapter 2, section 2.2. The equipment/glassware necessary for the 
setup of the Twin Stage Impinger (TSI) were purchased from Copley Scientific Limited 
(Nottingham, UK).  The equipment/glassware necessary for the identification of any 
undissolved crystalline FP, aerosolisation and characterisation of the aerosol output of 
the FP microemulsion and suspension formulations were provided by Intertek-Melbourn 
Scientific (Melbourn, UK). 
 
6.3 Methods 
6.3.1 Manufacture of FP microemulsion 
Fluticasone propionate microemulsion (20 mL) was prepared, using the ingredients 
listed in Table 6.1.  The ingredients were adapted from a commercially available 
budesonide nebuliser formulation (Amani et al., 2010 and Appendix D, Table D.1).  FP, 
4 mg, was dissolved in 156 µL of ethanol and vortexed for 5 min to form a drug mix 
[Dmix].  The surfactant mix [Smix] was prepared by vortex mixing 5 g tween 80 and 0.2 
g crodamol together.  The Dmix and Smix were combined and vortexed for a further 5 
min prior to the addition of normal saline.  The formulation was then sonicated for another 
10 min, using a high shear ultrasonicator probe, to ensure efficient homogenisation of 
the oil and aqueous phases of the formulation.  The concentration of FP in the 







6.3.2 Assessment of microemulsion solubilising capacity to FP 
To determine the solubilising capacity of FP into the microemulsion, the formulation 
was diluted and prepared for assay using RP-HPLC-UV.  A sample of the microemulsion 
(2-3 mL) was pushed through a 0.22 µm filter using a plastic syringe and the resulting 
filtrate was diluted 1:1 with methanol.  The unfiltered microemulsion was also quantified 
and the solubilising calculated, using equation (24): 
 
Solubilising capacity (%) = (filtered FP concentration / unfiltered FP concentration) x 100      (24) 
 
The experiments were carried out in triplicate. 
 
6.3.3 Identification of any undissolved crystalline FP 
Raman Chemical Imaging Technology (Morphologi G3SE-ID, Malvern 
Instruments, UK) was used for the identification of undissolved FP particles within the 
FP microemulsion and Flixotide® nebule formulations.  A single droplet of each 
formulation was placed carefully on a chrome-coated glass microscope slide and 
covered with a glass cover-slip, sealed tightly around the edges with silicone grease.  
Using the Morphologi software v. 8.23, particles were visualised and selected to obtain 
a full Raman spectrum, using a laser excitation of 532 nm and exposure time of 30 sec.  
Table 6. 1. List of the components of the fluticasone propionate microemulsion 
and their concentrations.  
200 
 
The spectra were compared with the FP standard, whereby a monolayer of FP powder 
particles was dispersed on the microscope slide and viewed under the instrument.  
Although full spectra were obtained, a duplet peak at Raman laser wavelength of 1663 
cm-1 was prominent and particularly characteristic of FP and thus was deemed API-
specific.  The work was carried out at Intertek Melbourn. 
 
6.3.4 Characterisation of the physicochemical properties of the FP 
microemulsion and Flixotide® suspension nebules 
The formulations were characterised in terms of their pH, density, viscosity, 
conductivity, surface tension and hydrodynamic diameter of the lamellar structures, 
using the methodologies described in Chapter 3, section 3.3.2.  All measurements were 
made at ambient temperature and recorded as a mean of six measurements ± SD. 
 
6.3.5 Aerosolisation of the FP microemulsion and Flixotide® suspension 
formulations 
The formulations were aerosolised using the Pari LC Sprint jet nebuliser, 
connected to a Pari TurboBoy SX compressor, provided by Intertek-Melbourn Scientific 
(Melbourn, UK).  Approximately 2 mL of the 0.25% w/v Flixotide® suspension and 2.5 mL 
of the FP microemulsion were aerosolised at a flow rate of 15 L/min.  A sputtering sound 
was taken as an indication that the entire drug concentration in the formulation had been 
aerosolised.  The Flixotide® suspension and FP microemulsion formulations was thus 
nebulised for 2 min 40 sec and 9 min respectively, providing an equal emitted dose of 







6.3.6 Characterisation of the aerosol output performance of the FP 
microemulsion and Flixotide® suspension formulations 
The delivery rate and delivered dose experiments were carried out using the 
apparatus set up according to the European Pharmacopoeia specification (Figure 6.1).  
The Pari LC Sprint nebuliser, containing the formulation, was connected to the breath 
simulator (Copley Scientific, Nottingham, UK), which was set to run at 15 breaths per 
minute.  Three filters, held in filter pads (Pari GmBH, Germany) were used to collect the 
FP released from the nebuliser, two of which (filters 1 and 2) were the inhalation filters 
and one exhalation filter (filter 3).  Filter 1 was replaced with filter 2 after 1 minute of 
nebulisation.  After testing, the filters were washed with diluent, consisting of 65:35 % v/v 
methanol: water, into 50 mL volumetric flasks to provide three solutions for filters 1, 2 
and 3 respectively. The nebuliser device was washed into a 250 mL volumetric flask for 
mass balance.  The solutions were then analysed by RP-HPLC-UV (Section 6.3.8).  The 
delivered dose was calculated using equation (25): 
 
Delivered dose (%) = [(filter 1 + filter 2) / total emitted dose] x 100                                     (25) 
 
 
Figure 6. 1. A Schematic diagram of the delivery rate test 
 
The aerosol droplet size distribution was obtained using Spraytec Laser diffraction 
technology (Malvern Instruments, UK), with an inhalation cell to support the nebuliser.  
Following aerosolisation of the formulations, the stable phase of the generated aerosol 
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was selected, and data was generated automatically on the accompanying Spraytec v. 
3.20 software (Malvern Instruments, UK).  The Dv(90), Dv(50), Dv(10), alveolar deposition 
and oropharyngeal deposition were obtained from the generated data.  The span was 
calculated using equation (26): 
 
Span = [Dv(90) – Dv(10)] / Dv(50)                                                                                                                                               (26) 
 
To obtain an aerodynamic particle size profile of the formulations, samples were 
nebulised into the Next Generation Impactor (NGI).  The NGI experiments were carried 
out in a cooling cabinet, maintained at temperatures between 2-8 °C.  The NGI body, 
stage cups and throat were stored in the fridge for at least 60 min prior to start of the 
experiment.  After nebulisation, the FP content of each stage of the NGI was washed 
with methanol into volumetric flasks, prefilled with water.  The volumetric flasks were 100 
mL, 50 mL x 7 and 250 mL, corresponding to the mouthpiece and throat, stages 1 to 7 
of the NGI, and the device respectively. At the filter stage, the filter was removed carefully 
with a tweezer and placed into a crystalliser.  Diluent (65:35 % v/v methanol: water), 50 
mL, was added and the crystalliser was covered in parafilm and allowed to sonicate for 
10 min.  Using a syringe, 5 ml of the sample was filtered through a 0.45 µm PTFE 
ACRODISC CR filter for analysis by HPLC.  The mass median aerodynamic diameter 
(MMAD) and geometric standard deviation (GSD) values were calculated using an online 
MMAD calculator.  The fine particle fraction (FPF) was calculated using equation (27).  
All data were expressed as a mean of six measurements ± SD. 
 
FPF = [(amount of deposited particles < 5.39 µm)/total deposited amount] *100                     (27) 
 




6.3.7 Assessment of the dissolution of FP microemulsion and Flixotide® 
suspension formulations 
The dissolution method used in this study was as described and concluded in 
Chapter 5, whereby the optimum conditions were applied.  In brief, the Transwell® 
dissolution system was used, with a dissolution media of 0.1% w/v SDS in PBS.  1 mL 
of FP microemulsion and 5 mL of Flixotide® suspension was aerosolised for 2 and 5 min 
respectively, and the fine particle fraction was collected by the TSI, under a vacuum flow 
rate of 45 L/min.  Dissolution was carried out at a stirring rate of 15 rev p min and 
performed at 37°C.  The dissolution time points were prolonged to 8 hours, whereby the 
time points were 2, 5, 10, 15, 30, 45, 60, 120, 240, 360 and 480 min.  The recovery 
sample was at 540 min and treated the same way as the 180 sample was treated in 
previous methods.  For sample collection, 100 µL of each sample at each time point was 
collected and diluted with 100 µL methanol prior to analysis via RP-HPLC-UV. 
 
6.3.8 Quantification of FP by RP-HPLC-UV  
For experiments carried out at King’s College London, quantification of FP in the 
samples was carried out using the method described in Chapter 2, section 2.3.2.   For 
experiments carried out at Intertek Melbourn, quantification was made using an assay 
developed by the Intertek laboratory team (Parry, 2015)  
 
6.3.9 Statistical analysis 
Data were normally distributed (Histogram; Skewness and Kurtosis).  Therefore, 
the non-parametric paired sample T-test was applied.  Statistical analysis was performed 
using the IBM SPSS software, version 24, (SPSS, Armonk, NY, USA).  Data was 




6.4.1 Manufacture, nebulisation and characterisation of the physicochemical 
properties of FP microemulsion 
Preparation of a stable microemulsion, incorporating the FP drug appeared to be 
successful.  The final product was a visually clear and transparent yellow liquid.  The 
solubilising capacity of the system towards FP was 100 ± 0.00%.  This was confirmed 
further by the Raman Chemical Imaging technique, when the microemulsion was 
compared with the Flixotide® suspension and the pure FP powder particles (Figure 6.2).  
The particles present in the suspension appeared to be finer and much smaller than pure 
FP particles, with many agglomerated (Figure 6.2b).  However, each particle presented 
spectrums that resembled that of pure FP, although of lower intensity (Figure 6.2d).  On 
the contrary, for the images of the FP microemulsion, agglomerated particulate matter 
was only visible under high magnification (20x) and the Raman spectrum of the particle 
did not match that of FP (Figure 6.2c and Figure 6.2d). 
 
Figure 6. 2. Raman chemical imaging data. Microscopy images of a) standard fluticasone 
propionate (FP) powder (5x magnification), b) Flixotide® suspension (10 x magnification), c) 
FP microemulsion (20x magnification) and full Raman spectra for all three formulations (d). 
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The physicochemical properties of the FP microemulsion was identified and 
compared to the commercially available Flixotide® suspension (Table 6.2).  The pH of 
the microemulsion was 6.52 ± 0.01 and this was complied with the standard for nebuliser 
preparations (Amani et al., 2011).  The pH, density and conductivity of the microemulsion 
was slightly higher than that of the suspension.  However, the viscosity of the 
microemulsion was almost five times greater.  According to the photon correlation 
spectroscopy data, although the microemulsion possessed a wider range of particle 
sizes than the suspension, the average diameter (z-average) of the particles in the 
microemulsion was 12.31 ± 1.50 d.nm and the average diameter of the particles in the 
suspension was 5682.67 ± 827.64 d.nm (Table 6.2).   
 
Table 6. 2. The physicochemical properties of the Flixotide® suspension and 








6.4.2 Characterisation of the aerosol output of the FP microemulsion and the 
Flixotide® suspension formulations 
The FP microemulsion and Flixotide® suspension aerosol output performance was 
characterised in terms of its delivered rate, delivered dose, aerosol droplet size 
distribution and aerodynamic deposition profiles.  The delivered rate and dose of the 
formulations is shown in Table 6.3.  The delivery rate of both formulations was the same.  
However, the microemulsion delivered a significantly higher percentage of FP after 1 
min, almost double the amount, and the amount of drug deposited on the inhalation and 
exhalation filters for the microemulsion were significantly larger than for the Flixotide® 
suspension (p ≤ 0.05). 
 
The aerosol droplet size distribution for the formulations, obtained from the 
Spraytec Laser Diffraction, is shown in Figure 6.3 and Table 6.4.  Both formulations 
appear to have produced a bimodal distribution and exhibit a wide range of particle 
diameters (Figure 6.3).  However, this was more profound for the Flixotide® suspension, 
indicating a slightly less polydisperse particle size distribution for the microemulsion.  The 
differences in the volume distributions (Dv(90), Dv(50) and Dv(10)), the spread of the droplet 
size distribution (span) and % of droplets ≤ 2.15 µm were insignificant (p ≤ 0.05), 
highlighting an overall similar aerosol droplet size distribution profile. However, the % of 
droplets ≥ 11.66 µm appeared to be significantly higher for the suspension than the 




Table 6. 3. The delivery rate, % delivered dose and % exhaled from the Flixotide® 





Figure 6. 3. Droplet distribution by volume of a) Flixotide® suspension and b) 
fluticasone propionate microemulsion, obtained from Spraytec Laser Diffraction. 
Data expressed as mean ± SD (n=3). 
 
Table 6. 4. Aerosol droplet size distribution for the Flixotide® suspension and 
fluticasone propionate microemulsion. Dv(90), Dv(50) and Dv(10) represent the volume 
diameter of 90%, 50% and 10% of aerosol droplets respectively. Data expressed 








The particle deposition pattern for both formulations is shown in Figure 6.4.  The 
suspension evidently had a significantly higher percentage of particles than the 
microemulsion at stages 2 to 4.  However, the microemulsion had a significantly higher 
percentage of particles than the suspension in stages 5 to 7 and on the filter, indicating 
the FP microemulsion consisted of and aerosolised more small-sized FP particles in the 
size range of 1-2.80 µm.  It was evident that the FP microemulsion presented a 
significantly higher FPF, lower MMAD and higher GSD value in comparison to the 
Flixotide® suspension (p ≤ 0.05) (Table 6.5). 
 
 
Figure 6. 4. In vitro aerodynamic deposition profile of the Flixotide® 
suspension and fluticasone microemulsion, obtained from the Next 
Generation Impactor (NGI). Data expressed as mean ± SD (n=6). 
 
Table 6. 5. The fine particle fraction (FPF), Mass Median Aerodynamic 
Diameter (MMAD) and Geometric Standard Deviation (GSD) of the Flixotide® 





6.4.3 Assessment of the dissolution of FP microemulsion and the Flixotide® 
suspension formulations 
The dissolution profiles of the fluticasone microemulsion and the Flixotide® 
suspension is presented in Figure 6.5.  Under the dissolution conditions, a higher 
percentage of FP was dissolved from the FP microemulsion compared to the suspension 
formulation, reaching up to approximately 70% by the end of the 8 h experiment.  The 
FP microemulsion showed an overall improved dissolution profile over the suspension, 
where the % dissolved continued to increase with time, unlike the suspension, where the 
% dissolved appeared to reach a plateau after 60 min.   
 
Figure 6. 5. The dissolution profiles of fluticasone microemulsion and Flixotide® 
suspension, obtained from the TSI/ Transwell dissolution system.  Data expressed 










6.5.1 Manufacture, nebulisation and the physicochemical properties of FP 
microemulsion 
The successful manufacture of a stable microemulsion as a drug delivery system 
requires the harmonious contribution of multiple factors.  The choice and proportion of 
excipients, the order in which they are incorporated into the formulation and the 
physicochemical properties of the active pharmaceutical ingredient (API), all affect the 
final product and its characteristic properties (Lawrence and Rees, 2000; Fanun, 2012).  
Although microemulsions have been formulated for drug delivery via a range of 
administration routes, not many of these have been designed for the respiratory route.  
This may be due to the relatively small number of pharmaceutically acceptable excipients 
available for inhaled drug delivery (Tiwari et al., 2012).  In particular, the formulation of 
microemulsions of the pulmonary route is limited by the sensitivity of the respiratory tract 
to some of the surfactants and co-surfactants typically used to stabilise the 
microemulsions. The chosen excipients were selected to have good overall 
biocompatibility and the preparation method of the FP microemulsion specific for 
nebulisation was done in accordance to the methodology used in a study conducted by 
Amani et al (Amani et al., 2010). 
A particularly important consideration when formulating microemulsions for the 
inhaled route, is to avoid the precipitation of the API on deposition in the lung and dilution 
in the fluids (Thakkar et al., 2011).  Also, to achieve localised effects, a balance is 
required between completely dissolving sufficient API to have a pharmacological action 
and limit the clearance mechanisms so that a persistent concentration of the dissolved 
drug in the lung can be maintained.  Therefore, the delivery system should have high 
solubilisation capacity for the API, hence why an experiment to identify the solubilising 
capacity was carried out.  The assumption that formed the basis of the test, was that FP 
particles contained in a droplet of disperse phase or micelle with size ≤ 0.2 µm was 
solubilised in the microemulsion.  Therefore, the amount of FP determined from the 
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filtrate was considered as the fraction representing ‘microemulsion-encapsulated FP’.  
The microemulsion formulation manufactured in this study had excellent solubilising 
capacity towards FP.  This was made more evident by the Raman imaging which showed 
undissolved crystalline FP particles in the suspension and none in the microemulsion.  
The agglomerated clump found in the FP microemulsion however may have been 
undissolved surfactant. For this imaging technique, although the whole spectra can be 
compared for the formulations, attention was made to the duplet peak at 1663 cm-1, 
because it is the Raman band previously identified to be specifically characteristic to FP, 
when compared to the Raman bands of other materials often present in an FP 
suspension (Doub et al., 2007; Ali et al., 2009).  
These results indicated that the microemulsion formulation does present an 
advantage over the suspension, since the system improved the solubility of the poorly 
aqueous soluble FP.  FP is hydrophobic thus its solubility in a microemulsion occurs via 
encapsulation in the micelles or incorporation into the oil phase of a microemulsion, 
particularly in the oil-in-water variety (Gibaud and Attivi, 2012).  Since micelles form at 
high surfactant concentrations, it can be concluded that the composition of the 
surfactants which made up the Smix in the formulation, allowed for the successful 
encapsulation of all the FP particles and hence its complete solubilisation.  While this is 
advantageous from a formulation perspective, the high surfactant concentration (25% 
Tween 80), although this surfactant is biocompatible, presents a limitation in terms of 
potentially causing toxicity to the cells and tissues of the respiratory tract (Alany and 
Wen, 2007).  Therefore, further investigations into the safety of the formulation is 
necessary. 
In terms of the physicochemical properties, the greater viscosity was likely 
contributed by the thickness of the surfactant solution and the oil phase of the formulation 
i.e. the Tween 80 and crodamol.  Presence of surfactants in the microemulsion was also 
responsible for its lower surface tension, as expected, although the difference was not 
statistically significant.  According to the photon correlation spectroscopy results, the 
colloidal phase of the microemulsion appeared to be more polydisperse than the particle 
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size of the suspension, giving rise to 3 peaks of varied particle diameters/sizes unlike 
the suspension, which had a single 100% intensity peak at a much greater particle 
diameter.  Consequently, for the microemulsion, the peak corresponding to 10.4 d.nm 
was the highest and this further confirmed the successful preparation of the 
microemulsion, since microemulsions often possess droplet sizes in the diameter range 
of 10 – 100 nm (McClements, 2012). 
 
6.5.2 Characterisation of the aerosol output of the FP microemulsion and the 
Flixotide® suspension formulations 
In a clinical setting, how quickly an inhaled dose is administered has major effects 
on patient adherence and this often presents as a disadvantage of nebuliser drug 
delivery in comparison to other forms of inhaled drug delivery, such as the pMDIs and 
DPIs.  The amount of drug delivered to the lung is also a measure of the efficiency of the 
process and could determine the frequency of dosing of the drug.  Therefore, in the 
context of aerosol output performance of an inhaled product, it would be ideal for the 
nebulised formulation to have a relatively high delivery rate and percent delivered dose 
so that the patient receives the maximum amount of drug over a short period of time.   
In this study, the FP microemulsion exhibited a higher delivered rate and dose over 
the Flixotide® suspension and this indicated a major improvement in performance for the 
microemulsion formulation over the commercially available product.  However, there was 
some inefficiency observed with the formulations overall and this may be attributed to 
drug wastage, which is common to continuously operated jet nebulisers (McCallion et 
al., 1996). This is where FP that was nebulised during the non-inspiratory parts of the 
breathing cycle is released into the surrounding environment.  The nebulisers also 
experience evaporative losses and slight temperature reduction as the air flows through 
the device (Cockcroft et al., 1989). This causes some drug to be trapped in the nebuliser 
device or lost through the valve, characteristic of the ‘breath assisted, open-vent’ 
technology of the Pari LC sprint (O’Callaghan and Barry, 1997).  
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Another important characteristic property of an inhaled formulation is the size of 
the droplets produced when aerosolised.  The size of the droplets is a major determinant 
of the lung particle deposition pattern of aerosols.  The larger droplets i.e. greater than 5 
µm deposit preferentially by inertial impaction in the oropharyngeal regions of the 
respiratory tract, droplets in sizes between 1 to 5 µm deposit by sedimentation in the 
lower airways in the bronchioles and droplets less than 0.5 µm are mostly removed on 
expiration with exhaled air (Smola et al., 2008; Carvalho et al., 2011).  This study 
considered the % droplets ≤ 2.15 µm and % droplets ≥ 11.66 µm, as they represent the 
predicted fraction of aerosol droplets that deposit within the alveolar region and the 
oropharyngeal deposition respectively (Najlah et al., 2014).  The results indicated that 
although both formulations would deliver similar amount of FP to the alveoli to achieve 
localised effects, a lot more FP particles from the suspension would either deposit by 
impaction, at the back of the throat or on the upper airways where it is subject to ciliary 
clearance.  This has been reported previously in studies on suspension (Cheng, 2014).  
In a clinical setting of the delivery of inhaled corticosteroids, this presents an advantage 
to the FP microemulsion because a slightly reduced impaction of FP in the mouth and 
throat, results in a reduced potential for side effects such as oral candidiasis and thus an 
overall improvement in patient compliance (McCallion et al., 1996). 
However, whilst aerosol droplet size distribution estimated by laser diffraction has 
been shown to correspond to favourable lung deposition pattern (Clark, 1995), the 
measurements correspond to the size of the droplets generated by the nebuliser and 
does not consider whether the droplets contain FP drug particles or not.  Therefore, to 
obtain a more accurate prediction of the distribution of the FP particles in the respiratory 
tract, the NGI was used.  The experiment was carried out in temperatures between 2 
and 8°C to reduce the effects of evaporation which have shown to significantly affect the 
deposition patterns of aerosols (Abdelrahim, 2011). 
In the pathology of asthma, it is well known that inflammation occurs predominantly 
in the lower airways thus an optimal formulation would be expected to have a high 
proportion of aerodynamic particle size in the range of 1 to 5 µm, quantified as the 
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respirable fraction or the FPF.  Consequently, it is favourable for the formulation to exhibit 
a lower MMAD since it indicates that it consists of smaller aerodynamic droplet sizes 
overall, so essentially are more likely to deposit into the lower airways in vivo, as 
required.  The higher FPF and lower MMAD exhibited by the FP microemulsion in 
comparison to the suspension highlights that it is the favourable formulation and this 
difference between the two types of formulations was also seen in previous studies 
conducted by Amani et al, who compared a nanoemulsion preparation to a suspension 
preparation of Budesonide (Amani et al., 2010).  This is likely explained by the difference 
in surface tension, even if only slight different.  The FP microemulsion and the Flixotide® 
suspension had surface tensions of 35.50 ± 0.5 mN/m and 40.60 ± 0.5 mN/m 
respectively.  Surface tension represents the energy barrier that must be overcome for 
a new surface to form which occurs when larger droplets collapses into smaller droplets 
(McCallion et al., 1996).  Since the microemulsion consisted of surface active agent that 
acts to reduce the interfacial tension between the oil and water interfaces, it likely 
facilitated the production of smaller droplet sizes. 
 
6.5.3 Assessment of the dissolution of FP microemulsion and the Flixotide® 
suspension formulations 
The conditions under which the dissolution experiment was carried out were: 0.1% 
w/v SDS in PBS dissolution medium, stirring rate of 15 rev per min and under a 
temperature of 37°C.  They were the optimal and physiological conditions identified by 
the DOE study carried out in Chapter 5.  The time points were prolonged to 8 h to allow 
for better discrimination between the dissolution profiles and evaluate for differences 
better. The volumes selected for aerosolisation and the flow rate selected for particle 
deposition via TSI, were based on preliminary investigations that indicated that these 
conditions ensure equal quantity of FP deposition on the filter paper (Appendix D, Table 
D.2) hence, the dissolution profiles are likely normalised to the amount deposited. 
In terms of the dissolution method, upon observation, it appeared that the 
suspension produced a more distributed deposition within the TSI and on the filter, with 
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droplets depositing everywhere on the equipment.  However, the microemulsion was 
easier to handle and the droplets deposited predominantly on the filter paper.  The 
dissolution profiles produced were discriminatory and showed a clear difference in the 
dissolution rate between the formulations.  This highlighted the positive benefit of 
applying dissolution testing to provide a more holistic evaluation of inhaled formulation 
performances. 
The enhanced dissolution rate and improved profile is likely accounted for by the 
higher solubility of FP in the microemulsion formulation, in comparison to the suspension.  
For poorly soluble drugs, dissolution is thought to be an important determinant of their 
pharmacokinetics and pharmacodynamics in the lungs (Hastedt et al., 2016).  Therefore, 
the profile exhibited by the microemulsion many indicate lower non-absorptive clearance 
via mucociliary clearance and enhanced bioavailability. 
 
Summary and conclusions 
This study was carried out for the purpose of evaluating the application of the 
developed biorelevant dissolution test and assessing the dissolution of nebulised 
formulations.  Results highlighted that formulation of an FP microemulsion for nebuliser 
devices is certainly a realisable approach.  Although there are formulations proposed as 
viable alternatives to a suspension, when formulating poorly aqueous soluble drugs for 
pulmonary delivery, the ease and scaleup of an optimised formulation and the simplicity 
of manufacture make microemulsions a unique choice for the formulation of drugs for 
inhaled delivery. 
Like previous studies that considered preparing a nebulisable microemulsion 
formulation for inhaled drugs, such as budesonide, a microemulsion of fluticasone 
propionate has been successfully prepared and can be delivered effectively to the lung 
via the nebulised route.  The microemulsion solubilised FP sufficiently and showed an 
overall improved in vitro aerodynamic performance over the commercially available 
Flixotide® suspension, exhibiting larger FPF, higher alveolar deposition and significantly 
greater delivered dose. 
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Application of dissolution testing during the development of the microemulsion 
provided discriminatory power to distinguish the dissolution performance of the two 
formulations.  It allowed for a better insight into the prospects of success of the 
microemulsion preparation and allowed the evaluation of dissolution of nebulised 
formulations in general.  Consequently, the slightly improved dissolution demonstrated 
by the microemulsion indicated a potentially higher therapeutic bioavailability, making 


























7.1 Basis for the project 
This thesis reports investigations into novel dissolution systems and their fitness to 
evaluate the dissolution of aerosols emitted orally inhaled pharmaceutical products.  
Studies were based on considerations of importance regarding the dissolution of 
pharmaceutical aerosols from scientific, academic and industrial pharmacy perspectives.   
It is appreciated that dissolution assays are widely used tests in medicines 
development and manufacture, not least during the early stages of product development, 
for the optimisation of various formulations.  There are well-established dissolution 
methods for the evaluation of solid oral dosage forms which are used in all phases of 
development for characterising drug release and evaluating product performance 
between batches and over time.  Over the past 50 years, dissolution testing has been 
commonly employed as a QC test in R&D, where drug release constitutes a critical 
product attribute and can be used to detect the impact of manufacturing variables (Chen 
et al., 2016).  The FDA guidance on dissolution testing for immediate release solid oral 
dosage forms has been included in the BCS guidelines, which is based upon API dose, 
solubility and permeability.  According to the BCS guidelines, in vitro dissolution testing 
may be a useful tool to compare the performance of drug products and for BCS class 
API reduce the number of bioequivalence clinical studies.  However, despite being 
already entrained in pharmaceutical and biotechnology industry, it has not been 
recognised as a vital test for the development of OIPs. 
As mentioned previously, the EMA and FDA have issued guidelines and specific 
requirements for the approval of OIPs, which include the need to assess the dose content 
uniformity and the ASPD.  However, it has been recognised that these tests come with 
their limitations, one of which is that they do not fully predict the in vivo performance of 
OIPs (Newman and Chan, 2008).  This provided motive for scientists and researchers to 
attempt to develop dissolution testing as a requirement test for the development and 
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approval of inhaled pharmaceutical products.  In 2012, a review by an IPAC-RS working 
group, consisting of a cross-company team evaluating the need for dissolution testing 
for OIP, concluded that ‘dissolution testing would be a valuable tool in the development 
of inhaled dosage forms’.  In an APS-organised symposium in 2015, there was an 
emphasis that dissolution was currently a neglected aerosol property, most likely 
because its usefulness as a QC test was unproven.  For any in vitro test to be accepted 
for QC purposes, it must be at reliable, simple, discriminatory and relatively economic as 
a minimal requirement.  Many studies have taken these considerations into account and 
proposed a variety of aerosol particle collection and dissolution testing methodologies, 
with the advantages and disadvantages of each method as documented in this thesis.  It 
was also well recognised in a number of conference presentations and talks that in fact, 
the factors influencing the PK of an inhaled drug, e.g. absorptive clearance, are still 
poorly understood and they are not well predicted from the current in vitro aerosol 
collection tests and dissolution tests proposed.  Hence, to date, there is yet no reliable, 
standardised nor universal pharmaceutical dissolution system present for OIPs.  
For dissolution testing to be used as a predictive IVIVC tool, it was realised that 
the in vitro system must mimic the important features of the in vivo environment and 
hence, for OIPs, it must present conditions that replicate the physiology of the lungs.  
Although some systems have emerged that attempt to mimic aspects of the lung 
environment, such as the TS/Transwell® system or the DissolvIt® system and the various 
proposed simulated fluids that have been applied to them, they do not closely mimic the 
in vivo RTLF in terms of its composition and characteristics.  Therefore, using fluticasone 
propionate as the model drug, this thesis predominantly aimed to address these 
drawbacks and limitations and develop a dissolution system for OIPs, that can be used 




7.2 Conclusions from the project 
The objectives in this thesis were completed successfully, providing new insights 
into and developing methods for dissolution testing, while opening opportunities for future 
work to investigate hypotheses based on the findings.  The study first evaluated two 
dissolution systems, both of which were simple, easy to conduct and repeatable.  The 
NGI/rotating paddle system included a novel aerosol collection technique and utilised 
apparatus already available for pharmacopoeial quality control testing.  Using the filter-
holding device and collecting particles externally from stage 2, provided a means of 
collecting the respirable fraction.  It provided a large surface area and ensured an even 
distribution of particles, overcoming the recognised limitation shown in other dissolution 
systems that used the NGI to collect the aerosol particles, where particles collected in 
piles under the nozzles (Son and McConville, 2009; Son et al., 2010). The system also 
had the advantage of using standard USP 2 dissolution apparatus, giving confidence in 
the reliability of the dissolution profiles generated and increasing the likelihood of the 
system being used universally.  Whilst many published prototype systems possessed 
deficiencies such as poor repeatability, difficulty in handling or poor discriminatory ability, 
this novel system appeared to be excellent to take forward for QC purposes, proving to 
be robust and sensitive to experimental changes, providing greater discrimination 
between the dissolution profiles when experimental variables were modified, such as the 
composition of the dissolution media, and presenting repeatable data.   
However, from the perspective of developing a dissolution test with the potential to 
be utilised as an IVIVC tool, the TSI/Transwell® system emerged as the preferred 
contender.  Optimisation of the system was performed in accordance to techniques 
applied previously (Arora et al., 2010; Rohrschneider et al., 2015).  The adapted system 
appeared to provide the best representation of lung physiology, since it was fluid-
restricted, provided a thin wet layer for particles to deposit on the surface of the filter and 
required small volumes of fluid for the dissolution of the inhaled particles.  The latter 
aspect meant that biorelevant fluids (some of which are expensive, such as Survanta®) 
220 
 
can be utilised in small volumes, making the system economic in accordance with the 
key requirements of the assay. 
There were suggestions that due to the limited volume used in the Transwell® 
system and the low aqueous solubility of FP, it may be difficult to maintain sink conditions 
(Rohrschneider, 2012; Rohrschneider et al., 2015).  However, by moving the Transwell 
to new receiver chambers (i.e. from one well to another), each containing a fresh volume 
of medium, this limitation can be overcome.  The modification to replace the membrane 
in the Transwell insert was undertaken to avoid this providing an excessive diffusion 
barrier and being the rate-limiting steps.  This was first reported as an issue and the 
adaptation proposed in the study by Rohrschneider et al (Rohrschneider et al., 2015).  
The findings in this thesis supported the findings in the study, in that the measured 
dissolution rate was greater when this experimental modification was applied.  This 
becomes particularly useful when evaluating the dissolution and overall performance of 
poorly aqueous soluble inhaled drug compounds, in which their PK profiles are presumed 
to be dissolution-rate limited (Hastedt et al., 2016).  Therefore, the TSI/Transwell® 
dissolution system was selected as the system to be developed further as a more 
biorelevant system with the aim of providing dissolution data with relevance to PK and 
establishing predictive IVIVC. 
Having observed the dependency of dissolution rate on the dissolution medium, 
the first approach in developing a biorelevant dissolution test was to devise a biorelevant 
medium that represents the in vivo RTLF, then establish a manufacturing method to 
provide a consistent, standard product that is readily available for use as a dissolution 
medium with appropriate in vitro systems.  In this thesis, a novel SLF, of biorelevant 
composition was developed and manufactured, and shown to possess physicochemical 
properties comparable to those of the RTLF.  The stability of SLF was also assessed 
and indicated that although it must be stored in the fridge and used within 14 days of 
manufacture, the SLF could also be used on the bench, at room temperature, for short 
period of time up to 48 h, for dissolution studies for example, and can also be used at 
37oC temperature, if required.  The ability to freeze-dry SLF was established and meant 
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that it could be stored for prolonged periods, in its powder form and so can be more 
easily handled and transported for reconstitution at its required place and time of use, 
providing an added advantage.   
On a wider scale, the SLF has huge applicability within the field of inhalation 
biopharmaceutics, besides dissolution, such as for solubility of inhaled compounds and 
to study the interactions of the aerosol drug or particle with lung cells.  Drug solubility is 
a key consideration in the development of inhaled medicines, including drug 
design/discovery (Edwards et al., 2016), formulation (Hastedt et al., 2016) and 
toxicokinetics (Jones and Neef, 2012).  Consequently, it is an essential characteristic 
required for the development of the BCS for OIPs.  When assessing the solubility of FP 
in this study for example, in various proposed lung fluids, the value obtained in SLF 
seemed to closely support the estimated solubility of FP in lungs used as an input for 
mechanistic modelling of PK after inhaled administration (Boger et al., 2016).  The SLF 
can also be used to study for interactions since it has been suggested that particle-lung 
fluid interactions can impact on inhaled drug delivery (Das and Stewart, 2016).  For 
example, significant interactions between inhaled nanomaterials and lung fluid have 
been demonstrated (Kumar et al., 2016; Beck-Broichsitter et al., 2017).  For lung-particle 
interaction studies, the SLF must be biocompatible with respiratory cells and the 
biocompatibility of SLF with the A549 cells indicated by the MTT assay in this thesis, was 
followed up by exploring any morphometric or transcriptional changes induced by 
exposure of A549 cells to SLF, in another study conducted by collaborators (Kumar et 
al., 2017).  Both results highlighted the biocompatibility of SLF and hence maximised its 
utility.  Studies of all these phenomena benefit from biorelevant fluids, i.e. SLF, to make 
meaningful in vitro measurements.  Experimental in vitro data such as those obtained 
here, has been increasingly in demand to provide inputs to computational models that 
predict the drug bioavailability in the lungs or the rate and extent of absorption to the 
systemic circulation (Bäckman et al., 2018).   
In Chapter 4, experiments were designed to explore an application of SLF in 
dissolution experiments by incorporating the SLF onto a dissolution system and 
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assessing the impact on dissolution profiles and evaluating these by computational 
modelling that evaluate the role of dissolution rate on PK.  It was hypothesised that using 
more physiological conditions for in vitro investigations may improve the accuracy of 
physiologically-based mechanistic modelling.  The DissolvIt® system was utilised as a 
system designed to mimic the in vivo lung luminal environment, while incorporating 
transfer of dissolved drug to a flow-through perfusate where drug concentration can be 
measured.  The system had been developed to use a simple polyethylene oxide gel as 
the dissolution matrix and hence, there was room to incorporate SLF to introduce a more 
biorelevant medium to the system.  The in-silico model was developed by collaborators 
at University of Graz, Austria, to explore the impact of the dissolution rates derived from 
the medium on the in vivo PK.  However, it was found that simply adding SLF to the 
DissolvIt® chamber did not significantly modify FP dissolution profiles and although the 
model provided reasonable estimates of PK, further work would be required to explore 
the impact of assay conditions on dissolution profiles and how these might influence PK. 
Although studies using the DissolvIt® system did not support the hypothesis that 
using more physiological conditions for in vitro investigations may improve the accuracy 
of physiologically-based mechanistic modelling, further studies were concocted.  It was 
rationalised that if simpler aqueous or surfactant-based solutions, such as those 
commonly used for OIP dissolution studies, were to be used for applications in the 
dissolution systems, then these should provide equivalent solubilising capacity for the 
API as RTLF. To enable studies to be conducted using small amounts of aerosol in the 
TSI/Transwell system, a novel solid phase extraction method for the assay of FP in the 
dissolution medium (SLF) was required.  Thus, a sensitive technique with the ability to 
quantify picogram quantities of the drug was developed which proved to be reliable and 
can be used more widely, to quantify FP in a variety of biological fluids. 
Based on these findings, a biorelevant dissolution test for OIPs was developed and 
evaluated in Chapter 5.  It relied on using a surfactant-based dissolution medium, SDS 
in PBS, and the TSI/Transwell dissolution system.  A DOE approach was used i.e. a 
three-level three factorial Box-Behnken experimental design was used, constructed 
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using Design-Expert 11, to identify assay conditions based on physiologically-relevant 
features that were hypothesised to impact on dissolution profiles and to investigate their 
impact.  It was hypothesised that dissolution can be influenced by the dissolution media, 
temperature and stirring rate, which were all applied variably in reported dissolution 
methods.  Although many studies have used simple aqueous solutions such as PBS 
alone or surfactant solutions, such as 0.5% w/v SDS in PBS, they provided an 
overestimation on the solubility of FP.  Therefore, for the medium to be of biorelevance, 
the selection of the concentration of SDS in the medium that provides the same 
solubilising capacity towards FP as the SLF was determined.  The experimental design 
required a quantitative measure of dissolution which was provided by mathematical 
modelling of the profiles.  There were many theoretical and logical reasons as to why 
Weibull was selected, one of which it has been used to model the dissolution of FP from 
the Transwell system in a previous study (Kippax et al., 2016).  Preliminary experiments 
found this model to be the most appropriate for the data obtained and T25 was selected 
as the ‘Response’ parameter for the study design. 
The experimental outcomes suggested interactions between the factors evaluated 
on dissolution rate but demonstrated the dependency of dissolution rate on the 
experimental conditions in the assay.  A dissolution medium of 0.1% w/v SDS in PBS 
(the concentration of medium at which the FP solubility matches its solubility in SLF), 
conducting the experiment at 37°C and under a stirring rate of 15 rpm was considered 
as physiologically relevant.  The thesis presents a TSI/Transwell® dissolution system, 
under these specified conditions as a biorelevant system that can explored for IVIVC 
purposes.   
The concluding experimental chapter focused on the dissolution of nebulised 
dosage forms, as there appeared no data evaluating the dissolution of such formulations 
to date.  An opportunity was taken here to develop a novel nebulised formulation in which 
the drug was solubilised as a comparison to FP suspension, then explore the 
performance of the nebuliser solutions using the biorelevant dissolution system.  The 
study showed that formulation of a nebulisable FP microemulsion is a realisable 
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outcome, with advantages over some limitations of the suspension version currently on 
the market.  The dissolution assay discriminated between the two different nebulised 
formulations for the same drug, highlighting how that the biorelevant system could have 
an important role or application in the development of novel aerosol medicines.   
It is interesting to compare the dissolution of various inhaled FP products (pMDI, 
powder, nebuliser) in the biorelevant TSI/Transwell® system, conducted under these 
physiological conditions: temperature of 37°C, dissolution medium of 0.1% w/v SDS in 
PBS and stirring rate of 15 rpm (Figure 7.1).  The dissolution profile of FP from the 
Flixotide® pMDI and DPI seemed to very closely overlap, providing an f2 value of 88.56%, 
and this was as expected according to previous findings in the thesis and in previous 
studies.  However, dissolution from the nebuliser suspension appeared to be greater, 
with a higher % of FP dissolved at each time point.  Although the test ensured similar 
amounts of FP was deposited from each formulation, the difference in profiles is likely 
attributed to the difference in the ingredients present in the different formulations, such 
as presence of surfactants in the nebulised suspension formulation In the DPI, the FP 
particles are formulated such that it is blended with larger lactose carrier particles, or in 
some cases blended with other excipients and when aerosolised, the lactose fines 
deposit on the filter and assist dissolution.  In MDIs, the drug is dissolved or suspended 
in its micronized form in a propellant, HFA 134a, of ethanol composition, on the basis 
that FP is completely soluble in ethanol.  It has been suggested that the DPI formulation 
increases the wetting of the FP particles, more than the MDI formulation, although the 
exact mechanism is not fully understood (Shur, 2016).  However, this did not seem to be 
the case here and may be due to the fact that upon actuation of both the DPI and MDI 
formulations, the apparatus ensured dry solid FP powder particles, of the same physical 
form, to deposit for dissolution in both cases, causing similarity in the dissolution rate 
and profiles (Arora et al., 2010).  However, in the case of the nebulised formulation, the 
FP is presented as a suspension, and is nebulised to deposit FP in the form of droplets, 
stabilised by surfactants, such as   Polysorbate 20 and Sorbitan Laurate.  Presence of 
surfactants have shown to hugely increase the wetting and solubility of inhaled particles 
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within the nebulised formulation and since the FP particles deposit in the form of droplets 
on the filter paper, for dissolution, they are available in a more soluble form than the dry 
solid particles.  Upon dissolution in the 0.1% w/v SDS in PBS dissolution media, the 
added presence of the SDS surfactants further increases the wettability of the particles 
as they enter.  Hence, the nebuliser suspension provides a higher initial dissolution rate, 
in comparison to the DPI and MDI.  The impact of these formulation variables on 
dissolution provide opportunities for further research. 
 
 
Figure 7. 1. Dissolution of fluticasone propionate from the Flixotide® 50 µg 
Evohaler (pMDI), Flixotide® 50 µg Accuhaler (DPI) and Flixotide® 0.5 mg/ 2 mL 
nebuliser suspension.  Data obtained via the TSI/Transwell® dissolution system.  










7.3 Future work 
In satisfying the main objectives of the thesis, a number of observations were made 
that should be investigated in future work.  For example, a biorelevant TSI/Transwell 
system has been developed.  Although the system demonstrated discriminatory ability 
between various inhaled formulation types, future work could involve assessing the 
sensitivity of the system to detect formulation-dependent factors such as particle size, 
physical stability or amorphous versus crystalline particles. 
In terms of the NGI/Rotating Paddle system, which provided an excellent starting 
point to be utilised for QC purposes, it would be interesting to compare the novel particle 
collection system developed in this study with a recently emerged collection system 
developed by Jag Shur and Robert Price, at the University of Bath (Shur, 2016; Price, 
2018).  The novel UniDose collection system was developed to also overcome the 
limitations of previously published NGI particle-collection methods and allow for more 
uniformly distributed particles to deposit onto a glass microfibre filter membrane.  The 
UniDose allows for the whole impactor stage mass i.e. below stage 2 of the NGI to 
deposit and the filter is then placed into a disk cassette and placed into a USP II Paddle 
apparatus.  Data obtained from their system indicated excellent repeatability and 
accuracy and therefore, when the method is published, it would be interesting to compare 
the performance of the system against the novel system NGI/Rotating Paddle system 
developed in this study. 
With regards to development of a biorelevant simulant, the work is yet considered 
to be at early stages.  It provides a ‘base’ model reflective of the RTLF of a healthy 
individual.  Future work would extend biorelevance of this by attempting to reflect any 
differences in the RTLF in lung disease states and consider making SLF specific to the 
lung disease being studied.  For example, in the case of cystic fibrosis (CF), the disease 
is characterised by a build-up of mucus throughout the lung tubes, including the alveolar 
lining and therefore, when evaluating the performance of drugs used for the treatment of 
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CF in vitro, using a more reflective SLF of the disease state i.e. incorporating mucins 
may be more beneficial. 
When evaluating the compatibility of SLF with respiratory cells, although findings 
from the MTT analysis carried out in this thesis, and morphometry transcriptomic 
analysis, proved biocompatibility with human epithelial A549 cells, future work would 
require establishment on how robust this finding is across different lung cell lines and in 
primary cell models.  With regards to SLF applicability in inhalation biopharmaceutics 
studies, the solubility of a few inhaled compounds has been measured in this thesis.  A 
list of inhaled compounds that are considered dissolution-rate limited, i.e. their predicted 
solubility is significantly less than their inhaled dose, has been identified and listed in 
Appendix A, Table A.4.  Measurement of solubility of those compounds in SLF to provide 
inputs to computational models that require this data for PBPK modelling would be 
extremely useful.  
Over the course of this thesis solubility measurements and dissolution 
data/performance of FP in SLF has been rationalised in terms of the post-deposition fate 
of inhaled aerosols.  For example, in SLF very stable colloidal structures may form due 
to tight packing of the lipid components providing a sink that may sequester the lipophilic 
FP particles.  On the contrary, it was suggested that albumin in SLF may interact with 
cholesterol, which is required to form stable micelles, causing the structures to break 
down and inhibiting its ability to solubilise the FP particles.  Future work would be 
required, to visually see if and how efficiently, the FP interact or sequester within the 
micelles in SLF. This can be done via titration calorimetry, whereby a quantitative value 
of the binding affinity as well as the stoichiometric properties can be obtained.  It would 
also be interesting to investigate the impact of albumin alone on the solubility and 
dissolution of FP in the SLF medium.  This is because, it has been suggested in this 
study that the presence of lipids and surfactants likely impact FP solubility and 
dissolution, however, other studies have identified and considered the impact of albumin 
in increasing the solubilisation of a range of drugs (Khodor et al., 2016; Khodor et al., 
2018; Leon-Ortega et al., 2018).  An increase in drug solubility, mediated by albumin, 
228 
 
has been reported for a range of drugs, such as antifungal compounds and poorly 
aqueous-soluble drugs, and it has been thought to be through complexation mechanisms 
(Leon-Ortega et al., 2018). 
With regards to the developed nebulisable microemulsion formulation for FP, 
although it has now been recognised as a realisable outcome, it required a large 
concentration of the Tween 80 surfactant to solubilise the concentration of FP.  The 
concentration is above the typical used in inhaled formulations i.e. 15% w/v, future work 
on this would be to assess the toxicity of various concentrations of Tween 80 in the 
human lung using alveolar cell lines, such as A549 cells via MTT analysis and perform 
acute toxicity studies in vivo to identify the maximum concentration that can be used 
before detrimental effects on the cells is visualised. 
 
7.4 Conclusions 
The key conclusions drawn from the thesis are: 
1. A novel NGI/Rotating paddle dissolution system has been developed that has the 
attributes of an assay suitable for QC purposes suitable and is available for 
validation and testing. 
2. A biorelevant TSI/Transwell® system has been developed that provides a step 
closer towards establishing IVIVC for dissolution in the lungs. 
3. The biorelevant TSI/Transwell® system appears to be the most ideal system to 
date, fulfilling the minimum requirements of a dissolution system that can be 
utilised universally for QC, classification and IVIVC 
4. A novel biorelevant dissolution medium has been developed that has promising 
applicability in the field of inhalation biopharmaceutics. 
5. In silico modelling has been applied to assess the implications of in vitro 
experimentations on the in vivo drug PK profile and illustrates an approach to 
understanding the impact of dissolution on inhaled drug delivery. 
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6. A novel nebuliser formulation of FP, in the form of a microemulsion, has been 
manufactured, providing an example of how suspension products can be 
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Appendix A Table A. 1. Cryo-TEM images of human respiratory tract lining fluid.  






Appendix A Figure A.1. Thermogravimetric graphs of the simulated 





Appendix A Figure A.2. Thin Layer Chromatography (TLC) preliminary study.  TLC 
plate runs of DPPG, DPPC, cholesterol, simulated lung fluid and their force-





Appendix A Figure A.3. Thin layer chromatography runs of 100, 75, 50 and 25% v/v 
concentrations, and a plot of the mean grey value of TLC spot/spot intensity as a 










Appendix A Table A.2. The salt components of Gamble’s solution and their relative 
concentrations.  The components were added in that specific order to avoid 
precipitation of salts.  Citrate was used in place of proteins and acetate to replace 
organic acids, adapted from method by Marques et al (Marques et al., 2011) 
 
 












































































































































































































































































Appendix B Table B.5. System-specific input parameters for humans (table 





Appendix B Table B.6. System-specific input parameters for the central lung and 
peripheral lung in human (adapted from Boger et al (Boger et al., 2016). 
 
 
Appendix B Table B.7. Drug and formulation specific input parameters for 




Appendix B Table B.8. Concentration of fluticasone propionate (FP) in the 
perfusate over time following dissolution in 1.5% w/v Polyethylene oxide + 0.4% 
w/v L-alphaphosphatidyl choline (PEO), simulated lung lining fluid (SLF) and 
diluted Survanta®. Data represent mean ± SD (n=3). 
 
Appendix B Table B.9. Concentration of fluticasone propionate (FP) in the 
perfusate over time following dissolution in rat isolated perfused lung (IPL).  Data 











Appendix C Table C.1. The cumulative amount of fluticasone propionate dissolved (FP) at 
each time point, for experiments 1 to 45 and the total amount of FP deposited on the 








Appendix C Table C.2. The cumulative percent of fluticasone propionate dissolved (FP) at 





Appendix C Figure C.1. Dissolution of fluticasone propionate from the 


























Appendix D Table D.10. List of the components of the Budesonide nanoemulsion 




Appendix D Table D.11. Preliminary investigations for dissolution testing.  The 
flow rate, volume of solution in the nebuliser, time for nebulisation and the 
amount of fluticasone propionate deposited on the Transwell® filter paper, for the 
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